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Abstract 
Background 
Oxygen therapy remains a cornerstone of medical practice and is generally regarded as 
being safe. However, there is a lack of clinical evidence to support the routine use of 
oxygen therapy, and in certain conditions, injudicious oxygen may cause harm. In this 
thesis, I will present two audits and three randomised controlled trials of oxygen therapy. 
 
Methods   
 A prospective audit of the prescription and use of oxygen therapy before and 
after the introduction of an oxygen prescription section on a drug chart 
 A retrospective audit of ambulance oxygen administration, in patients with acute 
exacerbations of chronic obstructive pulmonary disease (AECOPD) 
 Two randomised controlled trials of high flow versus titrated oxygen in 150 
patients with community acquired pneumonia and 106 patients with acute severe 
asthma 
 A randomised controlled trial of 24 subjects with obesity hypoventilation 
syndrome (OHS) comparing 100% oxygen with air 
 
Results   
 Oxygen prescription is suboptimal in hospital inpatients. Whilst an oxygen 
prescription section improved prescription, this intervention did not improve 
clinical practice 
 Over 70% of patients presenting with AECOPD received high flow oxygen prior to 
presentation to the emergency department. The risk of adverse outcomes 
increased progressively with increased PaO2 
 High concentration oxygen leads to a rise in PaCO2 compared to titrated oxygen, 
when administered to patients presenting with asthma or pneumonia 
 Breathing 100% oxygen leads to a rise in PaCO2 in patients with OHS 
 
Conclusion 
This series of studies has shown that further measures are warranted to ensure the safe 
practice of oxygen therapy in the pre-hospital and hospital setting. In addition, the 
findings suggest that the potential for high concentration oxygen therapy to increase 
PaCO2 is not limited to COPD but may occur in other respiratory conditions  in which 
abnormal gas exchange or respiratory drive are present. 
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Chapter 1.1 Historical Perspective 
  
Oxygen was first discovered as an element in the late 18th century.  The history, however, 
surrounding its discovery remains a contentious issue.  In 1774, the English clergyman, 
Joseph Priestly liberated a gas from sunlight and mercury oxide which he described as 
“dephlogisticated air”. He published his findings “Experiments and Observations on 
Different Kind of Air” the following year in which he postulated a medical use for it. As he 
was the first to publish his findings, he is usually given priority for the discovery of 
oxygen1 . However, Carl Wilhelm Scheele, a Swedish apothecary, unaware of Priestly’s 
work, may have generated the gas as early as 17712 but erroneously, Scheele’s 
observations were not published until 1777 and thus he has not gained credit for its 
discovery.  
Whether or not it was Priestly whom made the discovery of oxygen, he was amongst the 
first to suggest that there may be adverse effects of ‘pure air’, when in 1775, he observed 
a candle to burn out faster in oxygen than in air, and wondered if “the animal powers be 
too soon exhausted in this pure kind of air”1. 
Shortly after its discovery, Antoine Laurent Lavoisier a French chemist in 1778, conducted 
the first experiments on oxidation and named the gas ‘oxygène’ meaning “acid 
generator”. 
Following its discovery as an element, oxygen was used as a therapy particularly in the 
treatment of tuberculosis. By the 1800s, it was widely touted as a panacea and was 
delivered by wafting buckets of oxygen towards the face of the patient. Further, 
unconventional routes of administration were developed including intra-abdominal, 
intravenous, rectal and subcutaneous routes which were claimed to provide the cells of 
the body with a direct source of oxygen 3 4. The first use of continuous oxygen therapy 
was described by Dr Albert Blodgett5 in a 37 year old woman with severe pneumonia to 
whom he administered two hundred gallons in twenty-four hours. He noted “the patient 
not only obtained the relief desired, but was enabled to continue the function of 
respiration”. 
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Oxygen therapy was revolutionized during the early part of the 20th century. This was in 
part due to better understanding of basic oxygen physiology brought to light by Adolph 
Fick and Paul Bert who described oxygen tension in terms of units of partial pressure. 
These units were used to describe the difference in oxygenation between arterial and 
venous blood relating the difference to tissue oxygen consumption and cardiac output; 
they also described central nervous system toxicity at high oxygen tensions, named the 
‘Bert effect’6. J Lorrain Smith in 1899, in trying to reproduce the ‘Bert effect’, was one of 
the first to demonstrate local pulmonary toxicity of oxygen at ambient pressure, the so 
called ‘Smith effect’.7 
It was John Scott Haldane, the eminent Scottish respiratory Physiologist who brought 
oxygen therapy to a rational and scientific basis and is often heralded the “father of 
oxygen therapy”. His ardent interest on the effect of various gases on the respiratory 
system, lead him to use his own son in his investigations. At the age of 9, the younger 
Haldane was sent down a coal mine shaft to test the state of the air and at 12, his father 
put him in a leaking diving suit to descend 40 feet in the waters of a freezing lake8. In 
1917, Haldane published “The Therapeutic administration of Oxygen”9 which is 
considered to mark the beginning of modern oxygen therapy. In this publication Haldane 
describes the concepts of anoxaemia, the regulation of respiratory drive and the 
concepts of ventilation- perfusion matching.  
Haldane went onto publish “Respiration” 10 in which he discusses oxygen and carbon-
dioxide transport, the nervous control of breathing and the effects of low and high 
atmospheric pressures. Following Haldane’s work and the experience of the benefits of 
oxygen in the First World War, oxygen as a therapeutic agent became widely accepted. 
However, even in these early days of oxygen therapy, Haldane recognized the benefits of 
keeping inspired oxygen percentage as low as possible “and to know roughly what 
percentage is being breathed”. He also warns of the potential dangers9 
“The probable risks of prolonged administration of pure oxygen must be borne in 
mind, and if necessary balanced against the risks of allowing the oxygen want to 
continue. No fixed rule can be given. The proper course to pursue must be 
determined by the physician after careful observation of the patient” 
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Since its discovery and the work of Haldane it has been used in a wide range of settings 
and conditions, and remains one of the most effective therapeutic agents available. 
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Chapter 1.2 Physiology of Oxygen 
 
The transport of oxygen from the air to the tissues involves complex physiological 
processes which include pulmonary gas exchange, transport of oxygen in the blood and 
delivery of oxygen to the mitochondria. In this section I will describe in detail the 
physiology of oxygen, paying attention to the pathophysiology of hypoxia.  
Oxygen transport  
Oxygen is transported in the blood in two forms: the majority is carried in the blood 
bound to the haemoglobin molecule and a small amount is carried dissolved in the 
plasma. The latter is usually very small and negligible. Haemoglobin is a molecule in red 
blood cells that consists of an iron-containing porphyrin compound and a protein with 
four polypeptide chains. The avidity which oxygen binds to haemoglobin is modulated by 
its molecular structure and the changes it undergoes as oxygen is bound or released. 
When oxygen binds to haemoglobin, oxyhaemoglobin is formed and is easily reversible. 
The molecular weight of haemoglobin is nearly 68,000 Daltons and each molecule can 
potentially bind to four oxygen atoms. The number of molecules bound to haemoglobin 
is a function of the PaO2 in the blood known as the oxygen dissociation curve. 
Figure 1. Oxygen-Haemoglobin dissociation curve 
    
This illustrates the PaO2 in blood and the percentage of the oxygen binding sites that are 
occupied by haemoglobin molecules (saturation). The curvilinear shape of the curve has 
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two particular features that serve to protect from tissue hypoxia. The upper flat portion 
of the curve means that a marked fall in PaO2 is still compatible with a nearly complete 
oxygen saturation. Secondly the steep portion of the curve means that despite rapidly 
falling oxyhaemoglobin saturation, the oxygen tension remains relatively well preserved. 
This property facilitates the continued delivery of oxygen to the tissues despite 
progressively lower levels of saturation. 
Various factors influence the position of the oxygen dissociation curve. The curve is 
shifted to the right because of an increase in temperature, PaCO2 and hydrogen ion 
concentration (low pH) or an increase in 2,3-diphosphoglycerate (DPG). This shift to the 
right enhances release of oxygen to the tissues and improves oxygen availability, named 
the Bohr Effect. 
 
Ventilation 
Effective ventilation is controlled by three elements: respiratory centres in the 
brainstem, chemoreceptors and the respiratory muscles11. The respiratory centres in the 
brainstem comprise of different groups of neurons in the medulla and pons which are 
responsible for the automatic control of breathing. The cortex can override these centres 
if voluntary control is desired.  
The chemoreceptors are divided into central and peripheral. The central chemoreceptors 
are near the ventral surface of the medulla. They are surrounded by brain extracellular 
fluid and respond to changes in its hydrogen ion (H+) concentration- an increase in H+ 
stimulates ventilation whereas a decrease inhibits it. Peripheral chemoreceptors are 
located in the carotid bodies at the bifurcation of the common carotid arteries, and in 
the aortic bodies above and below the aortic arch. The peripheral chemoreceptors 
respond to decreases in arterial PaO2 and pH, and increases in arterial PCO2. Further 
receptors are found in the respiratory tract and respond to stretch and irritants. 
 The volume of gas inspired and expired with each breath is the tidal volume (Vt). The 
total lung capacity (TLC) is defined as the volume of gas contained in the lungs at 
maximum inspiration; the residual volume is the gas remaining in the lungs after maximal 
expiration. The functional residual capacity is the volume of gas remaining in the lungs at 
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the end-tidal expiration. At functional residual capacity, most of the gas volume, approx 
30 mls/kg in healthy adults, is contained in the alveoli. About 150ml is contained in the 
conducting airways and does not take part in gas exchange. During inspiration, the 
alveolar volume increases by an amount equal to tidal volume Vt, 7mls/kg, as the volume 
in the conducting airways remains essentially unchanged during quiet breathing. Yet the 
amount of fresh gas entering the alveoli during quiet breathing is only two-thirds of Vt, 
approximately 350mls or 12% of total alveolar volume, since the first gas to enter the 
alveoli is the gas located in the anatomical dead space. The product of Vt and respiratory 
frequency is known as minute ventilation (MV). Alveolar ventilation (Va) is the 
component of total ventilation that goes to ventilate alveoli. Dead space (Vd) is the 
remainder portion of MV that does not take part in gas exchange. It is divided into 
anatomical dead space (mouth, nose, pharynx and large airways not lined with 
respiratory epithelium) and alveolar dead space (ventilated lung that normally 
contributes to gas exchange, but does not because of impaired perfusion). Physiological 
dead space equals the anatomical plus alveolar dead spaces.  
The Bohr Equation is used to derive physiological dead space (see Appendix 5). In normal 
subjects the anatomical and physiological dead space volumes are nearly the same as the 
alveolar dead space is negligible. However, in patients with lung disease the alveolar 
dead space may be considerably larger because of inequality of blood flow and 
ventilation within the lung. This is discussed in detail below.  
Efficient gas exchange requires matching of alveolar ventilation and perfusion. 
Historically, the three compartmental model of Riley and Cournand in the 1940s12 
divided the lungs into (1) ideal lung where ventilation and pulmonary blood flow are 
equal; (2) shunt fraction in which the compartment remains perfused but not ventilated 
and (3) dead space in which lung units are ventilated but not perfused. Inequalities of 
ventilation or perfusion are termed ventilation-perfusion (V/Q) mismatch. V/Q mismatch 
occurs to an extent in the normal, healthy lung due to unevenness of ventilation and 
blood flow topographically from apex to base.  However in lung disease where the 
inequality is more marked, it can lead to hypoxaemia, hypercapnia or both. 
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Figure 2. Three Compartment Lung 
  
The lung is represented by three units on the basis of the arterial and the expired partial 
pressure of oxygen and carbon dioxide. One type of unit (dead space) is unperfused so its 
V/Q ratio is infinity. A second type of unit (V) is unventilated so its V/Q ratio is zero. 
Finally, a third type of unit (ideal, A) presents balanced ventilation and perfusion ratios 
(V/Q ratio =1). Adapted from West, Respiratory Physiology11 
  
Oxygen delivery  
Oxygen is transported from the atmosphere to each cell in the body. In general, gases 
move from an area of high concentration to an area of low concentration. The oxygen 
cascade describes the process of declining oxygen tension from the atmosphere to the 
mitochondria. Oxygen, being a gas, exerts a partial pressure which is determined by the 
prevailing environmental pressure. At sea level, the atmospheric pressure is 760mmHg. 
As oxygen makes up 21% of air, the partial pressure of oxygen in ambient air is 760 X 
0.21= 159mmHg. 
 
PaO2 
P
aC
O
2
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When oxygen is inspired, water vapour humidifies air and dilutes oxygen thus reducing 
the inspired partial pressure of oxygen (PIO2) to 149mmHg. 
 
On reaching the alveoli, a third gas, carbon dioxide, is present. The partial pressure of 
oxygen in the alveolus (PAO2) can be calculated by the alveolar gas exchange equation 
for oxygen. It relates to three variables: R, the respiratory exchange ratio (oxygen 
uptake/carbon dioxide elimination); PIO2, inspired partial pressure of oxygen; and the 
partial pressure of carbon dioxide in the alveolus.  
PAO2= PIO2 –PACO2/R 
In normal conditions, the PAO2 is around 100mmHg. 
From the alveolar air, oxygen diffuses into the pulmonary capillaries. The partial pressure 
of oxygen in the pulmonary arterioles is around 40mmHg which allows for the passive 
diffusion of oxygen from a zone of high partial pressure to one of low pressure. In 
accordance with Fick’s principle of diffusion the wide surface area and thin alveoli 
membrane of the blood-gas interface are well suited for the purposes of gas exchange. 
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Figure 3. Alveolar-Capillary Unit  
Adapted from BTS Emergency Oxygen Guidelines 2008
13
 
 
 
 
The alveolar-arterial PO2 gradient is a measure of the difference between the alveolar 
partial pressure of oxygen and the arterial partial pressure of oxygen  
A-aPO2=( PIO2 – PaCO2/R) – PaO2 
Under air-breathing conditions, this equation is useful for estimating the degree of 
alveolar hypoventilation. Normally there is a small A-aPO2 gradient in the range of 4-
8mmHg due to the bronchial circulation. Any differences greater than this between the 
calculated PAO2 and the directly measure PaO2 becomes a rough estimate of V/Q 
mismatch, increased intrapulmonary shunt and/or diffusion limitation, alone or in 
combination. 
Oxygen delivery (DO2) is dependent on the arterial content of the blood i.e. the sum of 
the oxygen dissolved in the blood and the amount of oxygen carried by haemoglobin 
(CaO2) and the cardiac output and can be illustrated by the following equation: 
PVO2 45mmHg 
PVCO2 53mmHg 
 
PIO2 149mmHg 
PICO2 ~ 0mmHg 
PaO2 98mmHg 
PaCO2 38mmHg 
PAO2 100mmHg 
PACO2 38mmHg 
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 DO2 = CaO2  X  cardiac output 
As the amount of dissolved oxygen in the blood is very low, CaO2 is largely determined by 
the total amount of haemoglobin and the proportion which is bound by oxygen. 
Oxygen is then delivered to the tissues and organs by a process of diffusion across the 
extracellular matrix between the tissues and capillaries and individual cells to the 
mitochondria. The amount of diffusive oxygen movement depends on the oxygen 
tension gradient and the diffusion distance14. 
 
Hypoxia 
Hypoxia occurs when oxygen stores are insufficient to meet oxygen demand in a 
particular compartment. Hypoxia can be classified as hypoxaemic due to a fall in the 
oxygen saturation of arterial blood, anaemic due to a reduction of haemoglobin 
concentration, ischaemic due to inadequate blood flow or histiotoxic due to an inability 
of the tissues to use oxygen due to interruption of normal cellular mechanisms such as in 
severe sepsis. Oxygen therapy is used to treat hypoxaemic hypoxia and the mechanisms 
leading to arterial hypoxaemia are discussed in further detail below. 
 
Reduction in the Inspired Oxygen Partial Pressure 
The percentage of oxygen in inspired air is constant at 21% and does not change with 
altitude. However the fall in atmospheric pressure at higher altitude decreases the partial 
pressure of inspired oxygen and hence the driving pressure for gas exchange in the lung. 
Adaptive mechanisms allow people living at such altitudes to tolerate chronic 
hypoxaemia which is not associated with increased morbidity15. In a recent study 
performed on healthy subjects climbing Mount Everest, the mean PaO2 when breathing 
ambient air was 24.6 mmHg16. 
Intrapulmonary Shunts 
Shunts occur when alveoli are perfused but not ventilated. Normal subjects have a right-
to-left shunt of 2-3% of their cardiac output, this can be greatly increased by lung or 
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cardiac disease. Shunt is the main mechanism of hypoxaemia in congenital heart disease 
and pulmonary arteriovenous malformations. 
Ventilation-Perfusion Mismatching 
V/Q mismatching is the commonest cause of arterial hypoxaemia in lung disease. The 
assessment of V/Q inequality is discussed in detail below which will identify the 
physiological processes involved. Changes in the bronchi, parenchyma and pulmonary 
vessels can lead to severe imbalance of V/Q. The pulmonary circulation, however, is 
unique in that it responds to hypoxia by vasoconstriction, thus diverting the flow of blood 
away from poorly ventilated areas of the lung and reducing V/Q mismatch. This 
mechanism is known as hypoxic pulmonary vasoconstriction (HPV). Because of the 
relevance to this thesis, HPV is discussed in detail below. 
 Alveolar Hypoventilation 
Hypoventilation may be caused by an overall reduction in ventilation due to muscle 
weakness or from decreased alveolar ventilation due to respiratory disease such as 
COPD. Hypoventilation results in hypoxaemia and hypercapnia. 
Diffusion Impairment 
Impairment of oxygen diffusion across the alveolar-arterial membrane can occur in 
diseases such as pulmonary fibrosis. This is due to thickening of the alveolar capillary 
membrane. 
 
Hypoxic Pulmonary Vasoconstriction 
Hypoxic pulmonary vasoconstriction is an adaptive mechanism that diverts blood flow 
away from hypoxic alveoli and thus shifts in blood flow from poorly ventilated areas to 
better ventilated areas. This reduces ventilation-perfusion mismatch which minimizes 
arterial hypoxaemia.  
This response differs to the systemic circulation which dilates in response to hypoxia. The 
threshold for vasoconstriction is a PAO2 60mmHg
17. The response begins in seconds, 
reaches a maximum within minutes and can be sustained for hours. It is seen in the 
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normal as well as the abnormal lung which has been demonstrated by the administration 
of vasodilator drugs.  
The mechanism is modified by a number of factors including changes in pH, age and 
gender. In addition in severe hypoxia, PAO2 below 25mmHg, HPV is lost and there is a 
vasodilator response. 
The mechanism of HPV remains largely unknown. There are 2 postulated mechanisms: 
the first is thought to be due to the release of a vasoactive mediator, and the second is 
due to a direct effect on the vasculature from hypoxia. 
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Chapter 1.3 Physiology of Oxygen Therapy 
 
Oxygen is used as an acute therapy and for long term use as discussed below.  
Acute Oxygen Therapy 
The rationale for oxygen therapy in the acute setting is to increase PAO2 and therefore 
should be used to treat or prevent hypoxaemia in order to resolve or avoid tissue 
hypoxia. Oxygen therapy is only effective when alveolar capillary units have some 
functional ventilation. If units are poorly ventilated i.e. low V/Q ratio, increasing the 
fraction of inspired oxygen FiO2 will increase the PAO2 and hence, PaO2. If hypoxaemia is 
caused by impaired diffusion due to thickening of the alveolar-capillary membrane, 
increasing the PAO2 will augment diffusion by increasing the gradient. Oxygen therapy 
will not resolve hypoxaemia caused by a pure shunt where mixed venous blood does not 
pass through an alveolar-capillary unit. 
The level of PaO2 at which oxygen therapy should be commenced is debatable. A level of 
60mmHg or above is physiologically defensible given that haemoglobin saturation is 90% 
complete at this PaO2. However, patients with chronic respiratory disease have been 
shown to tolerate much lower levels of PaO2
18-21  and the threshold for administering 
oxygen to these patients may not be different from normal if tolerating hypoxaemia. 
Conversely, certain disorders of oxyhaemoglobin saturation, such as carbon monoxide 
poisoning require treatment with high levels of oxygen to detach carbon monoxide from 
haemoglobin molecules and speed elimination of carbon monoxide.  
Administering oxygen to patients with normal saturations will not increase the delivery of 
oxygen to tissues and may impact adversely on other physiological parameters which will 
be discussed in the next section on hyperoxia. The British Thoracic Society Guidelines 13 
therefore advocate the prescription and administration of oxygen to a target saturation 
range rather than for presumed need. 
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Long-Term Oxygen Therapy (LTOT) 
Long term oxygen therapy is used to treat COPD patients with severe hypoxemia. Two 
randomized controlled trials22 23 published in the early 1980s showed a reduction in 
mortality when oxygen was used for at least 15 hours per day. On the basis of these 
studies, LTOT is recommended in patients with a PaO2 of  less than 55 mmHg (7.3 kPa) or 
a PaO2 of less than 60 mmHg (8 kPa) if there is evidence of pulmonary hypertension, 
secondary polycythaemia, nocturnal desaturation or peripheral oedema24 
The mechanism for the increased survival in these patients with LTOT is not precisely 
understood. Reduction in pulmonary artery pressure may play a part, but these changes 
were only modest in one of the studies. It is thought that survival may be related to a 
reduction in arrhythmias related to hypoxia. The effects of LTOT in COPD have been 
extended to the treatment of other respiratory conditions, although there is no evidence 
to support this. 
 
Methods of oxygen delivery 
Face Masks 
Oxygen masks are designed to fit over the mouth and nose and deliver increased 
concentrations of oxygen in the inspired gas.  
 High concentration reservoir masks can increase the inspired concentration to 
between 60% and 90% when used at a flow rate of 10-15 l/min. However the 
concentration is variable depending on oxygen flow and the patient’s minute 
ventilation and pattern. 
 Simple face masks can deliver concentrations between 40-60%. As the patient 
may have an inspiratory flow rate greater these masks should not be used with a 
flow rate <5l/min25. However, like the high concentration masks, they are a 
variable performance device and do not deliver a known, fixed oxygen 
concentration. 
 Venturi masks are a fixed performance device and deliver a constant 
predetermined oxygen concentration to the patient’s mouth unaffected by tidal 
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volume or pattern of breathing. They work on the Bernouilli effect whereby air is 
entrained through the side port of the venturi valve and the amount entrained is 
related to the flow of oxygen.  Different concentrations of oxygen can be 
administered and are available in the following concentrations 24%, 28%, 35%, 
40% and 60%. 
Nasal Cannulae 
Nasal cannulae overcome the difficulties of face masks allowing the patient to eat, talk 
and expectorate without discontinuing therapy. They are also cheaper than face masks. 
They can be used to deliver flows of 1-8l/min26. However, being a variable performance 
device, the concentration of oxygen delivered will vary and high flows may cause nasal 
irritation. 
 
Monitoring oxygen therapy 
Oximetry 
Pulse oximetry is non-invasive technique used to continuously monitor the oxygen 
saturation level (SpO2). An oximeter is a spectrophometric device that measures the 
different absorption of light by oxy- and deoxyhaemoglobin. Most instruments use only 
two transmitted wavelengths and therefore include in the measurement other forms of 
haemoglobin such as carboxyhaemoglobin and methaemoglobin. They do not provide 
information on pH or PaCO2 and are unreliable when SpO2 falls below 80%.  Oximeters 
may not be able to achieve a satisfactory reading in clinical situations where there is a 
poor signal such as shock, skin pigmentation and nail varnish. In addition movement 
artefacts may produce a false fall in saturations. 
 
Invasive Monitoring 
Arterial punctures can be taken from the radial, brachial and femoral arteries.  If 
repeated blood gas measurements are required, an arterial line can be inserted. Causes 
of error in blood gas measurements include excessive heparin, failure to keep the sample 
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iced if analysis is not done within 30 minutes, air contamination and a high white blood 
cell count. Technical errors in measurement are also an important source of error. 
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Chapter 1.4 Hyperoxia 
 
Hyperoxia is defined as an excess of oxygen in body tissues as a result of breathing 
elevated concentrations of oxygen. In this chapter I will discuss the effects of hyperoxia 
at normobaric pressures, that is, at a level equal to atmospheric pressure. The effects 
and therapeutic use of hyperbaric oxygen are outside the realms of this thesis, and will 
not be included. 
Whilst it cannot be argued that administering oxygen to the hypoxaemic patient leads to 
an increase in PaO2 which leads to favourable physiological effects and ultimately the 
prevention of cell death, administering oxygen to the non-hypoxaemic patient has a 
number of untoward functional and toxic effects which are not widely appreciated. 
These effects will be broadly discussed in this chapter. 
 
Oxygen-Induced Hypercapnia 
There are a number of mechanisms which are believed to cause oxygen induced 
hypercapnia in a group of vulnerable individuals. In this chapter I will briefly describe 
each proposed mechanism but will give a more extensive review of the literature with 
reference to COPD and asthma in the subsequent two chapters. 
Haldane Effect 
The Haldane effect was first described in 1914 by  Haldane and colleagues27. It 
characterises the haemoglobin molecule’s affinity for carbon dioxide at different oxygen 
concentrations. Low oxygen concentrations promote loading of carbon dioxide onto 
haemoglobin. Conversely, high oxygen concentrations enhance the unloading of carbon 
dioxide. Thus if a hypoxaemic patient is administered oxygen, the rise in arterial oxygen 
saturation will cause carbon dioxide to be released and the PaCO2 will rise. Although 
studies have been conducted to estimate the degree of oxygen-induced hypercapnia28 29,  
the magnitude attributable to the Haldane effect has not been quantified. Additionally, it 
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has been argued that although the Haldane effect does increase the PaCO2, it does so 
only transiently30.  
Ventilatory Drive 
The peripheral chemoreceptors in the carotid and aortic bodies sense both hypoxia and 
hypercapnia. The ventilatory response curve to hypoxia is shown in figure 4. 
 
Figure 4. Ventilatory response curve to hypoxia and hypercapnia 
Both responses are shown at different values of PaO2 and PaCO2 respectively, 
demonstrating the interaction between both stimuli. Hypoxaemia increases the slope of 
the ventilatory response curve. 
 
Because of interaction between hypoxia and hypercapnia, the sensitivity of the 
peripheral chemoreceptors for CO2 is substantially reduced at high levels of arterial PaO2. 
Hyperoxia thus removes some of the ventilatory drive in patients with chronic hypoxia 
and normal subjects. The contribution of “loss of hypoxic drive” to oxygen-induced 
hypercapnia is debatable and will be discussed in detail in the subsequent chapter.   
V/Q Mismatch 
Ventilation perfusion mismatch occurs when alveolar capillary units are perfused but not 
ventilated. As discussed in the preceding chapter the lungs have an adaptive mechanism 
named hypoxic pulmonary vasoconstriction which diverts blood away from poorly 
ventilated areas of the lung in order to reduce V/Q mismatch. When supplementary 
oxygen is administered, PAO2 will rise, causing release of hypoxic pulmonary 
vasoconstriction and ultimately a rise in PaCO2.  
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Absorption Atelectasis 
Absorption atelectasis is the tendency of an airway to collapse if proximally obstructed. 
In normal lungs, nitrogen is poorly soluble in plasma and therefore remains in a high 
concentration in alveolar gas. If high concentrations of oxygen are administered, it 
‘washes out’ nitrogen and the process of absorption atelectasis is accelerated, increasing 
V/Q mismatch. 
 
Pulmonary Toxicity 
As described in the opening chapter of this thesis the pulmonary toxic effects of oxygen, 
the ‘Smith effect’ have been known for some centuries6.  Gerschman and colleagues31 in 
1954 first suggested oxygen derived free radicals as being the probable aetiological 
factor in the development of these effects. Pathological changes including oedema, 
alveolar haemorrhage, inflammation, fibrin deposition, and thickening and hyalinization 
of alveolar membranes have been described32 . Specific cell damage is caused by free 
radicals present in the form of superoxide and hydrogen peroxide. Normally, various 
antioxidant enzymes such as glutathione peroxidise, catalase, and superoxide dismutase 
protect the body from these free radicals, but in hyperoxic conditions, there is increased 
free radical production leading to saturation of the enzyme systems and as a result free 
radicals escape deactivation32 33 
The precise concentration of oxygen which is toxic to human lungs is unestablished.  
Animal studies have shown a clear correlation between progressive increments of oxygen 
concentration and morphological damage in pulmonary cells34. As well as being dose 
dependent, oxygen toxicity has also been shown to be a function of duration of oxygen 
administered in human cells35.  From a synthesis of published data on pulmonary oxygen 
toxicity in humans, Jackson36 provides the following time course: decreased tracheal 
mucus velocity is detectable after six hours of 100% oxygen breathing, and signs of 
tracheobronchitis appear after 12 hours. Oedema, documented in some studies by 
bronchoalveolar lavage, occurs at 72-96 hours, and fibrosis follows. Although some of 
these changes may be reversible, even a short duration of hyperoxia can lead to 
significant alveolar-capillary ‘leak’ and induce processes that culminate in fibrosis in the 
alveolar wall37.  
  
38 
 
 
Cardiovascular Effects 
Hyperoxia has a number of well documented effects on the cardiovascular system. In 
healthy subjects it has been shown to reduce cardiac output, reduce stroke volume and 
increase systemic vascular resistance38-41. These effects have also been shown to occur in 
myocardial ischaemia42-45. More recently we undertook a systematic review 46 to 
investigate the effect of oxygen on coronary blood flow which found that hyperoxia 
caused a significant mean reduction in coronary blood flow of 8-29% due to a mean 22-
41% increase in coronary vascular resistance. The other major finding of this systematic 
review was the reduction in myocardial oxygen consumption due to both a reduction in 
myocardial oxygen delivery as well as a reduction in myocardial oxygen demand resulting 
in reduced myocardial contractility. The proposed mechanisms which coronary 
vasoconstriction occurs in the presence of hyperoxia includes the secretion of 
angiotensin II by myocytes, the production of reactive oxygen species and the 
sequestration of nitric oxide by the haemoglobin molecule. The clinical implications of 
these cardiovascular effects are discussed in section 1.7 
 
Central Nervous System Toxicity 
 Bert originally described that CNS toxicity occurred at oxygen pressures of >3 
atmospheres,  however even at lower pressures, hyperoxia has been shown to increase 
the formation of oxygen free radicals in the brain 47 48 inducing cerebral vasoconstriction, 
which may reduce cerebral blood flow 49 50. The clinical implications of this are discussed 
in section 1.7 
Although the focus of this thesis is on the use of oxygen in adults, it’s well recognised 
causative role in retinopathy of prematurity in children, warrants consideration. Oxygen 
therapy to reduce apnoea in the 1940s led to an increased incidence of retinopathy of 
prematurity, known then as retrolental fibroplasia. It was first linked to oxygen therapy in 
the 1950s51 52. It is caused by the disorganised growth of premature retinal vessels which 
is accelerated by supplemental oxygen exposure, although this is not the single causative 
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agent. However, a recent Cochrane review53, has shown a trend for supplemental oxygen 
to reduce the progression to threshold retinopathy of prematurity but this was not 
statistically significant. Perhaps of greater concern is the increased adverse pulmonary 
sequelae with higher oxygen targeting in this group of preterm infants. 
 
Delay in recognition of physiological deterioration 
Another less well recognised adverse effect of hyperoxia is the potential to delay the 
recognition of physiological deterioration54-56.  By measuring venous admixture and 
fraction of inspired oxygen Downs and colleagues54 have shown that worsening  
intrapulmonary right-to-left shunting of  blood occurs as a result of progressive 
worsening of disease. Despite the shunt increasing, there is only a minimal reduction in 
oxygen saturation. It is only when the shunt has achieved a certain level that this will be 
reflected by a low oxygen saturation. This may delay the detection and treatment of an 
unstable patient. In contrast, if a low concentration of oxygen is used to achieve 
normoxia, rather than hyperoxia, a subsequent clinical deterioration is likely to be 
recognised sooner through pulse oximetry. A clinical example to demonstrate this is 
shown in figure 5. 
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Figure 5. Intrapulmonary shunt and arterial PaO2 
  
 
Arterial oxygen tension (PaO2) plotted as a function of intrapulmonary shunt increasing 
at a rate of 1% per 6 min with fractional inspired oxygen (FiO2) of (a) 0.3 and (b) 0.6. In 
example (a) with FiO2 0.3, the time required for the PaO2 to decrease from 80 mm Hg 
(95% saturation) to <60 mm Hg (<90% saturation) is around 60 min. At this stage, with 
the same rate of increasing intrapulmonary shunt, an increase in FiO2 from 0.3 to 0.6 will 
maintain the PaO2 above 60 mm Hg for about a further 60 min. In example (b), if the 
patient receives an FiO2 of 0.6, it would take around 120 min for the PaO2 to decrease to 
<60 mm Hg (<90% saturation). At this stage, with the same rate of increasing 
intrapulmonary shunt, there will be a further deterioration in PaO2 despite maintenance 
of the FiO2 at 0.6. Adapted from Beasley, Thorax 2007
56 
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Chapter 1.5 Oxygen Therapy in Chronic Obstructive Pulmonary Disease 
 
In this chapter I will focus on the studies which have demonstrated the adverse effects of 
oxygen in COPD. As these have been known for over 60 years I will first give a summary 
of the early studies, move onto to discuss some of the findings of the more recent 
studies particularly those pertaining to the mechanism of oxygen induced hypercapnia 
and then finally present some of the clinically based studies. I will close this section by 
presenting the BTS guideline recommendations on ways to reduce oxygen induced 
hypercapnia in AECOPD.  
 
Early Studies of Oxygen induced Carbon Dioxide Retention in COPD patients 
The first reports of oxygen induced carbon dioxide retention date back over sixty years. 
In 1937, Barach57 observed that “oxygen treated patients developed a state of stupor, 
with irrationality when aroused” and in 194158 went onto record “A profound 
disturbance of mental function may take place in patients suffering from longstanding 
anoxaemia after inhalation of 50% oxygen”. Barach originally ascribed these neurological 
effects to a sudden change in cerebral oxygen tension. It was in 1949 that Donald59 first 
described a case of oxygen induced carbon dioxide retention. Following 12 hours of 
oxygen therapy, the PaCO2 of a patient with severe emphysema rose to 120 mmHg. The 
patient lapsed into a coma, but following withdrawal of oxygen, he recovered rapidly and 
had an abrupt fall in his PaCO2 to 60 mmHg. Donald postulated that this neurological 
effect was a result of hypoventilation due to removal of the anoxic stimulus to breathe. 
He suggested that administering oxygen intermittently would prevent carbon dioxide 
retention. 
Following this case report, further studies in the 1950s 60-62 described a number of cases 
in which hypercapnia developed in COPD patients after oxygen therapy. The cases 
describe the development of profound neurological effects ranging from  headache, 
muscle-twitching, coma and in some cases, death60. It soon became widely accepted that 
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patients with COPD were at risk of developing carbon dioxide retention from oxygen 
therapy and the mechanism for this was believed to be hypoventilation. 
One of the main contributors of our understanding of oxygen therapy and respiratory 
failure in COPD is from Dr Moran Campbell during the 1960s. Campbell disputed the use 
of intermittent oxygen therapy, arguing that this could potentially lead to more severe 
arterial hypoxaemia. He also argued that because of the shape of the oxygen dissociation 
curve, even a small increase in inspired oxygen would produce a useful increase in 
oxygen content and tissue supply63. Campbell recommended that patients presenting 
with respiratory failure secondary to acute exacerbations of COPD should be treated with 
continuous, controlled oxygen to prevent carbon- dioxide retention. 
In a subsequent paper64 in 1960, Campbell was the first to describe the Venturi mask and 
the concept of controlled oxygen delivery. He demonstrated how this specialised mask 
used air at a high flow-rate and with controlled oxygen enrichment, provided accuracy of 
delivery and minimised rebreathing. The prototype and early production models had a 
fixed Venturi orifice through which oxygen flowed at 2 l/min, entraining a much larger 
flow of air via holes in the loose fitting mask; a second inlet was supplied with oxygen at 
varying flow in order to adjust the concentration. This apparatus was modified to a single 
nozzle with different concentrations (24%, 28% and 35%) by modifying the size of the 
venturi orifice. Further studies 20 65-67 during this period confirmed the effectiveness of 
relieving hypoxaemia without causing CO2 retention using the Venturi mask. The Venturi 
mask is now universally accepted as the most accurate and safest way to administer 
oxygen to patients at risk of carbon dioxide retention. 
The effect of differing oxygen concentrations and magnitude of hypercapnia was studied 
in 1962 by Massaro and colleagues68. They administered 100% oxygen by face mask for 
10 minutes, 1-2 l/min by nasal cannula for 10 minutes and 1-2 l/min by nasal cannula for 
over 2 hours to patients with stable COPD and hypercapnia. They found that higher 
concentrations of oxygen would give greater rises in PaCO2   and they also showed that 
low flow oxygen could also cause CO2 retention which occurred over varied periods of 
time. 
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The Mechanism of Oxygen Induced Carbon Dioxide Retention 
Over the past 60 years, a number of studies have been conducted investigating the 
interesting and important mechanism of oxygen induced hypercapnia in COPD patients. 
These have been done on a variety of patients- stable and acutely unwell, spontaneously 
breathing and ventilated- using differing methods. These studies and changes in 
perception of the mechanism are discussed below. 
Following the early case reports and studies of carbon dioxide retention induced by 
oxygen in patients with emphysema, it was generally accepted that the most likely 
mechanism for this was due to a fall in ventilation due to relief of anoxia59 61. Previous 
work69 had demonstrated that these patients have a diminished response to carbon 
dioxide and low levels of oxygen took on a more important role in driving ventilation. It 
was postulated that on removal of this stimulus to breathe, a fall in ventilation would 
lead to a rise in PACO2 , a corresponding rise in arterial PCO2 and fall in pH. If the fall in 
ventilation was sufficiently large, carbon dioxide narcosis would ensue. 
In 1954, Prime and Westlake70 investigated the respiratory response to carbon dioxide in 
35 stable emphysematous patients. In support of earlier work, they found that on 
administering pure oxygen there was a fall in ventilation in 26 out of 35 of the 
emphysematous patients, compared to an average increase in ventilation observed in 
the control group. No patients with a normal initial PaCO2 showed increases in PaCO2. 
However, not all hypoxic patients had a fall in ventilation.  
The first study to suggest that other factors may be responsible for oxygen induced 
carbon-dioxide retention other than loss of hypoxic drive to breathe, was published in 
196571. Pain, Read and Read studied 54 patients with stable chronic lung disease. They 
made measurements of arterial blood gases and ventilation in a steady state and whilst 
breathing oxygen. They observed that there was not a close relationship between PaCO2 
and changes in ventilation, in particular, increases in PaCO2 occurred in the absence of 
comparable decreases of ventilation. They went on to propose that increases in the ratio 
of physiological dead space to tidal volume (Vd/Vt), also known as Bohr dead space, 
caused by reversal of hypoxic pulmonary vasoconstriction, may also be involved in 
increasing PaCO2. 
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In 1967, Lee and Read 72 provided scientific evidence to support the theory of release of 
hypoxic pulmonary vasoconstriction. They studied 58 patients with stable COPD. They 
measured arterial blood gases and mixed expired carbon dioxide using the Douglas bag 
method on air and after breathing oxygen. Using the Bohr equation (see Appendix 5),  
physiological dead space /tidal volume (Vd/Vt) ratio was derived from the simultaneous 
measurements of arterial and mixed expired carbon dioxide tension. Whilst breathing air 
the Vd/Vt did not increase significantly from baseline and at 15 minutes, but during 
oxygen breathing, there was an increase of  more than 0.05 in the Vd/Vt  in 39 out of 58 
subjects, and by less than this amount in the other 19 subjects. The authors agreed with 
the observations of Pain and colleagues, that the increase in Vd/Vt ratio due to increased 
blood flow to poorly ventilated regions of the lung is due to reversal of pre-existing 
regional pulmonary vasoconstriction and is at least partly responsible for CO2 retention 
during oxygen inhalation. 
It was in 1967 that Campbell delivered the J Burns Amberson Lecture: The Management 
of Acute Respiratory Failure in Chronic Bronchitis and Emphysema.73In this lecture he 
focused on exacerbations of COPD, emphasizing particularly on careful initial 
management with oxygen therapy. The assertion of the “loss of hypoxic drive” theory is 
usually attributed to his lecture. However, he is widely misquoted, and his exact words 
were “It is usual to attribute the rise in PaCO2 in these patients to removal of the hypoxic 
drive to ventilation, but I share the doubts of Pain 71 and co-workers that this is the 
whole story; changes in the pulmonary circulation may also be important”. 
The next landmark study in determining the mechanism of oxygen induced carbon 
dioxide retention came in 1980 from Aubier and colleagues74. This was also the first 
study on COPD patients in acute respiratory failure. They recruited 22 patients who were 
all severely hypoxaemic and hypercapnic at entry with mean values of PaO2 38mmHg ±2 
and PaCO2 65 mmHg ±3 mmHg respectively.  100% oxygen was administered for 15 
minutes and measurements of arterial blood gases and mixed expired CO2 were taken. 
These values were used to measure the Vd/Vt using the Bohr equation.  
Following the administration of oxygen, there was a transient decrease in minute 
ventilation, the nadir occurring at a mean of 71 seconds from the start of inhalation. The 
decrease in ventilation amounted to 18 ±2% of the control values.  However, minute 
ventilation increased and plateaued at about 12 minutes. The final ventilation 
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represented 93 ±6% of the control value. The initial decrease in ventilation was due to 
both a decrease in tidal volume and respiratory rate, but after 15 minutes of breathing 
oxygen, these were not significantly different from the corresponding room air values. 
PaCO2 was found to increase significantly in all subjects, average 23 ±5mmHg. However 
they did not find a correlation between the rise in PaCO2 and minute ventilation.  
Aubier and colleagues concluded that an initial reduction in minute ventilation in 
response to hyperoxia was observed in patients with COPD and respiratory failure. When 
compared to patients in a stable state, the rise in PaCO2 was of a greater magnitude and 
they proposed that the increase in PaCO2 may provide an excitatory influence on 
ventilation in this group of patients. 
They went onto argue that following prolonged administration of oxygen, the ventilatory 
response increases to essentially the same observed whilst breathing room air. This 
contradicts the common hypothesis that patients with COPD have a lower than normal 
respiratory sensitivity to changes in CO2 and rely on a strong hypoxic drive from 
peripheral chemoreceptors as their main chemical stimulus to breathe which is removed 
following the administration of oxygen.  
In addition, they argued that the observed rise in PaCO2 could not be explained by the 
“Haldane effect”, which may account for some of the increase, but not to the magnitude 
of a mean value of 23mmHg which was observed in these patients. An explanation for 
their findings of a rise in Vd/Vt  from 77% ±2 to 82% ±2 following the administration of 
oxygen represents shifts in pulmonary blood flow due to release of hypoxic pulmonary 
vasoconstriction. 
The findings of Aubier were supported by Sassoon and Colleagues in 198675. In this study, 
the hypoxic and hypercapnic drive of 17 stable COPD patients was examined. They 
hypothesised that if oxygen induced-hypercapnia was a consequence of diminished total 
minute ventilation, then patients who were susceptible would have a blunted 
hypercapnic drive, and an intact hypoxic drive; and patients who did not develop oxygen 
induced-hypercapnia should have an intact hypercapnic drive. In their study they also 
examined the contributions of carbon dioxide production, minute ventilation and 
physiological dead space to tidal volume ratio on oxygen induced hypercapnia. The Vd/Vt 
was calculated using the Bohr equation. 
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Sassoon found that on oxygen administration, the Vd/Vt and PaCO2 increased 
significantly. There was, however, no significant correlation between changes in the 
PaCO2 whilst breathing oxygen and hypercapnic or hypoxic drive which they measured by 
ventilatory and mouth occlusion pressures. Based on these observations, they concluded 
that oxygen induced hypercapnia was therefore not related to the control of ventilation. 
In 1991, Dunn76 and colleagues studied the effects of hyperoxia on 13 ventilator 
dependent patients with a history of COPD. They concurred with Aubier and Sassoon’s 
work that increases in Vd/Vt contribute to changes in PaCO2. However, by performing 
recruitment threshold measurements at normoxia and hyperoxia , they demonstrated 
that oxygen supplementation increased the level of inspired CO2 which induced 
spontaneous respiration over mechanical ventilation, indicating a suppression of hypoxic 
respiratory drive. 
In 1993, Berry and co-workers77 sought to determine the relationship between oxygen-
induced decreases in ventilation and mouth occlusion pressures (P0.1, an index of 
respiratory drive) in patients with COPD and the ventilatory responses to hypoxia. 
Fourteen patients with severe airflow obstruction FEV1 0.95 ± 0.41L with starting SpO2  
of 90.8 ±0.99 % on room air were administered supplemental oxygen (1-2L/min) or room 
air in a single blind fashion. Minute ventilation and mouth occlusion pressures were 
measured on air and oxygen. The tests were also repeated in hypoxic conditions (a 
reduction in O2 sats to 75%). On oxygen supplementation both ventilation and mouth 
occlusion pressures were reduced significantly, but there was no change in these 
measurements during hypoxic conditions. These findings concurred with Dunn’s, that 
respiratory drive plays a role in the mechanism of oxygen-induced hypercapnia. Although 
unlike other studies, only low flow oxygen was administered increasing saturations to 
95.2% ± 0.46, which may not have been sufficient to abolish vasoconstriction in the 
pulmonary circulation. 
Dick and co-workers78 recruited 11 patients with stable COPD who were oxygen 
dependent. At entry, the patients were hypoxaemic and hypercapnic: mean PaO2 
62.3mmHg and PCO2 58.7 mmHg with severe airflow limitation: mean FEV1 1.00 l/min. In 
order to clarify the relationship between the O2 induced change in ventilation and the 
ventilatory drive they measured the hypercapnic and hypoxic ventilatory response slopes 
(the expected change in ventilation as a function of ventilatory drive).  
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Following administration of 100% oxygen for 15 minutes, PaO2 and SaO2 increased 
significantly. The mean increase in PCO2 was 6.6 ± 3.3 mmHg, but the carbon dioxide 
production (VCO2) did not change significantly. 7 of 11 subjects decreased their minute 
ventilation at 15 minutes, but this did not achieve statistical significance. However there 
was substantial variation in minute ventilation in individual subjects. 
In addition the observed change in ventilation and the predicted change in ventilation  
were  not significantly different which the authors conclude suggests that the O2-induced 
change in ventilation is directly determined by the ventilatory response slopes to hypoxia 
and hypercapnia and the changes in SaO2 and PaCO2. 
In summary the authors concluded that the development of O2-induced hypercarbia is 
associated with only a small change in ventilation. The oxygen-induced decrease in 
ventilation due to suppression of hypoxic drive was almost equal to the expected 
increase in ventilation caused by the oxygen induced hypercarbia. 
The multiple inert gas elimination technique (MIGET) is a technique developed in the 
mid-1970s which has enhanced the understanding of the mechanism of the 
pathophysiology of pulmonary gas exchange in lung diseases. Because of its importance 
in determining V/Q inequalities and abnormal gas exchange, it will be discussed in some 
detail here.  
Multiple Inert Gas Elimination Technique 
As discussed in section 1.2 the three compartmental model of Riley and Cournand 
divided the lungs into (1) ideal lung where ventilation and pulmonary blood flow are 
equal; (2) shunt fraction in which the compartment remains perfused but not ventilated 
and (3) dead space in which lung units are ventilated but not perfused. These 
measurements were based on the arterial and expired pressures of O2 and CO2. Although 
this model defined the relationship between ventilation/perfusion ratios it did not 
provide information on extrapulmonary influences or changes that occur in the presence 
of gas exchange abnormalities. By using inert gases, the MIGET has two principle 
advantages: (1) it estimates the patterns of alveolar ventilation and pulmonary blood 
flow without disturbing either vascular or bronchomotor tone; and (2) it facilitates the 
unravelling of the extrapulmonary determinants (overall ventilation, cardiac output, and 
oxygen consumption) of abnormal gas exchange79. 
  
48 
The MIGET uses the simultaneous infusion of six inert gases. Inert gas measurements are 
then taken from three different sites: mixed venous (Pv), arterial blood(Pa) and mixed 
expired gas (Pe). For each inert gas , the retentions are calculated as the ratio between 
arterial partial pressure and mixed venous partial pressure (R=Pa/Pv) and the excretions 
as the ratio between mixed expired partial pressure and mixed venous partial pressure 
(E=Pe/Pv). By using a multicompartmental approach with reinforced smoothing, the 
retentions of the six inert gases allow the estimations of continuous distribution of the 
pulmonary blood flow against V/Q ratios on the logarithmic scale. Similarly, the 
excretions of the six inert gases provide an estimation of the distribution of alveolar 
ventilation against V/Q80.  
Figure 6. Ventilation-perfusion distributions in a healthy subject  
 
   
Ventilation (o) and perfusion (•) are plotted against ventilation-perfusion (VA/Q) ratio on 
a logarithmic scale in a resting young, healthy adult breathing room air. Both ventilation 
and blood flow curves are centred (first moment) around a VA/Q ratio of 1 and they are 
narrow (second moment). No perfusion to low VA/Q units (VA/Q<0.1) nor ventilation to 
high VA/Q areas (VA/Q>0.10) are observed. Note also the absence of shunt. Each 
individual data point represents a particular amount of blood flow (•) or alveolar 
ventilation (o) to the corresponding pulmonary compartment (VA/Q ratio). Total cardiac 
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output corresponds to the sum of the 50 blood flow points and total alveolar ventilation 
is the sum of the 50 ventilation points. From Roca, Thorax 199380 
The dispersion of pulmonary blood flow (log SD Q) and dispersion of alveolar ventilation 
(log SD V) are widely used overall descriptors of the amount of mismatch. These variables 
will provide a quantitative estimate of mismatching only when the V/Q distribution is 
unimodal and showing a logarithmically normal distribution. With other distributions it 
should be regarded as an index of abnormality only. In many patients with lung disease 
the most striking finding is the widening of the dispersion with or without the 
appearance of a true shunt (zero V/Q); in other disease states, however, bimodal or even 
trimodal V/Q distributions have been recovered. The example below shows ventilation-
perfusion distributions in two patients with COPD. 
 
Figure 7. Ventilation-perfusion mismatch in COPD 
 
 (A)Ventilation-perfusion ratio distribution in a patient with emphysema-type COPD. 
Note the bimodal pattern of ventilation distribution (o) with areas of high VA/Q ratio. 
(B) Ventilation-perfusion ratio distribution ratio in a patient with bronchitis-type 
COPD. The blood flow distribution (•) is bimodally shaped due to the presence of 
alveolar units with low VA/Q ratio. From Agusti Thorax 199381 
   
Robinson and colleagues82 were the first group to use the MIGET to investigate the 
mechanism of oxygen induced hypercapnia in acute exacerbations of COPD. In this study, 
22 patients with AECOPD were recruited within 72 hours of admission. Baseline 
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measurements of FEV1 and FVC, and PaO2 and PaCO2 on room air were taken. Other 
measurements taken were cardiac output and minute ventilation. Ventilation-perfusion 
distribution was measured using MIGET. Specific measurements used were log SD Q , log 
SD V and Disp R-E a measurement of retention and excretion of the 6 gases reflecting 
V/Q inequality. Patients were then given 100% oxygen via a sealed nasal mask for at least 
20 minutes. 
Following the administration of oxygen, patients were classified as being retainers 
(Group R) if there was a rise in CO2 of ≥ 3mmHg or non-retainers (Group NR) if there was 
less than a 3mmHg rise in CO2.  Of the 22 patients recruited, 12 patients were retainers 
and 10 patients were non-retainers. The degree of airflow obstruction was similar in both 
groups with a mean FEV1 of 0.71 l/min and 0.80 l/min in Group R and Group NR 
respectively. The baseline PaO2 on room air, however, was significantly lower in Group R, 
54.5mmHg ±9.4 (mean ± SD) compared with 62.7 mmHg ±10 in the NR group. Baseline 
PaCO2 was higher in Group R 56.3 ±13.6 mmHg compared with Group NR 49.7 mmHg 
±8.3, but this difference was not significant.  
Following the administration of oxygen, PaCO2 in group NR decreased by -1.3 mmHg ± 
2.2mmHg and in increased in Group R by +8.3mmHg ± 5.6 mmHg. 
Minute ventilation fell in Group R from 9.0 L/min ± 2.0 to 7.2 ±1.6, a 20% reduction, 
following oxygen administration. This was not demonstrated in Group NR, where there 
was a slight increase from 9.8 ±2.3 to 9.9 ±2.5. 
In terms of the ventilation and perfusion distributions, the log SD Q increased in both 
groups. However the log SD V increased only in Group R, but not Group NR. Bohr dead 
space (Vd/Vt) calculated by MIGET increased in R group, but not in NR group. 
The authors conclude that the significant reduction in minute ventilation seen in Group 
R, but not in Group NR makes this the likely mechanism of oxygen induced hypercapnia. 
In addition the increase in dispersion of pulmonary blood flow seen in both groups of 
patients, is due to release of hypoxic pulmonary vasoconstriction and does not 
discriminate between retainers and non-retainers. 
The increase in dispersion of alveolar ventilation seen in Group R is only likely to 
represent an increase in true alveolar dead space. The authors have proposed an 
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additional mechanism in that hypercapnia may lead to bronchodilatation increasing 
ventilation to some parts of the lung resulting in increasing alveolar dead space and 
worsening hypercapnia. 
Criticisms of this study83 argue that a rise in pCO2 of 3mmHg to divide the 2 groups of 
patients is not clinically significant. In addition the patients, in contrast to the Aubier74 
study, were not adequately hypoxaemic to allow the mechanism of hypoxic pulmonary 
vasoconstriction to play a physiological role.  
Santos and colleagues 84 have also used MIGET, but in mechanically ventilated patients. 
Of the patients that were studied, 8 patients had acute lung injury (ALI) and 4 patients 
had COPD as their predominant pathology. 
All patients had baseline measurements whilst breathing maintenance FiO2, then at 30 
and 60 minutes whilst breathing FiO2 100%, and then again at 20 minutes whilst on 
maintenance FiO2.  
They found that in patients with ALI, PaCO2 increased by 4mmHg at 30 and 60 minutes, 
and intrapulmonary shunt increased from 16% at baseline to 22% and 23% at 30 and 60 
minutes respectively. In patients with COPD the PaCO2 increased by 4 and 5 mmHg and 
the dispersion of pulmonary blood flow increased significantly. 
The authors conclude that in patients with ALI, hyperoxia deteriorates intrapulmonary 
shunting to collapse of unstable alveolar units with very low ventilation-perfusion ratios, 
as opposed to patients with COPD, in whom the dispersion of pulmonary blood flow is 
disturbed, suggesting release of hypoxic pulmonary vasoconstriction.  
In summary, there have been a number of well designed trials investigating the 
mechanisms of oxygen-induced hypercapnia in COPD. Initially this was believed to be due 
to suppression of hypoxic drive to breath but then through the 1960s and 1970s the 
mechanism of hypoxic pulmonary vasoconstriction has taken favour. More recently 
however, these data have been challenged using more powerful investigative techniques 
showing that both mechanisms play a part.  
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Clinical Studies and Audits of Oxygen in COPD 
The mechanism by which oxygen therapy and hyperoxia leads to hypercapnia in COPD 
has been discussed in detail. The next section brings together the clinical relevance of 
this in which I will present studies and audits over the years which have described 
outcomes and adverse events. 
An important study in determining the prevalence of respiratory acidosis in patients with 
AECOPD was published by Plant and co-workers85 in 2000. They undertook a one year 
prospective study identifying patients admitted to 3 large hospitals in the United 
Kingdom with AECOPD to determine the prevalence of respiratory acidosis and the 
relationship with oxygenation. Of the 983 patients studied, 11 required immediate 
intubation and 22 patients were admitted to intensive care. ABGs were performed in 
94.6% of patients on admission, nearly half were found to have hypercapnia and 20% had 
a respiratory acidosis (pH <7.35). Patients with acidosis had between a 6- and 8-fold 
increased risk of ICU admission depending on their pH, when compared with non-acidotic 
patients. 
The pH was inversely correlated with arterial oxygen tension in the patients who were 
hypercapnic, with more than 50% of patients with a PaO2 of >10kPa being acidotic 
indicating an association between acidosis and oxygen therapy.  
Subsequent audits have supported the association of oxygen therapy and acidosis. In 
2002 Denniston and colleagues86 undertook a prospective audit of 101 admissions of 
AECOPD. They found that over 50% received a FiO2 of 0.28 in their pre-hospital and 
hospital emergency management. The mortality in this group was 14% compared with 
2% in patients that received ≤ 28% oxygen. Similarly a quarter of the patients in the high 
flow group had evidence of a severe acidosis, compared with 3% in the low flow group. 
A retrospective audit carried out in Melbourne, Australia87 showed similar findings. Of 
the 65 AECOPD studied, 66% had ABGs of which nearly half showed hypercapnia. 
Patients who received >4 l/min were more acidotic, had higher PaO2 and PCO2 readings 
and a longer length of hospital stay. There was also a greater need for NIPPV and HDU or 
ICU. 
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In another UK study, Durrington et al88 performed an interventional audit. The first 
involved 108 admissions which again showed an association with high flow oxygen and 
lower pH and higher PaCO2. Following the first audit, the paramedics were educated and 
advised that patients with COPD should receive oxygen via a 28% venturi mask to keep 
oxygen saturations between 88-92%. The second audit showed that the proportion of 
patients receiving high flow oxygen was reduced to <1%, but complication rates 
remained unchanged. In addition, they showed that longer ambulance journeys and 
administration of high flow oxygen was clearly associated with a worse outcome (death, 
ventilation or IV aminophylline) 19.4% of ambulance journeys were under 30 minutes 
and 60% if ambulance journeys were greater than 30 minutes.   
Conversely, to other reported data, Gomersall et al89 found the patients with a higher 
PaO2 did not have worse outcomes compared to those with a lower PaO2. In their study 
17 patients with AECOPD were randomised to oxygen therapy to keep their PaO2 above 
50mmHg whilst the other group with 17 patients were randomised to oxygen therapy to 
keep their PaO2 above 70mmHg. The latter group had no poor outcomes whilst 2 patients 
in the low oxygen tension group died and another required mechanical ventilation. 
Moloney and colleagues performed90 a study in 24 patients with AECOPD presenting to 
the Emergency Department with hypercapnic respiratory failure. Each patient was 
administered controlled oxygen via a venturi mask to maintain SpO2 of 91-92%, for a 
period of 2 hours. Three patients developed CO2 increases of >1kPa, and of these one 
patient developed a respiratory acidosis with a pH <7.25. They also observed that the 
patients who were more hypercapnic at baseline were more at risk of developing 
worsening hypercapnia. Whilst the authors concluded the risk of CO2 retention is low, 
there was no control arm in the study. Furthermore, the oxygen was only titrated at 
intervals of 20 minutes during which time the subjects PaCO2 may have risen significantly.  
The Royal College of Physicians National COPD Audit 200891  reported on nearly 10,000 
admissions of AECOPD nationwide. Of these, 20% were acidotic on admission and 30% 
had received high-flow oxygen before ABGs were taken. 12% required ventilator support. 
Reassuringly, however, the proportion of patients receiving high-flow oxygen prior to 
ABGs has improved from 42% in the 2003 Audit. 
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The first randomised controlled trial investigating the effect of high flow compared with 
titrated oxygen in AECOPD was recently published in the British Medical Journal92. In this 
Tasmanian study, paramedics were randomised to administer titrated oxygen (to 
maintain SpO2 between 88 to 92%) or high flow oxygen to patients with an AECOPD in 
the pre-hospital setting. 405 patients were recruited during the trial period, with 214 of 
these having a confirmed diagnosis of COPD on pulmonary function testing. Their 
primary outcome variable was pre-hospital or in-hospital mortality. Protocol violations 
occurred in 37% of the study population (56% in the titrated arm and 21% in the high 
flow arm). In the intention to treat analysis, the authors found a significantly lower risk of 
death in the titrated group 7/179 (4%) compared with 21/226 (9%) in the high flow group 
(relative risk 0.42, 95% confidence interval 0.20 to 0.89). In the subgroup of patients with 
confirmed COPD (n=214) mortality was reduced even further (0.22, 0.05 to 0.91). In the 
intention to treat analysis for secondary outcomes, there were no significant differences 
between treatment arms for length of hospital stay, requirement for ventilation, or 
arterial blood gas measurements. In the per protocol analysis, death rates were similar 
for the intention to treat analysis for all patients and the subgroup confirmed with COPD, 
although the differences did not reach statistical significance. The per protocol analysis, 
did however, show patients who received titrated oxygen were less likely to have 
respiratory acidosis (p=0.01) due to acute hypercapnia (p=0.02). 
The authors recognise the main limitation of their study namely the lower than expected 
rate of adherence to study protocols, in both prehopsital oxygen treatment and the 
measurement of arterial blood gases on arrival at hospital. Paramedics violated the 
protocol by administering high flow oxygen to over half the patients in the titrated arm. 
Feedback indicated that some paramedics were concerned about insufficient delivery of 
oxygen in distressed patients despite adequate saturations. 
This randomised controlled trial of oxygen therapy in AECOPD, provides robust evidence 
to support the British Thoracic Society’s guideline13 to administer oxygen only at 
concentrations sufficient to maintain adequate oxygen saturations. 
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Minimising oxygen induced carbon-dioxide retention COPD 
The BTS Guideline for Emergency Oxygen use in Adult Patients13 describes a number of 
ways harm can be minimised from oxygen use in COPD. Two of these are discussed 
below 
Oxygen Prescription  
Medical oxygen is a drug. Like all drugs and other treatments, oxygen has potential risks 
as well as benefits and there is a need to prescribe it for defined indications, with 
specification of the dose and method of delivery, the target saturation range and for the 
patient’s response to be monitored. Numerous audits93-99 have demonstrated the 
suboptimal prescription of oxygen therapy by medical staff. An interventional audit of 
patients on a respiratory unit reported that the introduction of an oxygen prescription 
chart significantly improved oxygen prescription from 55% to 91%, and accurate 
prescription from 7% to 77% of patients96.  
It recommended that all healthcare facilities have a standard oxygen prescription chart 
or designated section and oxygen should be prescribed by a doctor with a target 
saturation range. Nurses should sign the drug chart at every drug round and check that 
the patient is receiving oxygen therapy correctly and is achieving the required target 
saturation. The aims of the charts are to improve standards of prescribing and ensure 
correct administration particularly in those who are at risk. 
Further on in this thesis, I will present an interventional audit of oxygen prescription  and 
its effects on clinical practice. 
 
Oxygen Alert Cards and Venturi Masks 
Oxygen alert cards and venturi masks have been shown to reduce the potential risks of 
respiratory acidosis in the pre-hospital and emergency setting in patients with COPD100. A 
study of 18 patients were administered with an “O2 Alert” card (see figure 8) and 24% 
venturi mask. The patients were instructed to show these to ambulance and A&E staff 
who will then use the mask to avoid excessive oxygenation. Of the 18 patients, 14 were 
readmitted on 69 occasions. Of these audited admissions, 63% were managed in the 
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ambulance, in line with card-holder protocol. This figure rose to 94% in the accident and 
emergency department. 
 
Figure 8. Example of oxygen alert card 
From Gooptu, Emergency Medicine Journal 2006100 
 
  
The BTS recommend patients with COPD who have had an episode of hypercapnic 
respiratory failure should be issued with an oxygen alert card and with a 24% or 28% 
Venturimask.
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Chapter 1.6 Oxygen Therapy in Asthma 
  
Until recently, high flow oxygen has been universally recommended in the treatment of 
acute severe asthma. It has been perceived as a safe therapy, without the risks of 
hypercapnia which are associated with oxygen use in AECOPD. However, the recently 
published BTS Emergency Oxygen Guidelines13 and Asthma guidelines update101 now 
recommend oxygen only for the treatment of hypoxaemia to aim for a target oxygen 
saturation of 94-98%. In this section I will review the evidence for oxygen therapy in 
acute severe asthma. 
Hypoxaemia is a common sequelae in acute asthma102 103. The treatment for hypoxaemia 
is to administer oxygen but there are very few studies investigating the physiological and 
clinical effects of oxygen in asthma. Most of the studies are laboratory based study with 
only one published randomised controlled trial. I have broadly divided these studies into 
the effects of oxygen on ventilation-perfusion and the effects of oxygen on arterial 
carbon dioxide pressures. 
Effects of Oxygen on ventilation-perfusion 
One of the earliest studies published on the effects of oxygen in acute severe asthma was 
published in 1967104. In addition to oxygen, Field investigated the effects of posture, 
isoproterenol and atropine on ventilation-perfusion relationships. Only the former will be 
discussed here. Twenty-six asthmatics were studied during an acute exacerbation. 
Following baseline measurements on air, 100% oxygen was administered for 20 minutes 
and the Vd/Vt calculated from the Bohr equation using expired CO2. There was a highly 
statistically significant increase in Vd/Vt on breathing oxygen and also an increase in 
mean PaCO2 which occurred despite an increase in minute ventilation. Furthermore the 
results in the sitting and supine positions demonstrated the same trends suggesting that 
changes in pulmonary artery pressure were unlikely to contribute to Vd/Vt increases. 
Field concluded that these changes were brought about from release in hypoxic 
pulmonary vasoconstriction. 
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Similar observations were made by Valabhji105 in 1968. As well as changes in 
physiological dead space-tidal volume ratio, he also investigated the effects of oxygen on 
the A-a gradient.  In a single-blind fashion twelve asthmatics breathed air then 100% 
oxygen for 20 minutes during the acute phase of the illness and again at least a week 
later when asymptomatic. He found that in the acute phase the A-a gradient and Vd/Vt 
ratio was raised in all patients and clinical recovery was associated with return of these 
parameters to normal. Furthermore changing from air to oxygen breathing resulted in a 
significant increase in mean Vd/Vt in both phases. The PaCO2 was low or normal through 
all phases of the study. The author concluded that the mechanism for these changes in 
Vd/Vt are secondary to redistribution of pulmonary blood flow due to either a reduction 
in cardiac output and pulmonary artery pressure or to reversal of pulmonary 
vasoconstriction. As these changes were also demonstrated in the asymptomatic phase 
Valabhji proposes that abnormalities in ventilation-perfusion still persist in the lung 
following clinical recovery. 
 Wagner 106 was the first to use the MIGET to demonstrate V/Q mismatch in asthmatic 
subjects, although these were asymptomatic patients. His study showed a bimodal 
distribution of Va/Q ratios, and essentially no shunt. However, further studies 107 108 have 
not found such an extent of Va/Q inequality despite similar airway obstruction. 
A series of later studies confirmed changes in V/Q distributions following the 
administration of oxygen in asthmatics using the MIGET. These studies include a 
spectrum of severity: exercise-induced108, moderately severe109and acute severe 110 
asthma.  Of note Corte et al’s study109 of 10 moderately severe symptomatic asthmatics 
showed  four whom had marked V/Q inequality and the remaining six had minimal V/Q 
inequality. Following the administration of 100% oxygen both groups developed 
widening of their V/Q distributions but this was more marked in the six with minimal V/Q 
inequality. The authors suggest that a greater degree of compensatory pulmonary 
vasoconstriction is necessary in this latter group which is abolished to a greater extent on 
the administration of oxygen.  
Rodriguez-Roisin111 and colleagues were the first group to study V/Q abnormalities in 
life-threatening attacks of asthma using MIGET. All eight patients studied in the first 48 
hours of admission required assisted ventilation. Following the administration of 100% 
oxygen V/Q mismatching substantially worsened such that the index of blood flow 
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dispersion (log SDQ) rose significantly. There were no significant changes on pulmonary 
artery pressure or cardiac output, but there was a significant increase in shunt. This study 
also demonstrated an increase in PaCO2 on maintenance oxygen (mean FiO2 0.37 ) to 
100% oxygen  from a mean of 39.8 mmHg (±SD 9.0) to a mean of 44.7 (± SD 8.7). 
Effects of oxygen on carbon dioxide levels 
Whilst the effects of oxygen on the pulmonary circulation provide important information 
on gas exchange abnormalities in acute severe asthma, there have been very few studies 
looking primarily at the effects on PaCO2. 
In 1979 Rudolf and colleagues19 compared the response to oxygen in ten patient with 
COPD and eight patients with asthma. The subjects breathed oxygen 4 l/min via a 
medium concentration mask for 60 minutes. Arterial blood gases were taken during 
oxygen inspiration and at 15 minute intervals following the cessation of oxygen. In both 
groups the PaCO2 rose but this rise was not significant in the asthmatic group. Following 
cessation of oxygen it took up to 10 minutes for the PaCO2 to return to baseline values. In 
addition the PaO2 fell to values lower than had been obtained before oxygen was given. 
Chien and colleagues112have provided useful data on the effects of uncontrolled oxygen 
on PaCO2 and FEV1. Following admission to the emergency department, 37 asthmatic 
subjects (FEV1 49 ± 3.6% predicted) were administered high-flow uncontrolled oxygen via 
a non-rebreathing face mask. Arterial blood gases were taken at baseline and during 
oxygen administration. Twenty-five patients had a rise in PaCO2 during oxygen breathing 
ranging from 1 to 10 mmHg (mean 4.1 ± 0.6 mmHg). In seven of the patients hypercapnic 
respiratory failure developed and in six patients it worsened. A fall in FEV1 was also 
demonstrated from 49.1 ± 3.6 % predicted to 47.0 ± 3.5 %. The authors do not comment 
on the mechanism for the rise in PaCO2 but state that rises >2mmHg cannot be attributed 
to the Haldane effect.  
The only randomised control trial of oxygen therapy was published in 2003 by Rodrigo 
and colleagues 113. This study was undertaken in two Emergency Departments in 
Uruguay.  Seventy-four patients with acute asthma were randomly assigned to receive 
28% oxygen via a standard face mask or 100% via a non-rebreathe facemask for 20 
minutes.  Measurements of PEFR, respiratory rate, heart rate and arterial blood gases 
were taken at baseline and at the end of oxygen administration. The primary outcome 
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variable was PaCO2 at the end of oxygen administration. The patients received 
bronchodilators after 20 minutes of oxygen therapy. 
The patients in this study had severe airways obstruction (mean PEFR, 41.0 ± 12.1% of 
predicted), moderate hypoxaemia (mean PaO2, 77.8  ±12.9mmHg), hypocapnia (mean 
PaCO2 36.4 ±4.4mmHg) and normal pH (7.39 ± 0.02). Patients in the 28% O2 group 
experienced a slight fall in their PaCO2 (-1.3 ±4.0 mmHg) in contrast to the 100% O2 group 
who showed an increase in PaCO2 (+1.8 ±3.9 mmHg). This magnitude of the increase was 
seen particularly in those patients with raised PaCO2 before treatment. A post hoc 
analysis was performed to look at the proportions of patients who had a rise in PaCO2 
>2mmHg which showed a greater proportion in the 100% O2 group (42.1%) compared to 
the 28% O2 group (16.6%), p value 0.02. 
The authors conclude that this rise in PaCO2 seen in the 100% O2 group is likely to be 
explained by release of hypoxic pulmonary vasoconstriction rather than the Haldane 
effect or changes in minute ventilation and that this rise is greatest in the patients with 
the most abnormal baseline condition. They advise against the use of uncontrolled high-
flow oxygen and oxygen dose in severe asthma should be variable and based on 
achieving target SpO2. 
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Chapter 1.7 Oxygen Therapy in Other Disorders 
 
In the two preceding chapters I have presented studies of the use of oxygen in COPD and 
asthma of which in the former there is a reasonably substantial body of evidence. There 
are very few studies investigating the use of oxygen in other respiratory disorders. 
In this next section, I will give an overview of the use of oxygen in non-respiratory 
disorders and the evidence base to support its use in myocardial infarction, stroke and 
other medical emergencies. 
  
Myocardial Infarction 
Oxygen has been used in the treatment of myocardial infarction (MI) and acute coronary 
syndromes for over 100 years114.  The rationale for its longstanding use is that it 
increases oxygen delivery to the ischaemic myocardium, thereby reducing the size of the 
MI and improving clinical outcomes. Up until recently current international guidelines115 
116 have recommended the use of supplemental oxygen in the treatment of MI, even in 
the absence of hypoxaemia. As a result, emergency calls to ambulance services because 
of chest pain have been treated with high concentration oxygen.  
The haemodynamic effects of hyperoxia in MI have been well documented.  Studies in 
man have shown that oxygen reduces cardiac output and stroke volume and increases 
the mean arterial pressure and systemic vascular resistance42-45 117 118. There is also 
substantial evidence that arterial oxygen tension is a major determinant of coronary 
artery regulatory tone,119 120 and that high concentration oxygen therapy resulting in 
hyperoxia reduced coronary artery blood flow121-126. The magnitude of the reduction in 
coronary artery blood flow with hyperoxia may be substantial in patients with coronary 
artery disease.  This has been shown with the measurement of intracoronary Doppler 
flow to be in the order of 20-30% with an associated 23-40% increase in coronary 
resistance122 123. 
To identify the clinical significance of the above haemodynamic effects, we recently 
performed a systematic review 127to identify randomised placebo-controlled trials of 
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oxygen therapy in the treatment of acute MI. Our search revealed only two RCTs of high 
flow oxygen therapy in the first 24 hours after an uncomplicated MI. The first, 
undertaken by Rawles and Kenmure128 in 1976, pre-thrombolysis,  randomised 200 
patients to receive either 6 l/min of oxygen or compressed air for 24 hours in a double-
blind controlled fashion. There were 9/80 (11.3%) deaths in the oxygen group and 3/77 
(3.9%) in the air group, relative risk of death 2.9 (95% CI 0.8 to 10.3, p=0.08). The 
maximum serum aspartate aminotransferase level which was used as a surrogate for 
infarct size was higher in the oxygen group compared to the air group. The authors 
concluded that there was “suggestive evidence of a deleterious effect of oxygen.” 
The only other RCT of oxygen therapy in MI129 was a non-blinded study randomising 50 
patients to 4 l/min oxygen or room air for 24 hours. However, this study was not 
designed to investigate infarct size or mortality, and so did not report which group the 
one death occurred in.  
In March 2010, the National Institute for Clinical Excellence published a guideline “Chest 
pain of recent onset”130 which now recommends oxygen should not routinely be 
administered to patients with chest pain and only offered if patients SpO2 is <94% aiming 
for SpO2 94-98%. 
In summary, there is little evidence to support the routine use of high-flow oxygen in the 
treatment of uncomplicated MI. The balance of the limited evidence that does exist, 
suggests that the routine use of oxygen in this situation may increase infarct size and 
possibly increase the risk of mortality. 
 
Stroke 
There has been only one randomised trial of oxygen therapy in stroke131. This study 
randomised nearly 300 patients with stroke, within 24 hours of presentation, to 100% 
oxygen or no additional oxygen for 24 hours. Overall, there was no difference in 
mortality in the two groups, but for patients with minor or moderate strokes, one year 
survival was 82% in the oxygen group and 91% in the control group (OR 0.45; 95% CI 0.23 
to 0.90; P=0.023). The authors propose the mechanism for this to be secondary to a 
reduction in cerebral blood flow due to the formation of oxygen free radicals.  Based on 
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this sole study, guidelines, recommend that patients with stroke should receive 
supplemental oxygen only if this treatment is required to achieve an oxygen saturation of 
94-98%. 
 
Resuscitation  
The Resuscitation Council UK, in their Advanced Life Support guidelines 132 recommend 
that high concentration oxygen is administered to all adult patients requiring 
cardiopulmonary resuscitation. This recommendation is based on Grade D evidence. 
Until recently there has been no clinical data to investigate the effects of hyperoxia 
following return of spontaneous circulation from cardiac arrest. There are numerous 
laboratory investigations which have demonstrated that reperfusion after an ischaemic 
insult is associated with a surge of reactive oxygen species which possibly trigger cellular 
injury and apoptosis, and this may be accelerated by hyperoxia which worsens the 
severity of oxidative stress.  As such, the administration of high concentrations of 
supplemental oxygen to patients after cardiac arrest has come into controversy133. The 
only clinical data available is from a study published recently in JAMA in 2010134. Using 
data from the project IMPACT critical care database of intensive care units, 6326 patients 
were included in this observational study. All patients were aged over 17 years, had 
suffered a nontraumatic cardiac arrest and received cardiopulmonary resuscitation 
within 24 hours prior to ICU arrival. Patients were divided into three groups based on 
PaO2 on their first ABG performed within 24 hours of arrival to ICU. Hyperoxia was 
defined as PaO2 ≥300mmHg, hypoxia PaO2 <60mmHg and normoxia not classified as 
either hyperoxia or hypoxia. Of 6,326 patients, 1156 had hyperoxia (18%), 3999 had 
hypoxia (63%) and 1171 had normoxia (19%). The primary outcome variable of in-
hospital mortality was highest in the hyperoxia group (732/1156; 63% [95% CI, 60%-
66%]) compared with the hypoxia group (2297/39999; 57% [95% CI, 56%-59%]) and the 
normoxia group (532/1171; 45% [95% CI 43%-48%]).  The hyperoxia group had 
significantly higher in-hospital mortality compared with the normoxia group (proportion 
difference , 18% [95% CI, 14%-22%]; P<0.001) and also compared with the hypoxia group 
(proportion difference, 6%[95% CI, 3%-9%]; P<0.001). In addition, amongst hospital 
survivors, patients with hyperoxia had a lower proportion of discharges from the hospital 
as functionally independent compared with patients who were normoxic (29% vs 38%, 
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respectively proportion difference, 9% [95% CI, 3-15%]; P=0.002). Hyperoxia was found 
to be a significant predictor of in-hospital death (OR, 1.8 [95% CI, 1.5-2.2]) which is an 
independent effect that persists after adjusting for all other significant risk factors 
including age, preadmission functional status and significant physiological factors. In the 
secondary analysis using a PaO2  of ≥ 400mmHg to define hyperoxia, mortality was even 
greater in the hyperoxia group. 
Whilst this present study is only an observational study suggesting an association 
between arterial hyperoxia and poor outcomes after cardiac arrest, it provides clinical 
evidence which is contrary to current international guidelines. There is a clear need for 
clinical trials of controlled reoxygenation in adults resuscitated from cardiac arrest.  
In neonates there is a large body of evidence that hyperoxia may be harmful in 
resuscitation due to slowing of blood flow in newborn preterm infants135 and the 
generation of oxygen free radicals, which have a role in reperfusion injury after 
asphyxia136 . A meta-analysis of five trials137reported a significant benefit on mortality for 
infants resuscitated on air (relative risk 0.71 (95% CI 0.54 to 0.94), risk difference -0.05 (-
0.08 to -0.01)).  
 
Obstetrics 
Oxygen is routinely given for difficult labour or foetal distress with the rationale that this 
may improve oxygen supply to the foetus. In 2003, a Cochrane systematic review failed 
to identify any randomised-controlled trials of oxygen use in foetal distress138. Two trials 
which looked at routine oxygen use in the second stage of normal labour showed a 
significant lowering of pH in the cord blood of the women given oxygen. Lowering of the 
pH in this setting is highly suggestive of lower blood flow resulting in less overall oxygen 
delivery.  A study139 not included in this review, however, did not show any change on 
foetal and maternal blood vessels flow following maternal oxygen administration.  
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Chapter 1.8 Aims of this Thesis 
 
Oxygen therapy remains a cornerstone of modern medical practice. In this introduction I 
have highlighted that there is very little in the way of well conducted clinical trials to 
support its routine use. Furthermore the potential detrimental effects of hyperoxia, in 
other conditions aside from AECOPD, need to be elucidated. In this thesis I will focus on 
the prescription of oxygen therapy, add to what is known on oxygen therapy in AECOPD 
and investigate its use in the treatment of other acute and chronic respiratory disorders 
where currently little evidence exists. The body of work is made up of two audits and 
three randomised controlled trials. 
 
AUDITS 
Audit 1: An Audit of the effect of oxygen prescription charts on clinical practice 
Aims: To obtain a “snapshot” of the use of oxygen in Wellington Hospital, a tertiary 
referral centre in New Zealand, and investigate whether the introduction of a new drug 
chart with an oxygen prescription section would improve hospital-wide prescription, 
administration and monitoring of oxygen therapy. 
 
Audit 2: An Audit of pre-hospital oxygen therapy in acute exacerbations of chronic 
obstructive pulmonary disease 
Aims : The three main aims of this study are to determine whether the management of 
AECOPD by the Ambulance Service is consistent with local and international guidelines, 
whether it is possible to identify particularly high risk patients based on the severity of 
their underlying disease or their status at presentation, and whether the amount of 
oxygen administered in the ambulance is associated with poor outcomes. 
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RANDOMISED CONTROLLED TRIALS 
RCT 1: Randomised controlled trial of high concentration versus titrated oxygen therapy 
in community-acquired pneumonia 
  
Aims: To investigate the effects of high concentration oxygen therapy on PaCO2 in 
patients presenting to the Emergency Department with suspected community-acquired 
pneumonia. 
 
RCT 2: Randomised controlled trial of high concentration versus titrated oxygen therapy 
in acute severe asthma 
Aims: to investigate the effects of high concentration oxygen therapy on PaCO2 in 
patients presenting to the Emergency Department with acute severe asthma 
 
RCT 3: Randomised double-blind cross-over study of the effects of hyperoxia in obesity 
hypoventilation syndrome 
 
Aims: To investigate whether breathing 100% oxygen results in worsening hypercapnia in 
subjects with OHS and to investigate the underlying mechanisms of any effect by the 
measurement of minute ventilation and physiological dead space. 
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SECTION 2 AUDITS OF OXYGEN THERAPY 
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Chapter 2.1 An audit of the effect of oxygen prescription charts on clinical 
practice 
 
2.1.1 Introduction 
 
Like all drugs and other treatments, oxygen has potential risks as well as benefits. The 
National Patient Safety Agency have recently produced a rapid response report140 
detailing nearly 300 serious incidents which were related to inappropriate administration 
and monitoring of oxygen between December 2004 and June 2009. Of these incidents, 
poor oxygen management appears to have caused nine deaths and may have 
contributed to a further 35 deaths. Clearly, there is a need to prescribe it for defined 
indications, with specification of the dose and method of delivery, the target saturation 
range and for the patient’s response to be monitored.  To facilitate this approach, the 
British Thoracic Society guideline recommends that every hospital should have a 
designated oxygen section on the drug chart on which oxygen should be prescribed and a 
target oxygen saturation range stated13.   
 
In support of this recommendation, an audit of patients on a respiratory unit reported 
that the introduction of an oxygen prescription chart significantly improved oxygen 
prescription from 55% to 91%, and accurate prescription from 7% to 77% of patients96 
This audit, however, did not report whether the improved prescription changed clinical 
practice in terms of assessment prior to commencing oxygen therapy, monitoring or 
titration which is the ultimate objective in improving prescribing standards.  Certainly 
there is a well documented need to improve current practice, as numerous audits have 
demonstrated the suboptimal prescription of oxygen therapy by medical staff, mostly 
among medical and respiratory patients93-99.  
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2.1.2 Objectives 
 
1. To obtain a “snapshot” of the use of oxygen in Wellington Hospital, a tertiary 
referral centre in New Zealand 
2. To investigate whether the introduction of a new drug chart with an oxygen 
prescription section would improve hospital-wide prescription, administration 
and monitoring of oxygen therapy. 
 
2.1.3 Methods 
 
Prior to commencing the audit, a pilot audit was performed to ensure the data collection 
sheets fulfilled the purpose of the audit. An example of the final data collection sheet is 
shown in Appendix 1. Written consent was obtained from the hospital’s audit 
department.   The first audit was performed between April 2007 and May 2007 in 
Wellington Hospital, Capital & Coast District Health Board, Wellington, New Zealand. All 
hospital inpatient areas were included except for the neo-natal unit, paediatric ward, 
psychiatric ward, emergency department (ED) and intensive care unit. The first audit, 
prior to introduction of a new drug prescription chart, occurred on three separate days, 
at least two weeks apart. I, co-ordinated the auditing, with four other co-workers. All 
patients were included unless they were off the ward at the time of the audit or they had 
been included in the preceding audit. Every patient was viewed to see if they were 
receiving oxygen at the time of the audit. Each patient’s hospital records and observation 
charts were reviewed and information on monitoring prior to starting therapy, 
prescription, and monitoring and titration whilst receiving oxygen was recorded. It was 
also noted if the patient was brought in by ambulance, received oxygen therapy in 
transfer, and whether the patient was admitted via the ED. Criteria were set to assess 
whether prescription, assessment, monitoring and titration of oxygen were adequate 
(Table 1).  
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Table 1. Criteria set to assess whether prescription, monitoring and titration of oxygen 
were adequate 
Category Criteria 
Prescription  Device  
 Flow rate or FiO2 
 Target oxygen saturations 
Assessment 
 
Monitoring  
 Oxygen saturations measured on room air and oxygen 
commenced only if saturations ≤92% 
 
 Oxygen saturations recorded ≥2 occasions within a 24 hour 
period 
Titration  Oxygen increased if saturations ≤92% on  ≥2 occasions 
 
  
For prescription, all criteria had to be met for this feature of oxygen therapy to be 
considered adequate. 
 
In November 2007 a new drug chart with a specific oxygen prescription section on the 
front of the chart (see Figure 9), was introduced into the hospital.  
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Figure 9. Front page of drug chart showing oxygen prescription box 
 
This section prompts the prescriber to state the flow rate, device and target oxygen 
saturations range. During the first few months following implementation of the new drug 
chart, the investigators presented the findings of the first audit and provided education 
about appropriate oxygen use at various medical meetings including the weekly internal 
medicine meeting, junior house surgeon teaching, and Grand Round. 
  
A second audit, using identical methodology, was conducted between April 2008 and 
May 2008, a year after the first audit and six months following the introduction of the 
new drug chart. 
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Statistical Analysis 
Statistical analysis was performed by Professor Mark Weatherall. The proportions of 
audited patients with characteristics related to oxygen use were compared using relative 
risks for 2008 versus 2007.  Data was provided for clinical practice in both the wards and 
the ED settings, and comparisons made between the first and second audit.  SAS version 
9.1 (SAS Institute, Cary, NC, 2003) was used for the analysis. 
 
2.1.4 Results 
 
There were 610 and 566 patients audited over the 3 separate days in 2007 and 2008 
respectively.  Approximately one-third of patients were brought in to hospital by 
ambulance. Of these, 99/188 (52.7%) and 70/177 (39.5%) were administered oxygen at 
any time during the ambulance journey, in 2007 and 2008 respectively.  
 
Just over half of the patients were admitted via the ED.  Of these 82/353 (23.2%) and 
66/287 (23.0%) were receiving oxygen at presentation to ED.  Of the patients who did not 
arrive on oxygen, it was commenced in 66/353(18.7%) and 41/287 (14.3%) at any time 
during their stay in the ED. 
 
The first audit identified 85/610 (13.9%) ward-based hospital inpatients who were 
receiving oxygen, and 98/566 (17.3%) during the second audit.  
 
Prescription 
No patients admitted through the ED who received oxygen therapy had it prescribed.  
The prescription of oxygen on the drug chart in ward-based hospital inpatients is shown 
in Table 2 
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Table 2. Prescription of oxygen therapy in patients receiving oxygen on ward 
 2007 2008 Fold change 
(95% CI) 
P 
value 
 
Oxygen prescribed 
 
Oxygen prescribed 
adequately 
 Device 
 
15/85 (17.6%) 
 
 
 
10/85 (11.8%) 
 
39/98 (39.8%) 
 
 
 
38/98 (38.8%) 
 
 
2.3 (1.3 to 3.9) 
 
 
 
3.3 (1.8 to 6.2) 
 
0.001 
 
 
 
<0.001 
 Flow rate or FiO2 10/85 (11.8%) 
 
37/98 (37.8%) 
 
3.2 (1.7 to 6.1) 
 
<0.001 
  
 Target SpO2 11/85 (12.9%) 
 
38/98 (38.8%) 
 
3.0 (1.6 to 5.5) 
 
<0.001 
 
 All three criteria 
 
5/85 (5.9%) 36/98 (36.7%) 6.2 (2.5 to 15.0) <0.001 
 
 In the first audit, 15/85 (17.6%) patients receiving oxygen had an oxygen prescription.  In 
the first audit only 5/85 (5.9%) prescriptions were adequate, i.e. delivery device, flow 
rate or fraction of inspired oxygen, and target oxygen saturations were clearly stated on 
the chart.  In the second audit, following introduction of the new drug chart with a 
specific oxygen prescription section, 39/98 (39.8%) patients receiving oxygen had an 
oxygen prescription, fold change compared to 2007, 2.3 (95% CI 1.3 to 3.9), P=0.001. In 
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the second audit in 36/98 (36.7%) oxygen prescriptions were adequate, fold change 
compared to 2007 6.2 (95% CI 2.5 to 15.0), P<0.001.   
 
Assessment prior to commencing oxygen therapy 
The proportion of patients who had assessment of oxygen saturations on room air and 
commenced on oxygen therapy if saturations were <92% in the ambulance, ED and on 
the ward are shown in Table 3.  
 
Table 3. Assessment of oxygen saturations on room air and commencement of oxygen 
if oxygen saturation ≤92% 
 2007 2008 Relative Risk 
(95% CI) 
P 
value 
Ambulance 22/99 (22.2%) 9/70 (12.9%) 0.6 (0.3 to 1.2) 0.10 
Emergency 
Department 
25/66 (37.9%) 18/41(43.9%) 1.2 (0.7 to 1.8) 0.54 
Ward 9/38 (23.7%) 10/26 (38.5%) 1.6 (0.8 to 3.4) 0.20 
 
This practice was generally better in the ED than in the ambulance or on the wards, 
although was still undertaken in a minority of patients.  There were no significant 
differences in the proportion meeting this criterion between the two audits, in the three 
sites studied. 
 
Monitoring 
The proportion of patients who had adequate monitoring of oxygen saturations whilst 
receiving oxygen was over 90% in both the ward and ED in both audits and there was no 
significant change between the audits, Table 4. 
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Table 4. Monitoring of oxygen saturations in patients receiving oxygen 
 2007 2008 Relative Risk 
(95% CI) 
P 
value 
 
Emergency 
 
137/148 (92.6%) 
 
104/107 (97.2%) 
 
1.1 (1.0 to 1.1) 
 
0.11 
 
Ward 
 
83/85 (97.6%) 
 
96/98 (98.0%) 
 
1.0 (1.0 to 1.1) 
 
 
0.89 
† Oxygen saturations recorded ≥2 occasions within a 24 hour period 
 
Titration  
The proportion of patients who had their oxygen treatment up-titrated in response to 
oxygen saturations 92% on at least two occasions is shown in Table 5.   
  
Table 5. Titration of oxygen saturations in patients receiving oxygen 
 2007 2008 Relative Risk 
(95% CI) 
P value 
Emergency Department 14/16 (87.5%) 9/12(75%) 0.9 (0.6 to 1.3) 0.39 
Ward 8/12 (66.7%) 4/9 (44.4%) 0.7 (0.3 to 1.5) 0.31 
† Oxygen up-titrated in response to oxygen saturations 92% on 2 occasions 
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2.1.5 Discussion 
 
This “snapshot” of oxygen therapy shows oxygen is a commonly used drug. Outside 
critical care areas of the hospital, the initial audit identified that less than 20% of patients 
receiving oxygen had an oxygen prescription, and in only 6% was the prescription 
adequate.  The institution of an oxygen prescription section on the drug chart led to an 
improvement in the prescription of oxygen therapy, including documentation of the 
delivery device, flow rate and target oxygen saturations.  However, it did not lead to 
improved clinical practice in terms of the initial assessment of the requirement for 
oxygen therapy, or the titration of oxygen therapy in response to low oxygen saturations.  
This suggests that a prescription box alone is not sufficient to achieve good clinical 
practice and that other measures are required.   
 
These findings of an improvement in oxygen prescription using a specific section on the 
drug chart have also been shown by Dodd et al96.  Although the provision of an oxygen 
prescription section improved the frequency and quality of oxygen prescription, in this 
study the quality of the prescription was poor in two thirds of patients receiving oxygen 
in the wards.  Failure to document hypoxemia before oxygen prescription, also reported 
by Brougher et al141 suggests that oxygen is commonly administered for presumed rather 
than documented need.   
 
A positive feature of the audit was that almost all patients receiving oxygen therapy had 
regular monitoring, defined as oxygen saturations recorded twice a day.  It could be 
argued that stricter criteria would have been preferable, such as those proposed by the 
BTS guidelines13, which recommend monitoring four-times-a day in stable patients and 
continuous  monitoring in unstable patients.  Nevertheless, the findings do indicate that 
this component of oxygen therapy is generally well undertaken.  However, the response 
to the documentation of repeatedly low oxygen saturations was disappointing, 
particularly in the ward situation.  Furthermore, the introduction of the new oxygen 
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prescription section which specifically included a target oxygen saturation range, did not 
improve this practice. 
Clinical practice but not prescription, was better in the ED when compared with the 
wards.  This may reflect the more frequent use of oxygen within this area of the hospital 
and the closer medical and nursing supervision provided.  This feature also illustrates the 
potential disconnect between prescription and clinical practice. 
 
In summary, this audit has demonstrated a statistically significant and clinically relevant 
improvement in the frequency and quality of the prescription of oxygen following the 
introduction of a new drug chart with a specific oxygen prescription section.  However, 
this improvement did not translate to improved clinical practice in the administration of 
oxygen therapy suggesting that strategies other than an oxygen prescription need to be 
developed to improve clinical practice.  On the basis of these findings it can be 
recommended that strategies and protocols are developed which facilitate the 
assessment of oxygen saturation prior to oxygen use and the change in oxygen therapy in 
response to low or high oxygen saturations.  It is likely that there are similar 
requirements for the delivery of oxygen in the community by doctors, nurses and 
paramedical staff. 
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Chapter 2.2. An audit of pre-hospital oxygen therapy in acute 
exacerbations of chronic obstructive pulmonary disease 
 
2.2.1 Introduction 
 
The British Thoracic Society Guidelines “Emergency oxygen use in adult patients” 
recommend that oxygen should only be administered to patients with acute 
exacerbations of chronic obstructive pulmonary disease (AECOPD) if oxygen saturations 
are <88% and that oxygen therapy should be adjusted to maintain saturations between 
88-92%13. This recommendation is based on the well established risk of hypercapnia and 
respiratory failure in patients with AECOPD when high concentration oxygen is 
administered20 66 67 74 85 92 142-147.  The clinical practice guidelines of the Wellington Free 
Ambulance Service state that patients with COPD should have their oxygen delivery 
adjusted to maintain saturations of 88 – 92%148. These recommendations are important 
as the ambulance service is often the first medical contact for patients with AECOPD and 
is responsible for their management during transfer to hospital.  Such transfers may take 
considerable time, particularly in rural areas, and the administration of inappropriately 
high concentrations of oxygen have the potential to lead to hypercapnia and worse 
clinical outcomes. 
 
2.2.2 Objectives 
 
To determine  
1. whether the use of oxygen in AECOPD by the Ambulance Service is consistent 
with local and international guidelines 
2. whether high flow oxygen administered in the ambulance is associated with poor 
outcomes 
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3. whether it is possible to identify high risk patients based on the severity of their 
underlying disease or their clinical status at presentation. 
 
2.2.3 Methods 
 
The data collection sheet (Appendix 1) was piloted prior to the start of the audit to 
ensure all the necessary data was recorded. Written permission was given by the 
hospital’s audit department. The audit was retrospective in nature, co-ordinated by 
myself and three co-workers. 250 presentations of AECOPD admitted to Wellington 
Hospital (Capital & Coast District Health Board) between June 2006 and June 2007 were 
audited. Only patients who were brought by ambulance to the Emergency Department 
were included.  Patients were identified by the medical records department and a list of 
all discharges with a primary diagnosis of COPD (ICD Code J440 or J441) was provided.  
This included readmissions, patients who were dead on arrival and those who died in 
hospital following presentation. Markers of the chronic background severity of COPD, 
severity markers of the acute exacerbation, and clinical outcomes following presentation 
to the Emergency Department were reviewed.  Sources of information included the 
ambulance case records for details of pre-hospital oxygen administration, and the 
hospital case records for documentation of management in the Emergency Department 
and subsequent medical admission.   
 
Particular attention was paid to identifying and documenting the oxygen therapy 
administered by the ambulance service.  Difficulties in identifying oxygen use from some 
of the ambulance records led to the categorisation of oxygen administration in two ways.  
First, where the exact flow rate was clearly documented, oxygen therapy was treated as 
a continuous variable based on the flow rate in L/min.  Second, we categorised oxygen 
therapy as a dichotomous variable, either “high flow” or “low flow”. Patients were 
categorised as “high flow” if they had a documented flow rate of ≥3 L/min, or received 
oxygen via a medium concentration mask or a non re-breather mask. Patients were 
categorised as “low flow” if either “room air” or a flow rate <3 L/min was documented, 
or if there was no mention of oxygen therapy. This categorisation was based on data 
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which indicates that 2-3 L/min of oxygen through nasal prongs delivers a FiO2 of 
approximately 26 – 30%.149 If oxygen was noted as given but no flow rate or device was 
recorded, the patient was excluded. All vehicles in the Wellington Free Ambulance fleet 
carry pulse oximeters but not transcutaneous or end tidal CO2 monitors. Venturi masks 
are not used, low flow oxygen is delivered with nasal cannuale, moderate flows with a 
medium concentration mask, and non re-breather masks are used with a flow rate of 
15L/min. 
 
Statistical Analysis 
Statistical analysis was performed by Dr Mark Weatherall. Logistic regression was used to 
describe associations between oxygen use, the main outcome measure, and the chronic 
and acute severity markers.  For multivariate logistic regression a backwards selection 
process was used with a P value for retaining a variable of 0.1.  Oxygen delivery was kept 
in logistic regression models regardless of the variable retention criterion to adjust for 
the independent predictors of poor outcome.  For univariate odds ratios where there 
were zero cell counts, Fisher’s exact test was used to generate a P value and Peto’s 
method used to calculate a univariate odds ratio. 
 
The main clinical outcome was a composite of death, requirement for invasive or non-
invasive positive pressure ventilation, or respiratory failure (defined as a PaCO2 45 
mmHg (6.0 kPa) and a pH <7.35 documented on an arterial blood gas within four hours of 
presentation.)  It was not possible to use death alone in multivariate models because no 
deaths occurred in subjects receiving low flow oxygen. 
 
2.2.4 Results 
 
There were 406 admissions with AECOPD identified from the Wellington Hospital 
database.   Of these, 113 were not brought in by ambulance, 16 were inpatient hospital 
transfers and in 27 the medical records were missing, resulting in 250 cases being 
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included in the audit.  The characteristics of the patients, including chronic and acute 
severity markers and clinical outcomes are shown in Table 6.  
Table 6. Characteristics of patients including severity markers and adverse outcomes 
Variable  
Mean Age in years: Mean (SD) 72.4 (9.3) 
Male Sex: N (%) 120 (48%) 
Ambulance time in minutes: Mean (Range) 49.8 (3 to 205) 
Chronic Severity Markers: n/N (%)  
 Long term oral steroid use 40/250 (16.0%) 
 Tiotropium use 67/250 (26.8%) 
 Home nebuliser 87/249 (24.8%) 
 Home long term oxygen therapy 62/250 (24.8%) 
 Previous respiratory failure†  132/250 (52.8%) 
 Previous assisted ventilation (NIPPV or IPPV) 59/247 (23.9%) 
Acute Severity Markers: Mean (SD)  
 Glasgow Coma Score (score out of 15) 14.8 (1.1) 
 Respiratory rate (per minute) 31.0 (9.7) 
 Heart rate (per minute) 103.0 (22.2) 
 Systolic blood pressure (mmHg) 155.2 (34.3) 
 Oxygen saturation (when clearly documented on air) (%) 86.9 (11.8) 
Outcomes: n/N (%)  
 Respiratory failure†  
 - Arterial blood gas within 1 hour 45/108 (41.7%) 
 - Arterial blood gas between 1 and 4 hours 11/61 (18.0%) 
 Non-invasive Positive Pressure Ventilation 49/250 (19.6%) 
 Invasive Positive Pressure Ventilation 2/250 (0.8%) 
 Death 10/250 (4.0%) 
 Death or assisted ventilation or respiratory failure within 4 
hours 
77/250 (30.8%) 
† PaCO2 ≥45mmHg and pH <7.35 
NIPPV:  Non-invasive positive pressure ventilation 
IPPV:  Invasive positive pressure ventilation 
  
82 
 
The patients had severe chronic disease with about half having previous respiratory 
failure documented, a quarter having previous assisted ventilation, and a quarter 
receiving long term oxygen therapy. Glasgow coma score, respiratory rate, heart rate and 
systolic blood pressure were documented by the paramedics in most (85% to 98%) 
patients.  However, clear documentation of room air oxygen saturation only occurred in 
92/250 (36.8%) of ambulance attendances. 
 
Oxygen flow rate was clearly documented in the ambulance case notes in 182/250 (73%) 
of patients.  Of these patients, 168 (92%) received oxygen at flow rates ≥3 L/min and 90 
(49%) received oxygen at ≥8 L/min. Using the dichotomous criteria, 181/250 (72%) 
received “high flow” and 52 (21%) received “low flow” oxygen.  
 
At presentation to the Emergency Department, 181/242 (75%) patients had an oxygen 
saturation >92%, and in 70/242 (29%) the oxygen saturation was 98%.  Of the 107 (43%) 
patients who had an arterial blood gas within 1 hour of presentation to Emergency 
Department, the median PaCO2 was 54 mmHg (range 29 mmHg to 133 mmHg), the 
median pH was 7.36 (range 7.07 to 7.56), and the median PaO2 was 66.0 mmHg (range 
17 mmHg to 300 mmHg).   
 
Ten patients (4%) died, all of whom received high flow oxygen therapy.  Overall 31% of 
patients met the main outcome criteria (either died, required assisted ventilation, or 
were in respiratory failure). When oxygen delivery was analysed as a continuous variable 
according to documented flow rate, increased oxygen flow was associated with an 
increased risk of death, assisted ventilation, or respiratory failure with an odds ratio of 
1.2 (95% CI 1.0 to 1.4) per 1 litre per minute in oxygen flow (table 7).   
 
For the dichotomous categories of “high flow” vs “low flow” oxygen the point estimate 
for risk in the multivariate analysis was consistent with an association between high 
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concentration oxygen and the main outcome variable however the associations were not 
statistically significant (Table 7). 
 
Table 7. The association between oxygen administration and clinical outcome: 
composite of death, positive pressure ventilation or respiratory failure 
 Univariate association 
with poor outcome 
Multivariate association 
with poor outcome2 
   
Oxygen flow rate (continuous)1 1.1 (1.0 to 1.3) 1.2 (1.0 to 1.4) 
   
High flow vs. low flow  1.0 (0.5 to 1.9) 1.4 (0.6 to 2.9) 
   
 
1 Odds ratio for association per l/min oxygen flow 
2 Multivariate analyses adjusted for all chronic severity markers, Glasgow Coma Scale, 
and heart rate 
 
Increasing arterial oxygen partial pressure was associated with a greater risk of death, 
requirement for assisted ventilation, or respiratory failure with an odds ratio of 1.1 (95% 
CI 1.0 to 1.3) per 10mmHg rise in PaO2. 
 
Patients were at significantly greater risk of death, assisted ventilation or respiratory 
failure if they were on long term oxygen therapy, had a past history of respiratory failure, 
had previously required assisted ventilation, or had a home nebuliser (Table 8). The only 
chronic severity markers not associated with a statistically significant increase in the 
likelihood of a poor outcome were long term steroid use and tiotropium use. 
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Table 8. The association between adverse clinical outcome (death, positive pressure ventilation 
or respiratory failure) and markers of chronic and acute severity 
a) Chronic severity markers 
 Odds ratio (95% CI) 
Long term oral steroids 1.1 (0.5 to 2.3) 
Tiotropium 1.4 (0.8 to 2.5) 
Home nebuliser 2.4 (1.4 to 4.3) 
Long term oxygen therapy 2.8 (1.5 to 5.1) 
Previous respiratory failure † 2.6 (1.5 to 4.6) 
Previous assisted ventilation ‡ 3.3 (1.7 to 5.9) 
 
b) Acute severity markers 
 Odds ratio (95% CI) 
Glasgow Coma Score (per unit higher) 0.7 (0.5 to 0.9) 
Respiratory rate (per 10 breaths/min higher) 1.3 (0.9 to 1.6) 
Heart rate (per 10 breaths/min higher) 1.1 (1.0 to 1.3) 
Systolic blood pressure (per 10mmHg higher) 1.1 (1.0 to 1.2) 
Oxygen saturations on air (per percentage point higher) 0.9 (0.9 to 1.0) 
† Previous respiratory failure: PaCO2 45 mmHg or pH <7.35 
‡ NIPPV (non-invasive positive pressure ventilation) or IPPV (invasive positive pressure 
ventilation) 
 
An increased heart rate and lower Glasgow Coma Score were weakly associated with the 
risk of death, assisted ventilation or respiratory failure, but an increased respiratory rate 
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and systolic blood pressure were not. Higher room air oxygen saturations were 
associated with a lower risk (Table 8b).  
 
2.2.5 Discussion 
 
This study has shown that in patients with AECOPD the administration of high flow 
oxygen in the ambulance is associated with an increased risk of death, assisted 
ventilation or respiratory failure, and that the risk of a poor outcome progressively rises 
as the flow rate of oxygen increases. The impact of pre-hospital oxygen treatment on 
adverse clinical outcomes was also demonstrated by the progressive increase in risk with 
increasing PaO2 following oxygen therapy. In addition, there were a number of easily 
identified markers of chronic disease severity which were associated with a markedly 
increased risk of a poor clinical outcome.  
 
At least 70% of patients with AECOPD were administered high flow oxygen therapy on 
ambulance transfer to the Emergency Department, contrary to local and international 
guidelines13 148 150.  Furthermore, of the patients in whom there was definite 
documentation of oxygen flow rates, about half received ≥8L/min.  This occurred despite 
most patients being at risk of serious adverse outcomes, with 53% having previous 
respiratory failure documented, 24% having previous invasive or non-invasive ventilation, 
and 25% receiving long term oxygen therapy.  This approach to oxygen delivery resulted 
in 75% of patients having oxygen saturations in excess of the target range of 88 to 92% at 
presentation to the Emergency Department, and nearly a third having oxygen saturations 
98%.  Although pulse oximetry is a critical part of the initial patient assessment, oxygen 
therapy in this study was not based on the routine assessment of oxygen saturations, 
with only 37% of patients having saturations documented on room air at baseline.  
The retrospective nature of the AECOPD audit meant there were a number of limitations 
in the methodology. Firstly, the use of discharge diagnosis as an identifier created a 
selection bias against those patients coded incorrectly. 
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Secondly, the charting of oxygen delivery from ambulance records was variable which 
relied on making assumption. For example patients were assumed to be on room air if 
oxygen was not mentioned on the ambulance sheet. Additionally, it was not possible to 
quantify the amount of oxygen delivered through nebulisers which in cases with long 
ambulance journey times would have been significant and possibly continuous.  
When oxygen was analysed as a continuous variable according to flow rate, there was a 
statistically significant association between increased flow rates and poor clinical 
outcomes, consistent with previous studies.85-88 Importantly, the strength of this 
association increased in the multivariate analysis, which adjusted for independent 
predictors of poor outcome. This indicates that there was no major confounding by 
severity, and that the association was not due to more unwell patients receiving higher 
concentrations of oxygen therapy. In addition, the observation that the risk of death, 
assisted ventilation or respiratory failure progressively increased with higher PaO2 levels 
suggests that inappropriate high flow oxygen therapy was an important contributor to 
poor clinical outcomes. The statistical power to detect an association between high flow 
oxygen therapy, when treated as a dichotomous variable, and poor clinical outcomes was 
limited because of the small number of patients in the “low flow” group. However, in 
multivariate analysis adjusted for acute and chronic severity markers, the point estimates 
were consistent with an association between high flow oxygen and poor outcomes. 
 
These findings complement other studies investigating the relationship between high 
flow oxygen therapy and poor outcomes in AECOPD discussed in the introduction of this 
thesis. The Plant study85 demonstrated an inverse correlation between pH and PaO2 and 
more than 50% of patients with a PaO2 of >10 kPa were acidotic.  Their data suggested 
that a significant number of patients had been made acidotic by injudicious oxygen 
therapy and that it may be possible to rapidly correct the pH once the inspired oxygen 
concentration was reduced. Joosten and colleagues reported that the use of high flow 
oxygen therapy in patients with high PaCO2 levels contributed to an increased length of 
stay, more frequent admission to a high dependency unit and greater use of NIPPV87. 
Inappropriate oxygen therapy was often initiated at the time of ambulance transfer, as 
92% of patients admitted via ambulance received oxygen at a flow rate >2 L/min despite 
one third having previously documented hypercapnia. Similar findings were reported in 
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the study by Durrington et al88 in which initial high concentration oxygen therapy caused 
significant acidosis and hypercapnia compared with low concentration oxygen.  There 
was a significantly increased complication rate during admission in those COPD patients 
receiving high concentration oxygen, particularly when ambulance journeys exceeded 30 
minutes.  This latter finding is relevant to our study in which the average ambulance 
transit time was 49 minutes. A prospective audit by Denniston et al showed that oxygen 
therapy >28% was associated with acute hypercapnic respiratory failure and a higher 
mortality.86 More recently, the first randomised controlled trial of oxygen therapy in 
AECOPD92 has shown that mortality was significantly lower in patients receiving titrated 
rather than high concentration oxygen (relative risk, 0.42, 95%confidence interval 0.20 to 
0.89) and this risk was reduced further in a sub-group of patients with confirmed COPD 
on pulmonary function testing (0.22, 0.05 to 0.91). 
 
In this present study, there were strong associations between indicators of severe 
chronic COPD and poor outcomes during an acute exacerbation.  For example, a previous 
episode of respiratory failure or assisted ventilation was associated with a two to three 
fold risk of death, assisted ventilation or respiratory failure in a subsequent exacerbation, 
albeit in the setting of initial high flow oxygen therapy by the ambulance service. In 
contrast to the chronic severity markers there were only weak associations with some of 
the acute severity markers.  The CURB-65 score, has recently been shown to predict risk 
of inpatient mortality in AECOPD151, similar to its use in community acquired pneumonia. 
 
One potential limitation when interpreting the results of this study is that less than half 
the patients (108/250) received arterial blood gas sampling within one hour of arrival to 
the emergency department. There are a number of potential reasons for this including 
patient refusal, reluctance of the doctor to perform the test, a perception by the doctor 
that the test is not indicated, or limited time and staff resources. Current guidelines on 
the management of AECOPD recommend all patients have arterial blood gas sampling152. 
Our observation that about one-third of patients who had a blood gas measurement had 
respiratory failure, defined as a PaCO2 45 mmHg and a pH <7.35 illustrates the 
importance of this recommendation.  Similarly, Plant et al85 reported that of nearly 1,000 
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patients admitted with AECOPD, almost half were hypercapnic and 20% had a respiratory 
acidosis on admission. 
 
In conclusion, this study has confirmed that the ambulance administration of high flow 
oxygen to patients with AECOPD is associated with poor clinical outcomes. This practice 
of ambulance staff administering oxygen at high flow rates to patients with AECOPD 
seems entrenched despite the demonstration over 60 years ago of the risks59. This study 
emphasises the importance in pre-hospital care of measuring oxygen saturation prior to 
starting oxygen therapy and identifying patients with severe chronic COPD who are at 
higher risk of respiratory failure, assisted ventilation and death. Another strategy that 
has been recommended is to issue all patients with a previous episode of hypercapnic 
respiratory failure a 24% or 28% venturi mask and an oxygen alert card, an approach 
which has been shown to improve outcomes and reduce the risk of respiratory failure.100 
However, the institution of an alert card system must be supported by assessment of 
oxygen saturation and a robust oxygen delivery policy. 
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SECTION 3 RANDOMISED CONTROLLED TRIALS OF 
OXYGEN THERAPY 
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Chapter 3.1 Materials and Methods 
 
In this section I will present three randomised controlled trials of oxygen therapy in 
respiratory disorders. As the methodology in the three studies varies each will be discussed 
in detail under the study heading. In this chapter, I will describe the non-invasive equipment 
used. The repeatability and validity of the data provided by the equipment will be discussed 
in Chapter 3.2. 
 
3.1.1 Spirometry 
Spirometry was measured using a Micro Spirometer, Cardinal Health UK electronic 
spirometer. Data on subject’s height and age were entered into the spirometer in order to 
calculate their predicted values. All investigators received training on how to perform 
spirometry by Mathew Williams, respiratory technician.  Subjects were given instructions on 
how to perform spiromtery, and if required, a number of attempts were made until a 
satisfactory technique was achieved. The following measurements were made: 
 Forced vital capacity (FVC) is the maximum volume of air that can be forcibly blown 
out after full inspiration, measure in litres 
 Forced expiratory volume in 1 second (FEV1) is the maximum volume of air that can 
be forcibly blown out in the first second during the FVC manoeuvre, measured in 
litres. FEV1 of 33-50% predicted is associated with acute severe asthma and FEV1 of 
<33% predicted is associated with life threatening asthma101.  
 FEV1/FVC ratio is the ratio of FEV1 to FVC. Airflow obstruction is defined as a 
FEV1/FVC <0.7
101. 
 
3.1.2 Transcutaneous Carbon Dioxide Monitor 
 
The “gold standard” measurement of PaCO2 requires an arterial blood gas. The original 
protocols for the pneumonia and acute asthma studies used arterial blood gases. However, 
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patients were reluctant to have two blood gases taken and therefore the majority who met 
the inclusion criteria declined to take part in the study. This led us to change the protocol 
and use an alternative method of CO2 monitoring. 
 
Portable devices to measure transcutaneous partial pressure of carbon dioxide (PtCO2) 
provide an alternative to an ABG. Transcutaneous CO2 devices have been studied in a variety 
of clinical scenarios including acute exacerbations of COPD, invasive and non-invasive 
ventilation in intensive care units and overnight studies of sleep disordered breathing.153-157 
Limits of agreement and bias have been reported in most studies, with a variation in results 
depending on the device used and the clinical setting.  
 
 They function on the principle that CO2 diffuses extremely well through tissues. A probe is 
attached to an area of skin and warms to 42°C which “arterializes” the underlying capillaries. 
Warming the skin also softens the keratin layer, thereby making the physical barrier to 
diffusion more permeable. CO2 diffuses from the skin through the sensor membrane. It 
reacts with water to form H2CO3, which in turn dissociates into H
+ and HCO3
-; the former 
modifies the pH in the electrolyte solution in the probe and the resulting signal is converted 
to an estimate of the PaCO2. 
 
For our studies, myself and my co-worker Dr Perrin chose the “TOSCA” (Radiometer, Basel, 
Switzerland) as this analyser has the advantage of a dual sensor which measures PtCO2 and 
SpO2. In addition it also had a “quick calibration” mode allowing the machine to calibrate 
within 5 minutes of being attached to the patient, as compared to some of the older 
analysers which can take as long as 20 minutes.  We received training on how to use the 
“TOSCA” from the manufacturers.  
 
After consent was obtained from each patient, the patient’s ear lobe was cleansed with an 
alcohol swab and allowed to dry. Where patients had excess hair on their ear lobes, this was 
  
92 
removed with the patient’s permission. A low-pressure, adhesive clip was attached to the 
ear lobe, two drops of contact gel were placed onto the skin and the probe was attached to 
the clip. After “quick calibration” was complete, the machine signalled that it was ready to 
use. 
 
At the end of the study protocol, the sensor was removed, cleaned and placed back in the 
analyser. The clip was removed from the patient’s ear lobe. The analyser was calibrated 
after each use. 
 
This device has a Stow-Severinghaus electrode and a probe membrane which was replaced 
every 14 days as per manufacturer guidelines.  It has integrated automatic calibration which 
uses a carbon dioxide canister to calibrate the sensor every 4 hours while the machine is 
switched on. 
 
Three identical “TOSCA” analysers were used for the three randomized-controlled trials. 
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3.1.3 Titrated Oxygen 
 
In the randomised controlled trials of oxygen and community acquired pneumonia and 
oxygen and acute severe asthma presented in chapters 3.3 and 3.4 respectively, patients 
were randomised to either receive high flow oxygen (8l/min via a face mask) or titrated 
oxygen to keep their SpO2 between 93-95%. Oxygen saturations were measured every 5 
minutes and oxygen was titrated according to the protocol set out below.  Less than 4 l/min 
of oxygen was delivered via nasal cannulae and higher flow rates were delivered by a face 
mask.  
Table 9. Oxygen dose adjustment for the titrated oxygen group 
Oxygen Saturation Dose Adjustment L/min Next Saturation Check  
> 98% Reduce by 2 L In 5 minutes 
96% - 98% Reduce by 1L  In 5 minutes 
93% - 95% No change In 5 minutes 
91% - 92% Increase by 1L In 5 minutes 
89% - 90% Increase by 2L In 5 minutes 
86% - 88% Increase by 4L In 5 minutes  
<86% withdraw    
 
3.1.4 Measurements of minute ventilation and deadspace to tidal volume ratio 
 
As discussed earlier in this thesis, continuous distributions of ventilation-perfusion ratios are 
best measured by the multiple inert gas elimination technique (MIGET).  However this 
requires invasive measurements, which potentially posed an unacceptable risk to our 
patients. We, therefore, chose a commercially available, compact monitor which in addition 
to measuring volumetric capnograms, can also measure multiple respiratory parameters, 
  
94 
including tidal volume (Vt), mixed-expired CO2 (PeCO2), and airway dead-space
 volume. 
(CO2SMO Plus! Respiratory Profile Monitor, Respironics, Murrysville, Pennsylvania, USA). 
The minute ventilation was used as a measure of ventilatory drive and the Vd/Vt as a 
measure of physiological dead space. By using this simple, non-invasive apparatus we were 
able to obtain validated information on respiratory drive and physiological dead space. 
 
Minute ventilation is defined as the quantity of gas exhaled expressed as volume per 
minute. It is calculated by measuring the tidal volume and multiplying it by the respiratory 
rate. The CO2SMO Plus! calculates the eight-breath moving average of expiratory volume in 
terms of volume per minute and updates every breath. 
 
To measure Vd/Vt, the CO2SMO Plus! uses volumetric capnography.  Flow is measured with 
a fixed orifice differential flow sensor. CO2 is measured by a mainstream infrared absorption 
technique with a solid state sensor.  
 
Mixed expired CO2 (PeCO2) is calculated from the volumetric capnogram as a volume 
weighted average of CO2. The PaCO2 (we used the PtCO2 as an estimate) is user entered into 
the CO2SMO Plus! Using the Enghoff modification of the Bohr equation, dead space to tidal 
volume ratio was calculated by the analyser: 
 
Vd/Vt=(PaCO2-PeCO2)/PaCO2 
 
where PaCO2 and PeCO2 are the arterial and mixed expired PCO2 respectively.  
See Appendix for further detail. 
 
The methods section of the OHS study describes in detail how the CO2SMO Plus! was used 
for the purposes of the study. 
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Chapter 3.2 Repeatability and Validation 
  
Non-invasive methods of measurement should be reliable and repeatable. Repeatability 
concerns the extent to which a measurement yields the same result on repeated testing. 
While repeated measurements will never precisely duplicate each other, their tendency 
toward being consistent is a measure of repeatability. Repeatability of a measurement 
however, does not imply validity, and a method that is not repeatable has no validity. A 
measurement is valid only if it measures what it is intended to measure. While repeatability 
focuses on consistency across repeated measurements, validity concerns the relationship 
between the measurement itself and the variable it is meant to be measuring. 
In all three studies we used a transcutaneous portable device “TOSCA” to estimate arterial 
carbon dioxide levels (PtCO2). In the OHS study we used volumetric capnography “The 
CO2SMO Plus!” to measure Vd/Vt and minute ventilation. 
To ascertain the repeatability and validity of the methods used in this thesis, the following 
analyses were undertaken: 
 The validity and precision of TOSCA to measure PaCO2 
 The repeatability of the TOSCA to measure PaCO2  
 The repeatability of the CO2SMO Plus! to measure Vd/Vt and minute ventilation 
 
3.2.1 Validity and precision of transcutaneous CO2 monitoring to measure PaCO2 
 
Methods 
As part of the two randomized controlled trials, 25 paired PaCO2 and PtCO2 recordings in 
patients attending the ED with either severe asthma or suspected community-acquired 
pneumonia. Patients were assessed by one of the study investigators on arrival and if the 
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enrollment criteria were met written informed consent was obtained. The PtCO2 sensor was 
attached to the patient’s earlobe as described in Chapter 3.1. The PtCO2 was monitored 
continuously and subjects had an ABG taken during the course of their routine assessment 
and treatment if the investigator felt it was clinically indicated.  The ABG samples were 
obtained by radial puncture with a 22 gauge needle into a heparinized syringe.  Samples 
were analyzed immediately with an arterial blood gas analyzer (Radiometer ABL800 
FLEX, Copenhagen, Denmark) and a simultaneous PtCO2 reading was recorded.  
Data are presented as a Bland-Altman plot of PaCO2 – PtCO2 versus the mean of PaCO2 and 
PtCO2 together with limits of agreement 
Results 
Subjects were recruited between June 2007 and December 2008. There were 25 pairs of 
data in total but one patient was excluded because of difficulty attaching the probe 
resulting in poor signal quality and unstable PtCO2 readings. This left 24 paired samples for 
analysis. No patients were in shock or hypothermic and none required vasopressor or 
inotropic support. The 24 patients (10 men and 14 women) had a mean age of 44 years and 
included 12 with asthma and 12 with pneumonia. The PaCO2 range for the group was 19 to 
64mmHg with a mean of 34.9mmHg. The mean time ABG samples were taken was 39.5 
minutes after starting the randomized oxygen treatment regime with a range of 5 to 110 
minutes. 
The Bland-Altman plot is shown in figure 11. The mean (SD) PaCO2 – PtCO2 difference was -
0.13 (1.9) mmHg with limits of agreement of plus or minus 3.8mmHg (-3.9 to +3.7). 
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Figure 10. Bland-Altman plot of the difference between the PaCO2 and the PtCO2, against 
the mean PaCO2 and the PtCO2 
 
 
Conclusion 
This portable PtCO2 device accurately assesses PaCO2 without significant bias and with 
clinically acceptable limits of agreement when compared to the gold standard measurement 
of ABG. 
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3.2.2 Repeatability of Transcutaneous CO2 Measurements 
Methods  
Twenty four patients enrolled for the Oxygen and OHS RCT were asked to attend the 
laboratory on two separate occasions within 7 days. The transcutaneous CO2 monitor was 
attached to the patient’s earlobe and a reading of PtCO2 using the methodology above, was 
taken whilst the patient was breathing room air. When the patient returned for visit two, a 
second PtCO2measurement was taken. All measurements were carried out by the same 
study investigator. Subjects were tested at approximately the same time of day (± two 
hours) on both occasions.  
Bland Altman analysis and Intra-class coefficients were used to analyse data 
Results 
Bland Altman analysis: 
The mean (SD) Visit 2 PtCO2 – Visit 1 PtCO2 difference was -0.13 (2.0) mmHg with limits of 
agreement of plus or minus 4mmHg (-4 to 4). 
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Figure 11. Bland-Altman plot of the difference between PtCO2 at Visit 1 and PtCO2 at Visit 
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Intra-class correlation coefficients: 
The intra-class coefficient with 95% confidence intervals is 0.87 (0.73 to 0.94) 
Conclusion  
Using both the Bland-Altman analysis and the intra-class correlation coefficient, PtCO2 was 
very reliable between measurements 
   
3.2.2. Repeatability of Minute Ventilation and Vd/Vt  Measurements 
 
Methods   
Twenty four patients enrolled for the Oxygen and OHS RCT were asked to attend the 
laboratory on two separate occasions within 7 days. Measurements of minute ventilation 
and Vd/Vt were taken using the CO2SMO Plus! as described in chapter 3.1 whilst the patient 
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was breathing room air. When the patient returned for visit two, a second set of 
measurements was taken. All measurements were carried out by the same study 
investigator. Subjects were tested at approximately the same time of day (± two hours) on 
both occasions.  
 
Results 
Minute ventilation 
Bland-Altman Analysis 
The mean (SD) Visit 2 MV – Visit 1 MV difference was 0.71 (2.70) L/min with limits of 
agreement of plus or minus 5.4 L/min (-4.9 to 7.9).  
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Figure 12. The Bland-Altman plot of the difference between MV at Visit 1 and MV at Visit 
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Intra-class correlation coefficient 
 
The intra-class correlation coefficient with 95% confidence intervals is 0.59 (0.25 to 0.80) 
 
 
Vd/Vt 
Bland-Altman analysis 
The mean (SD) Visit 2 Vd/Vt – Visit 1 Vd/Vt difference was -0.019 (0.065) with limits of 
agreement of plus or minus 0.13 (-0.16 to 0.11).  
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Figure 13. Bland-Altman plot of the difference between Vd/Vt at Visit 1 and Vd/Vt at Visit 
2 
V
d
/V
t 
d
if
fe
re
n
ce
, 
v
is
it
 2
 m
in
u
s 
v
is
it
 1
-0.20
-0.15
-0.10
-0.05
0.00
0.05
0.10
0.15
0.20
Average Vd/Vt of two visits
0.40 0.45 0.50 0.55 0.60 0.65 0.70
 
 
Intra-class correlation coefficient 
 
The intra-class correlation coefficient with 95% confidence intervals is 0.33 (-0.084 to 0.64). 
 
Conclusion 
Using both the Bland-Altman analysis and the intra-class correlation coefficient, MV 
measurements were moderately reliable, but Vd/Vt was not particularly reliable. 
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Chapter 3.3. Randomised controlled trial of high concentration oxygen 
therapy in community-acquired pneumonia 
 
3.3.1 Introduction 
 
Community-acquired pneumonia is a common respiratory condition associated with 
significant morbidity and risk of mortality158. Patients presenting with suspected 
community-acquired pneumonia routinely receive oxygen therapy irrespective of the 
presence of arterial hypoxemia. This therapeutic approach is likely to be due to many 
reasons, including the standard clinical practice of administering oxygen to breathless 
patients and the widely held perception that oxygen therapy is safe.  However,  there are no 
randomised controlled trials comparing high concentration oxygen therapy with titrated 
oxygen administered only to hypoxaemic patients, to relieve hypoxaemia but avoiding 
hyperoxia, as recommended in recent British community-acquired pneumonia159 and 
oxygen guidelines.13 
 
3.3.2 Objectives 
 
 To investigate the effects of high concentration oxygen therapy on PaCO2 in patients 
presenting to the Emergency Department (ED) with suspected community-acquired 
pneumonia.   
 
3.3.3 Methods 
Subjects 
Patients presenting to the Wellington (tertiary referral public), Kenepuru and Hutt 
(secondary referral public) Hospital EDs with suspected community-acquired pneumonia 
were enrolled in the study.   
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Inclusion criteria 
 Aged 18 to 75 years 
 Cough 
 Respiratory rate >18 breaths per minute 
 At least one systemic feature of sweating, rigors or fever >37.8°C   
 
Exclusion criteria 
 COPD  
 Disorders associated with hypercapnic respiratory failure (neuromuscular disease, 
chest wall disease, or obesity hypoventilation syndrome)  
 Patients presenting with respiratory failure requiring mechanical ventilation,  
 Acute ECG changes suggesting ischaemia or  
 Suspected neutropenic sepsis  
 
The study was approved by the Wellington Regional Ethics Committee (Appendix 4), 
patients were provided with a patient information leaflet (Appendix 2) and informed 
consent was obtained from each patient.  The study was registered on the Australia New 
Zealand Clinical Trials Registry, ACTRN12607000196448. 
 
Study Protocol 
A copy of the detailed study protocol is shown in Appendix 3. Patients were randomly 
assigned using a computer-generated method, to one of two oxygen regimes for one hour.  
All patients in the high concentration oxygen group received 8 L/min via a medium 
concentration mask.  Patients in the titrated group received oxygen only if their saturation 
was 92% on room air, with oxygen titrated as required at 5 minute intervals, to achieve an 
oxygen saturation of 93 to 95% according to the protocol outlined in Chapter 3.1, Table 9.  A 
computerized randomisation sequence was generated by the biostatistician, Professor Mark 
Weatherall, and the patients were enrolled and assigned to their treatment group by the 
clinical research fellows.  Allocation concealment was achieved by using a secure database 
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which contained the randomisation sequence.  Allocation was revealed to the researchers 
only, when the subjects name was entered.  The clinical research fellows and patients could 
not be blinded to the treatment regimes, due to the requirement to titrate oxygen therapy 
in the control group.   
 
A full history was taken and each patient underwent a physical examination.  Empirical 
antibiotics were administered in accordance with published guidelines160 and other 
therapies such as analgesia and intravenous fluids were administered at the discretion of 
the attending investigator.  All patients underwent a chest radiograph and blood tests 
including a full blood count, creatinine and electrolytes. 
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 Patient arrives in ED with suspected 
pneumonia. 
 Triage nurse notifies research fellow via 
cell phone 
 
 Room air for at least 10 minutes or 
titrated oxygen if sats <92% 
 Consent and randomize  
 CRB 65 score 
 
T = 0 
 Baseline tCO2  
 Start O2 protocol  
 Baseline recordings 
 
 
 At T = 20 and 40 mins: 
 CRB 65 score 
 O2 saturations 
 tCO2  
At T= 60 mins: 
 CRB 65 score and O2 saturations 
 Final tCO2 
 
Study protocol ends 
  
Figure 14. Study protocol community acquired pneumonia 
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Measures 
Transcutaneous carbon dioxide (PtCO2) was used to estimate arterial PaCO2 using a 
combined oxygen saturation/PtCO2 monitor. Baseline measurements of PtCO2 and oxygen 
saturation were recorded. Patients remained in a semi-recumbent position during the study 
protocol.  
 
Measurements of PtCO2, respiratory rate and heart rate were made at baseline (0 minutes) 
and at 20, 40 and 60 minutes.  The oxygen saturation was measured continuously 
throughout the study period and recorded at 5 minute intervals. 
 
The CRB-65 (confusion, respiratory rate >30 bpm, blood pressure systolic <90mmHg and/or 
diastolic ≤60mmHg and age over 65 years) was calculated at baseline and at 20, 40 and 60 
minutes to determine the severity of pneumonia. Urea was omitted as this was unknown on 
arrival. 
 
Arterial blood gas (ABG) measurements were performed according to clinical need and were 
not part of the study protocol. The ABG samples were obtained by radial puncture with a 22 
gauge needle into a heparinized syringe.  Samples were analyzed immediately with an 
arterial blood gas analyzer (Radiometer ABL800 FLEX, Copenhagen, Denmark). A 
simultaneous PtCO2 reading was recorded. 
 
All data was collected on a standardized data collection sheet shown in Appendix 1. 
 
Statistical analysis 
All statistical analysis was performed by Professor Mark Weatherall. The pre-specified 
primary outcome variable was the proportion of patients with a PtCO2 >38 mmHg at 60 
minutes.  However after initial recruitment and clinical monitoring of patients it was 
apparent that this outcome was inappropriate to determine if a physiologically relevant 
increase in PtCO2 had occurred.  For this reason, the primary outcome was changed to the 
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proportion of patients with a PtCO2 rise of 4 mmHg at 60 minutes and the proportion of 
patients with a PtCO2 rise of 4 mmHg and a PtCO2 38 mmHg at 60 minutes was included 
as a secondary outcome variable.  Other secondary outcome variables included the mean 
change from baseline PtCO2, the mean change in respiratory rate and heart rate, and the 
need for hospital admission.  The proportion of patients with a PtCO2 rise of 8 mmHg was 
included as a post hoc analysis.  Whether the risk of a PtCO2 rise of 4 mmHg at 60 minutes 
was influenced by the presence or absence of a pulmonary infiltrate on the chest radiograph 
consistent with pneumonia, was tested by an interaction term in a logistic regression model.  
 
The rate of change of PtCO2 was determined using a mixed linear model with random 
intercept and slope terms.  Continuous outcome variables were analysed as change from 
baseline using independent sample t-tests or for achieved oxygen saturation, for which 
normality assumptions were not met, by a Mann-Whitney test.  Analysis was by intention to 
treat.  SAS version 9.1 and Minitab version 14 were used. 
 
Sample size calculation 
Based on previous research,113 we calculated that to detect a difference in the main 
outcome variable of 20% in the high concentration oxygen group and 5% in the titrated 
group, with power of 80% at a type 1 error rate of 5%, 75 participants were required in each 
group. 
 
3.3.4 Results 
 
Patient Characteristics 
Eligible patients were recruited from July 2007 to April 2009.  Figure 16 shows the flow of 
the 150 patients through the study, with 75 randomized to high concentration oxygen and 
75 randomized to titrated oxygen.   
  
109 
 
Figure 15. Flow of subjects through community acquired pneumonia study
159 patients presenting to ED with 
suspected Community 
Acquired Pneumonia 
150 patients randomly assigned to 
oxygen protocol 
9 Patients declining to take 
part in study 
n=9 
75 patients randomised to 
titrated oxygen 
75 patients randomised to high 
flow oxygen 
Withdrawals (see text) 
n=3 
 75 patients included in analysis 72 patients included in analysis 
analysis 
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Three patients were withdrawn from the high concentration oxygen group prior to the 
administration of oxygen due to the inability to obtain PtCO2 recordings (n=1) and two 
protocol violations which included the inadvertent enrolment of a patient with COPD and 
another with obesity hypoventilation syndrome.  As a result there were 72 and 75 patients 
included in the high concentration and titrated oxygen groups respectively.  The two groups 
were similar in age, sex, respiratory rate, oxygen saturation, PtCO2, CRB-65 score and 
radiological confirmation of pneumonia at baseline as outlined in Table 10. 
 
Table 10. Characteristics of patients presenting with suspected community-acquired 
pneumonia, according to randomized oxygen treatment group 
  
High 
concentration                           
n=72 
Titrated                   
n=75 
All 
n=147 
Sex, male 32 28 60 
Age, yr 45.2 (16.3) 46.4 (16.3) 45.8 (16.2) 
Respiratory rate, breaths/min 24.2 (6.0) 24.6 (6.6) 24.4 (6.3) 
Heart Rate, beats/min 90.5 (16.8) 88.1 (18.2) 89.3 (17.5) 
SpO2, % 96.3 (3.4) 96.2 (3.2) 96.2 (3.3) 
PtCO2, mmHg 32.7 (4.6) 33.6 (5.9) 33.1 (5.3) 
PtCO2 38 mmHg 11/72 (15.3) 18/75 (24.0) 29/147 (19.7) 
CRB-65 Score ≥2 7 (9.7) 7 (9.3) 14 (9.3) 
Confirmed pneumonia 
 
35/72 (48.6) 
 
39/75 (52.0) 
 
74/147 (50.3) 
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Values are mean (SD) for age, respiratory rate, heart rate, SpO2 and PtCO2, number of 
participants (percentage) for sex, confirmed pneumonia, PtCO2 38 mmHg and CRB-65 
score 2 
  
 
 In 74/146 (50.7%) patients (one patient refused a chest radiograph), there was radiological 
confirmation of pneumonia, with the presence of a pulmonary infiltrate on the chest 
radiograph.  Patients with confirmed pneumonia had lower oxygen saturations: mean (SD) 
95.7% (3.7) vs 96.8% (2.8) and a greater proportion with a CRB-65 score 2: 12/74 (16.2%) 
vs 2/73 (2.7%). 
  
There was a wide range of PtCO2 levels at baseline ranging from 17 to 49 mmHg (Figure 17).   
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Figure 16. The PtCO2 levels at baseline and after 60 minutes in the high concentration (o) 
and titrated (•) oxygen groups 
 
 Most (134/147) (91.2%) presented with an oxygen saturation >92% at baseline.  In the 
titrated oxygen group 68/75 (90.7%) patients did not require oxygen therapy throughout 
the 60 minute treatment period as their oxygen saturations remained >92%.  In the titrated 
oxygen group 6/75 (8.3%) patients required oxygen between 1 to 4 litres per minute via 
nasal prongs and 1/75 (1.4%) patient required >4 litres per minute via medium 
concentration mask to achieve oxygen saturations 93%.  In the high concentration oxygen 
group the oxygen saturation at 60 minutes was 99% in 65/72 (90.3%) of patients and was 
between 93 and 98% in the remaining 7/72 (9.7%) patients. 
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Changes in PtCO2 
The proportion of patients with an increase in PtCO2 of ≥4 mmHg at 60 minutes was 
significantly greater in the high concentration group, compared with the titrated oxygen 
group, 36/72 (50.0%) vs 11/75 (14.7%) with a relative risk of 3.4 (95% CI 1.9 to 6.2; P<0.001) 
(Table 11).   
The proportion of patients with a rise in PtCO2 8 mmHg was significantly greater in the high 
concentration, 11/72 (15.3%), compared with the titrated group 2/75 (2.7%), with a relative 
risk of 5.7 (95% CI 1.3 to 25.0, P=0.007).  The proportion of patients with both a rise in PtCO2 
≥4 mmHg and a PtCO2 38 mmHg at 60 minutes was 19/72 (26.4%) and 5/75 (6.7%), in the 
high concentration and titrated oxygen groups respectively, with a relative risk of 2.7 (95% 
CI 1.2 to 6.0, P=0.001) 
Table 11. The proportion of patients with a predetermined rise in PtCO2 from baseline at 
60 minutes 
 High concentration 
n (%) 
Titrated 
n (%) 
Relative risk 
(95% CI) 
 
P value 
Change in PtCO2  
4 mmHg 
36 (50%) 11 (14.7%) 3.4 (1.9 to 6.2) P<0.001 
Change in PtCO2  
4 mmHg and   
PtCO2 38 mmHg 
19 (26.4%) 5 (6.7%) 2.7 (1.2 to 6.0) P=0.01 
Change in PtCO2  
8 mmHg 
11 (15.3%) 2 (2.7%) 5.7 (1.3 to 25.0) P= 0.007 
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The proportion of patients with a rise in PtCO2 ≥4 mmHg was also greater in the high 
concentration group at the 20 and 40 minute time points (Table 12).  In both groups the 
proportion of patients with a PtCO2 ≥4 mmHg progressively increased throughout the 60 
minute time course.  
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 Table 12. The time course of the changes in PtCO2 in the treatment groups 
(i) The proportion of patients with a rise in PtCO2 4 mmHg 
 
Time 
High concentration 
n (%) 
Titrated 
n (%) 
Relative risk 
(95% CI) 
 
P value 
 
20 minutes 
 
19 (26.4%) 
 
4 (5.3%) 
 
5.0 (1.8 to 13.8) 
 
P<0.001 
 
40 minutes 
 
 
27 (37.5%) 
 
8 (10.7%) 
 
3.5 (1.7 to 7.2) 
 
P<0.001 
60 minutes 
 
36 (50.0%) 11 (14.7%) 3.4 (1.9 to 6.2) P<0.001 
(ii) The mean change in PtCO2 (mmHg) 
 
Time 
High concentration 
mean (SD) 
Titrated 
mean (SD) 
Difference 
(95% CI) 
 
P value 
 
20 minutes 
 
1.9 (3.4) 
 
-0.2 (2.7) 
 
2.1 (1.1 to 3.1) 
 
P<0.001 
 
40 minutes 
 
 
2.9 (3.7) 
 
0.5 (3.6) 
 
2.4 (1.2 to 3.6) 
 
P<0.001 
60 minutes 
 
3.6 (3.9) 0.9 (3.7) 2.7 (1.5 to 3.9) P<0.001 
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The change in PtCO2 from baseline was significantly greater in the high concentration 
oxygen compared with the titrated oxygen group, with a mean difference of 2.7 mmHg (95% 
CI 1.5 to 3.9; P<0.001) at 60 minutes (Table 12ii).  In both randomized groups the PtCO2 
increased with time (Table 12ii).  The rate of increase in the high concentration group was 
0.058 (95% CI 0.044 to 0.072) mmHg/min and the titrated group was 0.017 (95% CI 0.0031 
to 0.031) mmHg/min.  The difference in the rate of change was 0.041 mmHg/min (95% CI 
0.022 to 0.06), P<0.001). 
 
In patients with radiological confirmation of pneumonia, the high concentration oxygen 
group had a higher proportion with a rise in PtCO2 4 mmHg (20/35 (57.1%) vs 5/39 (12.8%), 
relative risk 4.5 (95% CI 1.9 to 10.6), compared to those without consolidation 16/37 
(43.2%) vs 6/36 (16.7%), relative risk 2.6 (95% CI 1.1 to 5.9), however this interaction was 
not statistically significant, P=0.28.  
Clinical variables 
There was no significant difference in the change in respiratory rate (-2.9 vs -2.5 breaths per 
minute, high concentration vs titrated oxygen groups respectively, P=0.63).  The reduction 
in heart rate was greater in the high concentration compared to the titrated oxygen group (-
6.8 vs -2.6 beats per minute, mean difference -4.2, 95%CI -7.3 to -1.2, P=0.007).  The CRB-65 
did not differ between the two groups and there were similar rates of hospital admissions 
between the two treatment groups, 36/72 (50%) vs 37/75 (49.3%) for high concentration 
versus titrated oxygen respectively, relative risk 1.01 (95% CI 0.74 to 1.39, P=0.94). One 
patient in the titrated group required admission to the intensive care unit. 
 
3.3.5 Discussion 
  
This randomised controlled trial has shown that high concentration oxygen therapy results 
in a significant increase in PtCO2 when administered to patients presenting to an emergency 
department with suspected community-acquired pneumonia.  The three- to six-fold relative 
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risk of an increase in PtCO2 of at least 4 mmHg or at least 8 mmHg suggests that this effect 
may be of both physiological and clinical significance.   
 
There are a number of methodological issues relevant to the interpretation of the study 
findings.  The first is that we used a TOSCA transcutaneous CO2 monitor to measure PaCO2 
rather than the “gold standard” arterial blood gas (ABG) test. This method was chosen as it 
allowed continuous PtCO2 monitoring without the discomfort of arterial blood gas sampling 
or the risk of hand ischemia associated with indwelling radial artery cannulae. The accuracy 
of transcutaneous carbon dioxide monitoring has been demonstrated in a variety of settings 
including healthy subjects,161 162 AECOPD,153 163 sleep disorders,164 165 critical illness,166 and in 
a mixed group of 51 patients presenting to an ED.167  The accuracy of our device has been 
assessed in a subset of patients who had simultaneous ABG and PtCO2 recordings
168. The 
TOSCA accurately assessed PaCO2 without significant bias and with clinically acceptable 
limits of agreement when compared to the ABG measurement, thus validating the  
methodology used. 
  
By necessity the study was unblinded, as there was a clinical requirement for the 
investigator to have knowledge of the oxygen saturations in order to titrate the oxygen 
therapy in the “control” treatment group, and an ethical requirement for the investigator to 
monitor the patient’s progress with knowledge of the oxygen administered.  The objective 
display of PtCO2 on the TOSCA monitor avoided subjective assessment of the primary 
outcome variable. 
 
The decision to administer oxygen for 60 minutes was based on the evidence that CO2 
retention in COPD74 76 78 82 and asthma104 112 primarily occurs within 20 minutes of 
administration.  However, further increases in PaCO2 may occur beyond this time period and 
as a result the magnitude of the risk of an increased PtCO2 with high concentration oxygen 
therapy may have been underestimated in our study.  This was suggested by our 
observation that the difference in PtCO2 between the high concentration and titrated 
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oxygen groups progressively increased throughout the 60 minute period.  This is clinically 
relevant as relief of dyspnoea in pneumonia may take many days and oxygen therapy is 
often continued until the dyspnoea resolves. 
The pre-specified analysis plan was to use the proportion of subjects with a PtCO2 >38 
mmHg at 60 minutes as the primary outcome variable.  However, in the early phase of 
recruitment it was apparent that the pre-specified primary outcome variable did not reflect 
a physiological increase in PtCO2 as it was primarily determined by the presenting PtCO2.  
After a review of the records of the first 37 subjects (representing 25% of 150 participants 
contributing to the main outcome analysis) a change was registered in the primary outcome 
variable to the proportion of subjects with a PtCO2 rise of 4 mmHg.  We acknowledge that 
changing the primary outcome variable after the start of the study raises the possibility of 
creating a biased assessment of the outcome of the trial.  However, no formal interim 
statistical analysis, of either the pre-specified outcome variable or the new main outcome 
variable, was carried out prior to this decision and although the study itself was not masked 
as to treatment allocation the decision was made without reference to the randomised 
allocation of the research participants.   
 
Patients were excluded if they had a diagnosis of COPD due to the known effect of high 
concentration oxygen in exacerbations of this disorder59 60 74 75 78 82. Patients with established 
COPD were not included in this study based on their history. In addition, information was 
available from electronic medical records which documents any previous hospital 
admission, out-patients consultations and spirometry where available, allowing further 
investigation of a diagnosis of COPD.  However, given that spirometry was not performed on 
enrollment or prior to discharge, patients with a new diagnosis of airway obstruction may 
have been included in the study. In clinical practice, when patients present with symptoms 
to suggest pneumonia, spirometry is rarely available at the first point of oxygen therapy 
which is usually in the ambulance or Emergency Department, thus this study replicates what 
happens in clinical practice.  Indeed, it is probable that greater increases in PtCO2 may occur 
in an unselected population of patients with community-acquired pneumonia, which is 
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more likely to include those with concomitant COPD or other disorders associated with 
chronic respiratory failure. 
  
Patients presenting with suspected rather than confirmed community-acquired pneumonia 
were enrolled in the study, as oxygen therapy is usually administered to breathless patients 
presenting with suspected pneumonia rather than after the diagnosis is confirmed by chest 
radiography.  About half of the patients had pneumonia subsequently confirmed by the 
presence of consolidation on the chest radiograph.  Most of the other patients were likely to 
have had pneumonia without diagnostic changes on plain chest radiographs, which may 
occur in about one-third of patients with community-acquired pneumonia confirmed by 
high-resolution computed tomography.169  This may explain why the presence of 
radiologically confirmed pneumonia made no significant difference to the risk of a raised 
PtCO2 with  high concentration oxygen therapy.  When the analysis was restricted to 
subjects with radiologically confirmed pneumonia, there was a 4.5-fold increased risk of a 
rise in PtCO2 4 mmHg with high concentration oxygen therapy. 
 
In the absence of a clear view on what represents “physiologically” or “clinically” significant 
increase in PtCO2 we chose levels of 4 mmHg and 8 mmHg respectively.  The primary 
outcome variable was a rise of 4 mmHg which was considered to be physiologically 
significant, greater than the modest increase that might be expected from the Haldane 
effect.   The secondary outcome variable, a rise of 8 mmHg, was considered to represent 
an effect of clinical significance.  The findings of both the 8 mmHg rise in PtCO2 in 15% of 
patients with community-acquired pneumonia treated with high concentration oxygen 
therapy and the associated six-fold relative risk compared with titrated oxygen therapy is of 
potential clinical importance.  The study was not powered to investigate differences in 
clinical outcomes, in particular the adverse effects of severe hypercapnia.  This issue needs 
to be addressed in a large study of an unselected group presenting with severe community-
acquired pneumonia. 
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Both treatment groups were hypocapnic on presentation indicating a degree of 
hyperventilation. Over the course of the 60 minutes, there was a modest reduction in 
respiratory rate of <3 breaths per minute, with no significant difference between the two 
groups.  This suggests that the greater increase in PtCO2 in the high flow group could not be 
attributed to differential effects on minute ventilation.  High flow oxygen resulted in a 
reduction in heart rate, which is a well recognized cardiovascular response to oxygen 
therapy.39 45 46  This observed effect is not a marker of clinical benefit, as it is associated with 
an accompanying reduction in cardiac output and stroke volume, increases in mean arterial 
pressure and systemic vascular resistance, and reduction in coronary artery blood flow.39 45 
46 
 
In pneumonia, hypoxaemia is primarily due to intrapulmonary shunting and ventilation-
perfusion inequalities.170-172  Treatment with high concentration oxygen in pneumonia has 
minimal effect on intrapulmonary shunting, however it has the potential to significantly 
worsen ventilation-perfusion mismatch through release of hypoxic pulmonary 
vasoconstriction.171-173  This would lead to an increase in the physiological dead space and is 
likely to represent the predominant mechanism responsible for the increase in PtCO2 
observed.  Importantly, these data suggest that high concentration oxygen therapy may 
have the potential to cause an increase in PaCO2 across a wide range of respiratory 
conditions with abnormal gas exchange.  Indeed, this physiological response to high 
concentration oxygen therapy has now been reported in stable COPD,75 78 exacerbations of 
COPD59 60 74 82, asthma,104 112 113 and obesity hypoventilation syndrome.174  
 
Finally, this study reinforces concerns that the routine use of high concentration oxygen in 
pneumonia and other acute respiratory conditions has the potential to lead to a delay in the 
ability to recognize a subsequent progressive clinical deterioration.55 56 In subjects in the 
high concentration oxygen group, the oxygen saturations were 99% in 90% of patients. If a 
progressive clinical deterioration were to occur in these patients, there may be little or no 
change in oxygen saturation until a potentially life-threatening situation has developed.  At 
this stage there is limited opportunity to further increase the oxygen therapy while 
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interventions such as a medical review and transfer to the intensive care unit are 
undertaken.  In contrast, 90% of patients in the titrated oxygen group required no 
supplementary oxygen at all as their oxygen saturations remained >92%.  A subsequent 
clinical deterioration in these patients is likely to be recognized sooner through pulse 
oximetry, giving the option of increasing the oxygen therapy while further intervention is 
undertaken.  This is contrary to the common assumption that administration of high 
concentration oxygen in a breathless patient will have a protective effect in the event that 
their clinical condition worsens. 
 
In conclusion high concentration oxygen increases the PtCO2 in patients with community 
acquired pneumonia.  This suggests that the potential increase in PaCO2 with high 
concentration oxygen therapy is not limited to COPD, but may also occur in other 
respiratory disorders with abnormal gas exchange.  It also reinforces the importance of 
recognizing that oxygen is a drug that should be prescribed for defined indications in which 
the benefits outweigh the risks, that the prescription should specify the dose, method and 
duration of delivery, and that the patient’s response to oxygen therapy should be 
monitored.96  Based on the results of this study, It is recommended that in patients with 
suspected community-acquired pneumonia oxygen should be administered only to those 
patients with evidence of arterial hypoxemia in a dose that relieves the hypoxemia without 
causing hyperoxia, thereby achieving the benefits while reducing the potential for harm.175 
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Chapter 3.4   Randomised controlled trial of high concentration versus 
titrated oxygen therapy in acute severe asthma 
 
3.4.1 Introduction 
 
It is well recognised that high concentration oxygen therapy may lead to carbon dioxide  
(CO2) retention when administered to patients with acute exacerbations of chronic 
obstructive pulmonary disease (AECOPD)59 60 and that worsening ventilation-perfusion 
mismatch due to release of hypoxic pulmonary vasoconstriction with a resulting increase in 
physiological dead space is one of the major mechanisms causing this effect.74 75 78 82 176  In 
contrast, the risks and benefits of oxygen therapy in acute severe asthma are less well 
understood. As with AECOPD, the dominant gas exchange abnormality in severe 
exacerbations of asthma is ventilation-perfusion mismatch, and oxygen administration has 
been shown to worsen the degree of mismatch.104 105 109-111 As a result, it would be expected 
that high concentration oxygen therapy could also cause CO2 retention in severe asthma, 
similar to its administration in AECOPD.  There is preliminary data from case reports, case 
series and a single randomised controlled trial to suggest that high concentration oxygen 
therapy may cause CO2 retention in acute severe asthma.
112 113 177 19 104 110 111 178 179 However, 
there are no randomised controlled trials comparing high concentration oxygen therapy 
with titrated oxygen administered only to hypoxaemic patients, to relieve hypoxaemia but 
avoiding hyperoxia, as recommended in recent British asthma101 and oxygen guidelines.13 
 
3.4.2 Objectives 
 
 To investigate the effects of high concentration oxygen therapy on PaCO2 in patients 
presenting to the ED with severe exacerbations of asthma.   
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3.4.3 Methods 
 
Subjects 
The study was conducted in the EDs of three metropolitan hospitals in Wellington, New 
Zealand: Wellington Hospital (tertiary public), Hutt Hospital (secondary public) and 
Kenepuru Hospital (secondary public).  
 
Inclusion Criteria 
Patients presenting to the emergency department with asthma either by ambulance or self 
presentation were approached by the investigator to assess potential eligibility.  
 Aged between 18 and 65 years  
 previous doctor diagnosis of asthma,  
 history consistent with a current acute exacerbation of asthma,  
 forced expiratory volume in one second (FEV1) 50% of predicted values at the time 
of first assessment. 
 
Exclusion Criteria 
 Patients with a diagnosis of COPD,  
 Patients with disorders associated with hypercapnic respiratory failure such as 
neuromuscular disease, chest wall restriction, or obesity hypoventilation syndrome 
 Patients who were unconscious, unable to speak or unable to perform spirometry  
 
 Patients were provided with a patient information sheet (appendix 2) and written informed 
consent was obtained from each patient.   
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Study protocol 
A detailed study protocol can be found in appendix 3. Patients were randomly assigned to 
one of two oxygen regimes for one hour.  Patients in the high concentration group received 
oxygen at a flow rate of 8 L/min via a medium concentration mask (Hudson RCI, Durham NC, 
USA) which delivers a FiO2 of between 0.4 and 0.78
180 Patients in the titrated group received 
oxygen only if their saturation was 92% on room air, with oxygen titrated as required at 5 
minute intervals, to achieve an oxygen saturation of 93 to 95% according to the protocol 
outlined in chapter 3.1, table 9. Flow rates up to 4L/min were delivered via nasal prongs 
(Hudson RCI, Durham NC, USA). Flow rates higher than 4L/min were delivered by medium 
concentration mask. 
 
A computerised randomisation sequence was generated by the biostatistician, Dr Mark 
Weatherall, and patients were enrolled and assigned to their treatment group by myself and 
the other clinical research fellows. Allocation concealment was achieved by using a secure 
database which contained the randomisation sequence.  Allocation was only revealed to the 
researchers when the subjects were enrolled and their name entered in the database.  
Neither investigators or patients could be blinded to the treatment regimes due to the 
requirement to titrate oxygen therapy in the control group.   
 
A medical history was taken, each patient underwent a physical examination, and asthma 
therapy was administered in accordance with published guidelines.101 All patients received 
salbutamol 2.5mg and ipratropium bromide 0.5mg via air driven nebuliser (Portaneb, 
Respironics, Murrysville PA, USA) on arrival. Patients with severe asthma (FEV1 30 to 50% 
predicted) received salbutamol 2.5mg via a nebuliser every 20 minutes and prednisone 
40mg orally. Those with very severe asthma (FEV1 <30% predicted) received salbutamol 
2.5mg via nebuliser every 15 minutes, hydrocortisone 200mg intravenously and magnesium 
sulphate 2g in 100ml normal saline intravenously over 20 minutes. 
 
Measures 
Transcutaneous carbon dioxide (PtCO2) was used to estimate arterial PaCO2 using a 
combined oxygen saturation/PtCO2 monitor (TOSCA, Radiometer, Basel, Switzerland) as 
  
125 
described in Chapter 3.1.  Measurements of PtCO2, FEV1, respiratory rate and heart rate 
were made at baseline (0 minutes) and at 20, 40 and 60 minutes.  The oxygen saturation 
was measured continuously throughout the study period and recorded at 5 minute 
intervals. Figure 18 shows the study protocol and measures taken. 
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 Patient arrives in ED with acute 
exacerbation of asthma 
 Triage nurse notifies research fellow 
 Baseline FEV1 recorded 
FEV1 ≤ 50% predicted? 
  
 
 
 
 Room air for at least 10 minutes or start 
titrated oxygen if SpO2 <92% 
 2.5mg salbutamol + 0.5mg ipratropium 
 Consent and randomize  
 
 
T = 0 
 Baseline PtCO2 
 Start O2 protocol  
 Baseline recordings 
 
 
FEV1 30 to 50% 
Asthma treatment protocol 1 
(Severe) 
FEV1 < 30% 
Asthma treatment protocol 2 
(Very severe) 
At T = 20 and 40 mins: 
 FEV1 
 Respiratory rate 
 SpO2 
 PtCO2 
 
At T = 20 and 40 mins: 
 FEV1 
 Respiratory rate 
 SpO2 
 PtCO2 
 
 
At T=60mins:  
 Final recordings 
 Final PtCO2 recorded 
 
At T=60mins: 
 Final recordings 
 Final PtCO2 recorded 
 
 
Yes 
Figure 17. Study protocol acute severe asthma 
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Statistical Analysis 
 
The initial pre-specified primary outcome variable was the proportion of patients with a 
PtCO2 >38 mmHg and FEV1 50% at 60 minutes.  However, after recruitment of the initial 19 
subjects it was apparent that the main determinant of this outcome was the baseline PtCO2, 
rather than whether an increase in PtCO2 had actually occurred.  Specifically, of the 3/19 
subjects who met the primary endpoint, two had a decrease in PtCO2 (from 46mmHg to 
39mmHg and from 45mmHg to 44mmHg) and the other had a minimal increase (from 
39mmHg to 40mmHg). For this reason, the primary outcome was changed to the proportion 
of patients with a PtCO2 rise of 4 mmHg, and the proportion of patients with a PtCO2 rise 
of 4 mmHg and a PtCO2 38 mmHg at 60 minutes included as a secondary outcome 
variable.  Other secondary outcome variables included the mean change in PtCO2 from 
baseline, changes in respiratory rate, heart rate and FEV1, and the need for hospital 
admission at the end of the ED treatment period.  The proportion of patients with a PtCO2 
rise of 8 mmHg was added as a post hoc outcome variable.  The rate of change of PtCO2 
was determined using a mixed linear model with random intercept and slope terms. In the 
mixed linear model the fixed effects were the randomised treatment as a dichotomous 
variable, time as a continuous covariate, and a treatment times time interaction term. A 
random slope and intercept term with the individual participants as subjects and an 
unstructured covariance specified for the intercept and slope accounted for the correlation 
of repeated measurements on the same participants. Continuous outcome variables were 
analyzed as change from baseline using independent sample t-tests, or for achieved oxygen 
saturation for which normality assumptions were not met, by a Mann-Whitney test.  Logistic 
regression was used to model the risk of admission, expressed as an odds ratio, both 
unadjusted for other variables and adjusted for baseline FEV1, baseline oxygen saturation, 
and baseline PtCO2. Analysis was by intention to treat.  SAS version 9.1 and Minitab version 
14 were used.  
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Sample size calculation 
Based on previous research113 we calculated that to detect a difference in the primary 
outcome variable of 20% in the high concentration oxygen group and 5% in the titrated 
group, with power of 80% at a type 1 error rate of 5%, 75 participants were required in each 
group. 
 
Ethics approval 
Ethical approval was granted by the Central Regional Ethics Committee. See appendix 4. 
 
3.4.4 Results 
 
Eligible patients were recruited from July 2007 to December 2009.  A total of 106 patients 
were randomised, 53 to the high concentration group and 53 to the titrated group.  Three 
patients were withdrawn from the high concentration oxygen group, two due to protocol 
violations in which the subjects met an exclusion criteria after randomisation (one patient 
with COPD and one with obesity hypoventilation syndrome), and in one patient a reliable 
PtCO2 signal could not be obtained. As a result there was data from 50 patients in the high 
concentration group and 53 in the titrated group for final analysis.  Figure 19 shows the flow 
of the patients through the study.   
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Figure 18. Flow of patients through asthma study 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
129 patients presenting to ED with 
acute asthma 
106 patients randomised 
Declined to take part n = 11 
FEV1 >50% predicted n = 12 
53 patients randomised to 
titrated oxygen 
53 patients randomised to 
high flow oxygen 
Withdrawals (see text) 
n=3 
 
53 patients included in 
analysis 
50 patients included in 
analysis 
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The two oxygen treatment groups were well matched with respect to age, sex and 
respiratory rate (Table 13).   
Table 13. Baseline characteristics of patients in asthma study 
 
  
High flow O2 
n=50 
Titrated O2                
n=53 
All 
n=103 
Sex, male N (%) 27 (54) 18 (34) 45 (43.7) 
Age, yr  35.0 (14.4) 32.6 (11.1) 33.8 (12.8) 
Respiratory rate, breaths/min 23.4 (6.6) 22.7 (5.7) 23.0 (6.1) 
Heart Rate, beats/min 97.7 (23.4) 100.7 (18.8) 99.2 (21.1) 
SpO2, % 95.1 (3.2) 96.4 (2.7) 95.8 (3.0) 
PtCO2, mmHg 36 (7.1) 34.1 (5.7) 35 (6.4) 
PtCO2 38 mmHg 20 (40.0) 15 (28.3) 35 (34.0) 
FEV1, L/min 1.15 (0.43) 1.29 (0.44) 1.22 (0.44) 
FEV1 % predicted 32.1 (9.9) 36.9 (9.7) 34.6 (10.1) 
Values for age, respiratory rate, heart rate, SpO2, PtCO2 FEV1 and FEV1 % predicted are mean 
(SD). Values for sex and PtCO2 38 mmHg are number of participants (percentage)  
 
The baseline FEV1 in the high concentration oxygen and titrated oxygen groups were 1.15L 
and 1.29L respectively. 
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PtCO2 levels at baseline ranged from 14 to 50 mmHg (Figure 20).  
Figure 19. The PtCO2 levels at baseline and after 60 minutes in asthma study 
The PtCO2 levels at baseline and after 60 minutes in the high concentration (o) and titrated (•) 
oxygen groups.  The subject who received high concentration oxygen and was withdrawn after 11 
minutes due to safety concerns, following an increase in the PtCO2 from 41 to 52 mmHg, is not 
presented in the figure. 
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The majority of patients were hypocapnic at baseline with 68/103 (66%) having a PtCO2 <38 
mmHg. There were eight patients with an oxygen saturation <93% at baseline while 
breathing room air. In the titrated oxygen group 48/53 (90%) patients did not require 
oxygen therapy throughout the 60 minute treatment period, four patients required 1-
3L/min and one required more than 3L/min.  In the high concentration oxygen group the 
oxygen saturation at 60 minutes was 99% in 39/50 (78%) of patients and was 95% in the 
remaining 11 patients.   
 
The PtCO2 levels at 60 minutes ranged from 18 to 52 mmHg (Figure 20).  One patient who 
received high concentration oxygen was withdrawn after 11 minutes due to safety concerns, 
following an increase in the PtCO2 from 41 to 52 mmHg.  For the categorical outcome 
variables, the PtCO2 value at 11 minutes was used as the final measurement in this patient. 
A total of 10 patients had a final PtCO2 45 mmHg.  All 10 patients were in the high 
concentration oxygen group, and in five patients there was an increase in PtCO2 10 mmHg.   
 
The proportion of patients with an increase in PtCO2 of ≥4 mmHg at 60 minutes was 
significantly greater in the high concentration group, compared with the titrated oxygen 
group, 22/50 vs 10/53 with a relative risk of 2.3 (95% CI 1.2 to 4.4; P=0.006) (Table 14). The 
proportion of patients with a rise in PtCO2 8 mmHg was significantly greater in the high 
concentration group, with a relative risk of 3.9 (95% CI 1.2 to 13.1, P=0.016).  The proportion 
of patients with both a rise in PtCO2 ≥4 mmHg and a PtCO2 38 mmHg at 60 minutes was 
significantly greater in the high concentration group with a relative risk of 4.5 (95% CI 1.6 to 
12.5, P=0.001). A total of 10 patients had a final PtCO2 45 mmHg. All 10 patients were in 
the high concentration oxygen group, and in five patients there was an increase in PtCO2 
10 mmHg. 
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Table 14. The proportion of patients with a predetermined rise in PtCO2 from baseline at 
60 minutes 
 High flow O2 
n (%) 
Titrated O2 
n (%) 
Relative risk 
(95% CI) 
 
P value 
 
Change in PtCO2 4 mmHg 
 
22 (44%) 
 
10 (19%) 
 
2.3 (1.2 to 4.4) 
 
P=0.006 
 
Change in PtCO2 4 mmHg 
and PtCO2 38 mmHg 
 
17 (34%) 
 
4 (8%) 
 
4.5 (1.6 to 12.5) 
 
P=0.001 
 
Change in PtCO2 8 mmHg 
 
11 (22%) 
 
3 (6%) 
 
3.9 (1.2 to 13.1) 
 
P= 0.016 
 
The proportion of patients with a rise in PtCO2 8 mmHg was significantly greater in the high 
concentration group, with a relative risk of 3.9 (95% CI 1.2 to 13.1, P=0.016).  The proportion 
of patients with a PtCO2 >38 mmHg and an FEV1 percent predicted less than 50% after 60 
minutes was 20/49 (40.8%) in the high concentration group and 6/53 (11.3%) in the titrated 
group, relative risk 3.6 (95% CI 1.6 to 8.2; P < 0.001). 
 
The mean change in PtCO2 from baseline was significantly greater in the high concentration 
group with a mean difference between the groups at 60 minutes of 2.6 mmHg (95% CI 0.9 to 
4.3; P<0.003) (Table 15). The proportion of patients with a rise in  
PtCO2 was greater in the high concentration group at the 20 and 40 minute time points 
(Table 15).  The rate of increase in the high concentration group was 0.054 (95% CI 0.035 to 
0.074) mmHg/min and the titrated group was 0.012 (95% CI -0.0065 to 0.031) mmHg/min.  
The difference in the rate of change was 0.042 mmHg/min (95% CI 0.069 to 0.15, P=0.003). 
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Table 15. Time course of changes in PtCO2 in the treatment groups 
i)  The mean change in PtCO2 (mmHg) 
 
 
Time 
High concentration 
mean (SD) 
Titrated 
mean (SD) 
Difference 
(95% CI) 
 
P value 
 
20 minutes 
 
2.8 (4.1) 
 
0.3 (3.6) 
 
2.5 (1.0 to 4.0) 
 
P=0.001 
40 minutes 3.0 (4.7) 0.4 (3.8) 2.6 (0.9 to 4.3) P=0.002 
60 minutes 3.4 (4.5) 0.8 (4.1) 2.6 (0.9 to 4.3) P=0.003 
 
ii)  The proportion of patients with a rise in PtCO2 4 mmHg 
 
Time 
High concentration 
N (%) 
Titrated 
N (%) 
Relative Risk 
(95% CI) 
 
P value 
 
20 minutes 
 
15 (30%) 
 
7 (13%) 
 
2.3 (1.0 to 5.1) 
 
P=0.038 
40 minutes 21 (42%) 8 (15%) 2.8 (1.4 to 5.7) P=0.002 
60 minutes 22 (44%) 10 (19%) 2.3 (1.2 to 4.4) P=0.006 
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There were 26/50 (52%) of the high concentration group admitted to hospital compared to 
17/53 (32%) in the titrated group, odds ratio  2.3 (95% CI 1.0 to 5.1). P=0.042. After 
adjusting baseline FEV1, oxygen saturation, and PtCO2, this odds ratio was 1.7 (95% CI 0.68 
to 4.26, P=0.26) (Table 16). In the adjusted analysis, a higher baseline FEV1 and oxygen 
saturation were associated with a reduced risk of admission.   
  
Table 16. Risk of hospital admission 
i)  Unadjusted analysis  
  OR (95% CI) P-value 
High concentration oxygen 2.29 (1.03 to 5.10) 0.042 
   
ii)  Adjusted analysis   
 OR (95% CI) P-value 
High concentration oxygen 1.70 (0.68 to 4.26) 0.257 
Baseline oxygen saturation (per %) 0.80 (0.66 to 0.98) 0.028 
Baseline PtCO2 (per mmHg) 1.04 (0.96 to 1.12) 0.370 
Baseline FEV1 (per litre) 0.31 (0.10 to 0.94) 0.039 
 
3.3.5 Discussion 
 
This randomised controlled trial has shown that high concentration oxygen therapy results 
in a significant increase in PtCO2 compared to titrated oxygen when administered to 
patients presenting to the emergency department with acute severe asthma.  These results 
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are both physiologically and clinically significant, as indicated by the two- to four-fold 
relative risk of an increase in PtCO2 of at least 4 mmHg or 8 mmHg respectively in the group 
receiving high concentration oxygen.  Furthermore, all 10 patients in whom the final PtCO2 
was 45 mmHg had received high concentration oxygen therapy.  Hypercapnia is an 
indication for admission to an ICU or HDU.101 After adjustment for baseline predictors of 
severity, high flow oxygen was not statistically significant as a predictor of hospital 
admission, although the point estimate is consistent with increased risk. 
 
The results in the current study extend those of previous reports.112 113 178 There have been 
two prospective case series which have reported that oxygen therapy may lead to an 
increase in PaCO2 in adults
112 with acute severe asthma.  In the only previous randomised 
controlled trial comparing high and low concentration oxygen in acute severe asthma, 74 
patients were given 100% or 28% oxygen for 20 minutes on arrival to the emergency 
department prior to receiving any asthma therapy.113  The difference in the mean rise in 
PaCO2 between the groups was 2.7 mmHg, similar to the 2.6 mmHg noted in the current 
study.  However, the duration of oxygen therapy was 20 minutes and no concurrent asthma 
therapy was administered, limiting the generalisability of the study findings. Also, the 
administration of 28% oxygen rather than a titrated oxygen regime differed from the 
therapeutic approach currently recommended in guidelines13 101 181.  Our study and others182 
have shown that most adult patients presenting to the ED with severe exacerbations of 
asthma do not have hypoxaemia, and as a result, do not require initial oxygen therapy. 
 
There are a number of methodological issues relevant to the interpretation of the study 
findings.  The first is that we used a TOSCA transcutaneous CO2 monitor to measure PaCO2 
rather than the “gold standard” arterial blood gas test. This method was chosen as it 
allowed continuous PtCO2 monitoring without the discomfort of arterial blood gas sampling 
or the risk of hand ischemia associated with indwelling radial artery cannulae. The accuracy 
of transcutaneous carbon dioxide monitoring has been demonstrated in a variety of settings 
including healthy subjects,161 162 AECOPD,153 163 sleep disorders,164 165 critical illness,166 183 
184and in a mixed group of 51 patients presenting to an ED.167  The accuracy of our device 
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has been assessed in a subset of patients who had simultaneous ABG and PtCO2 
recordings.168The TOSCA accurately assessed PaCO2 without significant bias and with 
clinically acceptable limits of agreement when compared to the ABG measurement, thus 
validating the methodology used. 
  
By necessity the study was unblinded, as there was a clinical requirement for the 
investigator to have knowledge of the oxygen saturations in order to titrate the oxygen 
therapy in the “control” treatment group.  The objective display of PtCO2 on the TOSCA 
monitor avoided subjective assessment of the primary outcome variable. 
The pre-specified analysis plan was to use the proportion of patients with a PtCO2 >38 
mmHg and FEV1 50% at 60 minutes as the primary outcome variable. However, in the early 
phase of recruitment it was apparent that the pre-specified primary outcome variable did 
not reflect a physiological increase in PtCO2 as it was primarily determined by the presenting 
PtCO2.  After a review of the records of the first 19 patients (representing 17% of 106 
patients contributing to the main outcome analysis) we registered a change in the primary 
outcome variable to the proportion of patients with a PtCO2 rise of 4 mmHg. Whilst 
changing the primary outcome variable after the start of the study raises the possibility of 
creating a biased assessment of the outcome of the trial there was no formal interim 
statistical analysis, of either the pre-specified outcome variable or the new main outcome 
variable, was carried out prior to this decision and although the study itself was not masked 
as to treatment allocation the decision was made without reference to the randomised 
allocation of the patients. In the event, for the original main outcome variable, PtCO2 >38 
mmHg and an FEV1 percent predicted less than 50% after 60 minutes, the 3.6 fold increased 
risk associated with high concentration oxygen therapy was similar to the 2.3 and 3.9 fold 
increased risk observed with a PtCO2 rise of 4 mmHg and 8 mmHg respectively. 
  
It is unlikely that patients with established COPD were included in this study based on their 
history. In addition, immediate access to electronic medical records which documents any 
previous hospital admission, out-patients consultations and spirometry were available, 
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allowing further investigation of a diagnosis of COPD. The intention was to recruit 150 
patients, based on the power calculation derived from the previous randomised controlled 
trial of oxygen therapy in asthma.113  Due to difficulties with recruitment, the study sites 
were extended to include Hutt Hospital, and the planned 2 year study period by 6 months.  
With these measure 106 patients were enrolled which was less than the planned 150. 
However, as the study showed a statistically significant difference in risk the issue of type II 
error (and its complement statistical power) is not as important as it might have been if no 
statistically significant difference had been detected. It could be argued that the lower limit 
of the confidence interval for the risk includes a clinically irrelevant difference and that 
tighter confidence intervals arising from a larger sample size would give greater certainty 
than the achieved sample size. Patients with a diagnosis of COPD were excluded due to the 
known effect of high concentration oxygen in exacerbations of this disorder.59 60 74 75 78 82 176. 
It is probable that greater increases in PtCO2 may occur in an unselected population of 
patients with acute asthma, which is more likely to include those with concomitant COPD or 
other disorders associated with chronic respiratory failure.  
 
Although an attempt was made to include potential patients with severe or life threatening 
asthma, patients who were moribund, unable to speak, unable to perform spirometry, or so 
distressed that they could not consent, were not enrolled. Consequently, those with the 
most severe airflow obstruction, and hence the highest risk of hypercapnia at presentation, 
were not able to be studied.  In this regard it is relevant that with progressively more severe 
hypercapnia, smaller falls in alveolar ventilation are required to produce a given further rise 
in PaCO2
30. 
 
The increase in PtCO2 with high concentration oxygen is likely to be an underestimate of the 
magnitude of the effect that may be seen in standard clinical practice in which oxygen 
therapy may be administered for a longer period. The PtCO2 progressively increased in the 
high concentration group throughout the 60 minute study period, suggesting that some 
patients may have had further increases in PtCO2 had the high concentration oxygen regime 
continued.  
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The main mechanism for the elevation in PtCO2 demonstrated in this study is likely to be 
worsening ventilation-perfusion mismatching as a result of the release of hypoxic 
pulmonary vasoconstriction and a consequent increase in physiological dead space, as has 
been demonstrated in studies of the effects of oxygen therapy in both acute severe and 
chronic asthma.104 109-111  This is one of the main mechanisms which causes oxygen-induced 
CO2 retention in AECOPD.
74 78 82 176  The important clinical implication of this data is that high 
concentration oxygen therapy may have the potential to cause an increase in PaCO2 across a 
wide range of respiratory conditions with abnormal gas exchange due to ventilation 
perfusion inequality.  In support of this interpretation, this physiological response to high 
concentration oxygen therapy has now been reported in stable COPD,75 78, AECOPD,59 60 74 
asthma,104 112 113 and obesity hypoventilation syndrome174. This response contrasts with that 
observed in normal subjects in whom high concentration oxygen therapy leads to a small 
decrease in PaCO2
185 186 The observation that there was no difference in the change in FEV1 
between the two regimes suggests that the increase in PtCO2 with high concentration 
oxygen therapy was not due to a bronchoconstrictor effect related to the low humidity of 
the delivered oxygen. 
 
In conclusion, high concentration oxygen increases the PtCO2 in patients with acute severe 
asthma.  This suggests that the potential increase in PaCO2 with high concentration oxygen 
therapy is not limited to COPD, but may also occur in other respiratory disorders with 
abnormal gas exchange.  Consistent with recent guidelines,13 101 187this study  recommends 
that in patients with acute severe asthma oxygen should be administered only to those with 
evidence of arterial hypoxemia in a dose that relieves the hypoxemia without causing 
hyperoxia, thereby achieving the benefits while reducing the potential for harm.175 
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Chapter 3.5 Randomised double-blind cross-over study of the effects of 
hyperoxia in obesity hypoventilation syndrome 
  
3.5.1 Introduction 
 
Obesity has reached epidemic proportions with more than one billion overweight adults 
worldwide, of whom at least 300 million are obese188.  Obesity hypoventilation syndrome 
(OHS) is defined as a combination of obesity (body mass index (BMI) >30 kg/m2) and awake 
hypercapnia (PaCO2 ≥45mmHg) in the absence of other known causes of hypoventilation, 
accompanied by sleep disordered breathing189-191.  The prevalence of OHS in the general 
population is unknown; but studies have found hypoventilation in 10-20% of patients with 
obstructive sleep apnoea192 and as high as 31% in a cohort of obese hospitalised patients193. 
 
OHS is often under-diagnosed191-194 and as a result, clinicians treating patients with OHS 
presenting with an acute respiratory or cardiac disorder are unlikely to be aware of the 
presence of chronic respiratory failure and hypercapnia.  In this situation, the identification 
of hypoxaemia by pulse oximetry may lead to the administration of high concentration 
supplemental oxygen, which may have the potential to worsen the hypercapnia.  This could 
occur if there was a reduction in minute ventilation or an increase in the physiological dead 
space due to worsening ventilation/perfusion mismatch, similar to the effects of oxygen 
therapy in acute exacerbations of chronic obstructive pulmonary disease 70 74.  These 
concerns have led current guidelines13 to recommend the judicious use of oxygen in 
patients with OHS, although to the best of our knowledge, there have been no randomised 
controlled trials to support this recommendation. 
 
3.5.2 Objectives 
 
To determine 
 whether breathing 100% oxygen results in worsening hypercapnia in subjects with 
OHS 
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 the underlying mechanisms of any effect by the measurement of minute ventilation 
and physiological dead space. 
 
3.5.3 Methods 
 
Subjects 
Subjects with newly diagnosed OHS were approached to participate in the study. 
 
Inclusion criteria 
 obesity (BMI  >30 kg/m2) and have 
 evidence of daytime hypercapnia (PtCO2 ≥45mmHg) 
 
Exclusion criteria 
 Subjects were excluded if they had a diagnosis of COPD (defined by a post-
bronchodilator FEV1 to FVC ratio <0.7, and FEV1 <80% predicted and >10 pack year 
smoking history) 
 Already receiving treatment with continuous or bilevel non-invasive positive 
pressure ventilation. 
 
All potentially eligible obese subjects  were screened for hypercapnia by myself. There were 
a number of different sources: tertiary hospital sleep clinic and obesity clinic, prior to 
bariatric surgery and from the community identified from general practice records.  All 
patients were outpatients in a stable condition. The majority of subjects had full 
polysomnography, but this was not a requirement for entry into the study. Subjects who 
met the inclusion criteria were provided with a patient information sheet (appendix 2) and 
were invited to take part in the study. 
 
The study was approved by the Wellington Regional Ethics Committee (appendix 4) and 
informed consent was obtained from each patient.  The study was registered with the 
Australia New Zealand Clinical Trials Registry ACTRN 12608000592347. 
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Study Protocol 
A detailed study protocol is shown in appendix 3. The study had a cross-over, AB/BA, design 
with a randomised order of administration of the experimental condition, 100% oxygen or 
room air. Subjects attended a respiratory physiology laboratory for testing on two occasions 
within 7 days.  Each patient was fitted with a full face continuous positive airway pressure 
(CPAP) mask without positive airways pressure, held by elasticised straps around the head. 
Subjects sat upright at 90⁰ during the test.  A Douglas Bag was filled with  either 100% 
oxygen or room air which was attached to a three way tap and then connected via tubing to 
a one-way valve to the CPAP mask. Once the patient’s respiratory rate and minute 
ventilation had reached a steady state whilst breathing room air, the three way valve was 
opened  and the patient breathed the gas in the Douglas bag for 20 minutes. 
 
To ensure an adequate wash out period, subjects were asked to return to the laboratory for 
a second test on a separate day, during which the study protocol was repeated with the 
other gas. 
 
If the PtCO2 rose by more than 10mmHg at any stage during the 20 minute treatment 
period, the study was terminated due to a risk of acidotic hypercapnic respiratory failure 
and coma. 
 
Randomisation 
A computerised randomisation sequence was generated by the statistician and held by the 
respiratory physiologist who prepared the Douglas bags to ensure allocation concealment. 
 
Blinding 
The study was double-blind.  A respiratory physiologist and respiratory physician carried out 
the study protocol on each patient.  The role of the respiratory physiologist was to prepare 
the laboratory on each study day including filling the 200 L Douglas bag with oxygen or air.  
The respiratory physician’s role was to attend to the patient, attach the mask to the 
patient’s face and record the physiological measurements.  Oxygen saturations were not 
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recorded during the treatment period to ensure the patient and respiratory physician were 
blinded to the treatment throughout the duration of the study. 
 
Measurements 
Respiratory rate (RR), transcutaneous carbon dioxide tensions (PtCO2), minute ventilation 
(MV) and dead space to tidal volume ratio (Vd/Vt) were measured at baseline.  PtCO2 was 
used to estimate PaCO2 using a combined SpO2/PtCO2 monitor (“TOSCA”, Radiometer, Basel, 
Switzerland).  MV was measured using a flow sensor (CO2SMO Plus! Respiratory Profile 
Monitor, Respironics, Murrysville, Pennsylvania, USA) attached to the expiratory port of the 
mask, calculated by expressing the eight breath moving average of expiratory volume in 
terms of volume per minute, updated every breath.  The mixed expired CO2 (PeCO2) was 
measured using volumetric capnography (CO2SMO Plus! Respiratory Profile Monitor, 
Respironics, Murrysville, Pennsylvania, USA).  With measurements of the PaCO2 and PeCO2, 
the Vd/Vt was calculated by the machine, using the Bohr-Engoff equation195. The tidal 
volume (Vt) was calculated by the equation Vt = MV/RR, the physiological dead space 
volume (Vd) was calculated by the equation Vd = Vt x Vd/Vt, the alveolar volume (Va) was 
calculated by the equation Va = Vt - Vd, and the alveolar minute ventilation (MVa) was 
calculated by the MVa = Va x RR.  The minute ventilation was used as a measure of 
ventilatory drive and the Vd/Vt as a measure of physiological dead space. All data were 
recorded on a data collection sheet (Appendix 1) 
 
Statistical analysis 
The main outcome variable was PtCO2 and the primary analysis was a mixed linear model 
using the baseline value for the particular variable as a covariate, as well as a fixed term for 
the order of administration of the treatments.  The mixed linear model takes into account 
the correlation between measurements on the same participants in the cross-over design.  
The secondary outcome variables were RR, MV, Vd/Vt, Vt, Vd, Va, MVa and change in PtCO2 
4 mmHg.  Analysis was by intention to treat.  The association between the baseline oxygen 
saturation and change in PtCO2 after oxygen use was assessed by regression analysis. 
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We calculated that a study recruiting 24 participants would give 80% power to detect a 
paired difference of 4mmHg in PtCO2 based on a standard deviation of 6.5 for the paired 
difference from the study of Robinson et al82. 
SAS version 9.1 was used. 
 
3.5.3 Results 
 
Characteristics of subjects 
A total of 76 obese subjects (mean BMI 47.6 kg/m2), without a history of COPD, were 
screened for evidence of daytime hypercapnia (Figure 21). 
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Figure 20. Flow of subjects through OHS study 
76 obese subjects screened: 
55 from sleep clinic 
11 from obesity clinic 
6 prior to bariatric surgery 
4 from community 
  
  Excluded 
PtCO2 <45mmHg 
n=51 
 
 
25 subjects invited to 
participate in study 
 
  
   
Declined 
n=1 
 
 
 
24 subjects randomised 
 
  
   
Did not complete study 
n=1 
 
 
 
23 subjects completed 
study 
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Of these, 25 met the inclusion criteria and 24 consented to take part in the study.  As a 
result, 24 subjects were randomised; one subject did not attend for the second test.  The 
study took place between June 2008 and May 2009. 
 
Table 17 shows the baseline characteristics of the subjects included in the study. 
 
Table 17. Characteristics of subjects, OHS study 
Age, years 47.3 (12.4) 
Sex, male 14/24 
Weight (kg) 154.7 (37.8) 
BMI (kg/m2) 52.4 (11.3) 
PtCO2 (mmHg) 49.2 (5.6) 
SpO2 (%) 95.5 (4.0) 
FEV1/FVC 0.80 (0.08) 
Smoking history (pack years) 2.3 (3.3) 
 
Values are mean (SD) for age, BMI, PtCO2 SpO2 and pack years; 
number of subjects for sex 
 
The 24 subjects were morbidly obese with a median BMI of 50.7 kg/m-2 (range 37.4 to 83.6).  
There was a wide range in the severity of chronic respiratory failure, with a median PtCO2 of 
47 mmHg (range 45 to 67) and median oxygen saturation of 97% (range 80 to 99).  The 
median forced expiratory volume in one second/forced vital capacity (FEV1/FVC) ratio was 
0.80 (range 0.70 to 0.97).  The median pack years of cigarette smoking was 0 (range 0 to 10). 
 
Changes in PtCO2 
The mean PtCO2 increased from 48.7 to 52.7 mmHg breathing oxygen, compared with a 
decrease in mean PtCO2 from 48.6 to 47.7 mmHg in the room air group (Table 18). 
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Table 18:  Changes in transcutaneous CO2 and secondary outcome variables whilst breathing air and 100% oxygen 
 AIR  OXYGEN 
 Baseline (n=24) 20 mins 
(n=24) 
Difference 
 Baseline 
(n=23) 
20 mins 
(n=23) 
Difference 
PtCO2 (mmHg) 48.6 (4.0) 47.7 (5.4) -1.0 (2.6)  48.7 (3.8) 52.7 (6.5) 4.0 (4.1) 
RR (bpm) 15.8 (3.6) 15.7 (4.4) -0.12 (2.6)  15.6 (3.8) 14.7 (3.8) -0.91 (3.4) 
MV (L/min) 9.6 (3.3) 9.0 (3.4) -0.70 (2.3)  10.1 (2.9) 8.0 (3.3) -2.1 (2.2) 
Vd/Vt 0.58 (0.06) 0.59 (0.08) 0.01 (0.05)  0.57 (0.06) 0.65 (0.06) 0.09 (0.05) 
Vt (L) 0.65 (0.31) 0.63 (0.34) -0.02 (0.22)  0.69 (0.29) 0.56 (0.34) -0.13 (0.18) 
Vd (L) 0.37 (0.16) 0.36 (0.15) -0.01 (0.10)  0.39 (0.16) 0.36 (0.21) -0.03 (0.11) 
Va (L) 0.28 (0.16) 0.28 (0.19) -0.006 (0.12)  0.30 (0.14) 0.20 (0.14) -0.10 (0.09) 
MVa (L/min) 4.1 (1.6) 3.8 (1.9) -0.32 (1.32)  4.4 (1.3) 2.8 (1.6) -1.6 (1.2) 
All values are mean (SD) 
PtCO2: Transcutaneous carbon dioxide tension (mmHg)  RR: Respiratory rate (breaths per minute) 
MV: Minute ventilation (L/min)     Vd/Vt: Physiological dead space to tidal volume ratio 
Vt: Tidal volume (L)      Vd: Physiological dead space volume (L) 
Va: Alveolar volume (L)      MVa: Alveolar minute volume (L) 
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The PtCO2 adjusted for baseline increased by 5.0 mmHg (95% CI 3.1 to 6.8; p<0.001) with 
oxygen compared with room air (Table 19).  The number of subjects in whom the PtCO2 
increased by 4 mmHg was 10/23 (43.5%) when breathing 100% oxygen and 0/23 (0%) 
when breathing room air. There was a moderate association (r2=0.25) between the baseline 
oxygen saturation and the change in PtCO2 with oxygen therapy, with an increase in PtCO2 
of 0.50 mmHg (95% CI 0.11 to 0.89, P=0.014) for every 1% decrease in baseline oxygen 
saturation. 
 
Figure 21. The change in PtCO2 from baseline following breathing 100% oxygen or room air 
 
The test was terminated in 3 subjects when breathing 100% oxygen, due to a rise in PtCO2 of 
≥10mmHg which occurred after 10:35, 13:20 and 15:51 minutes. 
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Changes secondary outcome variables 
 
The mean MV decreased from 10.1 to 8.0 L/min breathing oxygen compared with 9.6 to 9.0 
L/min breathing room air (Table 18).  The mean MV adjusted for baseline decreased by 1.4 L 
(95% CI 0.11 to 2.6, P=0.03) with oxygen use compared with room air (Table 19).  The mean 
MVa decreased by 1.17 L per minute (95% CI 0.54 to 1.81, P<0.001) breathing oxygen.  The 
point estimate for the change in RR was 0.9 breaths per minute lower for the oxygen group; 
however this difference was not statistically significant. 
 
The mean Vd/Vt increased from 0.57 to 0.65 breathing oxygen, compared with 0.58 to 0.59 
breathing room air (Table 18).  The mean Vd/Vt adjusted for baseline increased by 0.067 
(95% CI 0.035 to 0.10, P<0.001) with oxygen use compared with room air (Table 19).  The 
increase in Vd/Vt breathing oxygen was associated with a statistically significant mean 
reduction in Va of 0.085 L (95% CI 0.025 to 0.14, P=0.007), without a statistically significant 
mean change in Vd (-0.007 L, 95% CI -0.058 to 0.044, P=0.79). 
 
Table 18. Mixed linear model estimates of the differences 100% oxygen minus air adjusted 
for baseline 
 Estimate (95% CI) P value 
PtCO2 (mmHg) 5.0 (3.1 to 6.8) <0.001 
RR (bpm) -0.9 (-2.4 to 0.67) 0.25 
MV (L/min) -1.4 (-2.6 to -0.11) 0.03 
Vd/Vt 0.067 (0.035 to 0.10) <0.001 
Vt (L)  -0.092 (-0.20 to 0.012) 0.08 
Vd (L) -0.007 (-0.058 to 0.044) 0.79 
Va (L) -0.085 (-0.14 to 0.025) 0.007 
MVa (L/min) -1.17 (-1.81 to -0.54) <0.001 
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Although the point estimate for the change in RR was lower for the oxygen group, this was 
not statistically significant. 
3.5.3 Discussion 
 
This randomised, double-blind cross-over study has demonstrated that breathing 100% 
oxygen causes worsening hypercapnia in subjects with OHS.  After 20 minutes breathing 
100% oxygen, the PtCO2 increased by a mean of 5 mmHg, with 3 of 24 subjects having to be 
withdrawn before completion of the study while breathing oxygen due to an increase in 
PtCO2 of at least 10 mmHg.  This indicates that subjects with stable OHS are at risk of an 
acute and marked decompensation of their respiratory failure with high flow uncontrolled 
oxygen therapy. 
 
There are a number of methodological issues relevant to the interpretation of the study 
findings.  Primarily, we used a TOSCA transcutaneous CO2 monitor to measure PtCO22 rather 
than the “gold standard” arterial blood gas test. This method was chosen as it allowed 
continuous PtCO2 monitoring without the discomfort of repeated arterial blood gas 
sampling or the risk of hand ischemia associated with indwelling radial artery cannulae196.  
The TOSCA has been shown to be an accurate means of estimating both PaCO2 and SpO2 
from a single probe in healthy subjects197 198, COPD 153 and obesity164 
 
For the secondary outcome variables volumetric capnography was used to estimate Vd/Vt, 
using the Bohr-Enghoff equation, based on measurements of the mixed expired CO2 and 
PtCO2
195.  It would have been informative to have measured continuous distributions of 
ventilation-perfusion ratios by the multiple inert gas elimination technique 199.  However 
this involves the invasive measurement of cardiac output, which is technically difficult in this 
population and would have posed an unacceptable risk to our subjects.  Furthermore, 
although MIGET has been used in COPD82 200, it has not been validated in OHS.  Given this 
study was primarily designed to investigate the effects of oxygen on PtCO2 we used simple, 
non-invasive methods which provided validated measures of respiratory drive and 
physiological dead space to assess the mechanisms of the effect observed. 
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Although in clinical practice it would be uncommon to administer 100% oxygen to patients 
with OHS,  this oxygen regime was chosen to ensure hyperoxaemia was achieved and to 
maximise the potential to determine an effect.  As a result, the magnitude of the increase in 
PtCO2 may have been greater than that which occurs with lower oxygen concentrations and 
further studies are required to examine this.  There is evidence  in COPD that the 
administration of oxygen may worsen hypercapnia across a range of concentrations from 
28% to 100%.74 68 70 72 75 82 201 202Whilst the majority of these patients were studied during 
acute exacerbations, the latter two were performed in stable COPD and showed similar 
increases in PaCO2 and Vd/Vt found in our group of patients with stable OHS.   
 
The strengths of this study include the double-blind design, which minimised any voluntary 
changes in respiratory pattern which may have occurred with knowledge of the inspired gas.  
The cross-over design allowed each patient to act as his/her own control with an adequate 
washout period between each gas.  The simple physiological methods used allowed 
continuous measurements to be made non-invasively without risk to the patient. 
 
Subjects were recruited in whom the diagnosis of OHS had not previously been made, and 
who were not already receiving treatment with continuous or bilevel non-invasive positive 
pressure ventilation, which has the potential to reduce the severity of baseline hypercapnia 
203-206, and the ventilatory response to hypercapnia203 207.   Additionally, subjects with 
concomitant COPD were excluded, based on their smoking history and spirometry, to 
ensure that the response to oxygen therapy was not confounded by this condition. Other 
causes of daytime hypercapnia other than COPD and OHS were not considered, although 
this is unlikely. Seventy-six subjects from a number of sources including a tertiary hospital 
sleep clinic, obesity clinic, bariatric surgery waiting list and general practice, to enable 24 
eligible subjects to be randomised.  The observation that about one in three morbidly obese 
subjects (with a mean BMI of 47.6 kg/m2) has OHS is in keeping with a study by Nowbar and 
colleagues193 who found 31% of a sample of severely obese inpatients (with a mean BMI of 
45 kg/m2),  had  evidence of daytime hypoventilation.  Other studies, have shown a lower 
prevalence in patients with obstructive sleep apnoea, ranging from 10-20%191 208 209, which 
may be due to a lower range of BMI (33 to 43 kg/m2) in comparison to this study in which 
the BMI range was from 37 to 84 kg/m2. 
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A significant mean increase in PtCO2  of 5 mmHg after 20 minutes of breathing 100% oxygen 
in OHS subjects has been demonstrated.  This was similar to the original report of  Barrera 
and colleagues in 1973174, who demonstrated a rise in PaCO2 from 58.3 mmHg to 63.4 
mmHg with 100% oxygen in four obese patients with chronic hypoxemia and hypercapnia.  
Of clinical concern is that in 1 in 8 of our subjects, the test had to be stopped due to a rise in 
PtCO2 of >10 mmHg, after 10 to 16 minutes of breathing 100% oxygen.  This illustrates the 
short time period in which the PaCO2 rises with oxygen therapy, similar to that observed 
with COPD76 78 82.  It is likely that the PaCO2 would have continued to rise if oxygen had been 
administered beyond the 20 minute time period, suggesting our findings are underestimates 
of the magnitude of the increase in hypercapnia that might occur with prolonged 
administration of high concentration oxygen therapy to OHS patients in clinical practice.  
Although pH was not measured, it is likely that subjects would have developed respiratory 
acidosis during this short period of oxygen administration. 
 
A moderate association between baseline oxygen saturation and increase in PtCO2 with 
oxygen therapy was observed, with an increase in PtCO2 of 0.5 mmHg for every 1% lower in 
oxygen saturation on room air.  This suggests that obese patients at greatest risk of 
worsening hypercapnia are those with the most marked hypoxaemia, that is, those most 
likely to receive high concentration oxygen therapy 
 
This study suggests that the main mechanism which led to worsening hypercapnia when 
breathing oxygen was a reduction in MV leading to alveolar hypoventilation.  The associated 
increase in Vd/Vt was associated with a reduction in Va, without a statistically significant 
change in Vd. 
  
These findings provide support for the recommendations to treat all morbidly obese 
patients with oxygen therapy in the acute setting cautiously, similar to the approach in 
COPD.13 Long-term supplemental oxygen is often administered in concurrence with 
domicillary bilevel positive airway pressure in patients with OHS, however oxygen therapy 
alone does not improve hypoventilation210 and has recently been shown in a retrospective 
study211  to be the only independent predictor of mortality. As shown, up to one-third of 
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morbidly obese patients may have coexisting OHS.  Given that OHS is an under-recognized 
and under-treated condition190 191 193 this study highlights the importance of adequate 
physiological assessment of morbidly obese patients, particularly on presentation to the 
Emergency Department, where high concentration oxygen is often administered to treat 
breathlessness 
 
This is the first randomised double-blind controlled study of high concentration oxygen 
therapy in subjects with OHS.  It has demonstrated that breathing 100% oxygen leads to 
worsening hypercapnia in subjects with OHS, and that the magnitude and speed of the 
effect may be striking.  This physiological response is due to a reduction in MV resulting in 
alveolar hypoventilation, and an associated increase in Vd/Vt.  In morbidly obese patients 
the possible presence of OHS needs to be recognized, as well as the potential for oxygen 
therapy to increase the PaCO2.  In morbidly obese patients it is recommended that oxygen 
therapy should be administered with caution. 
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SECTION 4 CONCLUSION 
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4.1 Summary of findings 
 
Oxygen therapy remains a cornerstone of medical practice. It is widely used in a variety of 
clinical settings and is generally regarded as being safe. The British Thoracic Society has 
recently published guidelines on how to prescribe, administer and monitor oxygen safely 
which are being implemented and disseminated throughout the United Kingdom. The 
guidelines have demonstrated the lack of clinical trials to support this widely used drug. 
 
In this thesis, I have presented a series of audits and randomised controlled trials on oxygen 
therapy in respiratory disorders with the overall aim to provide evidence for the use of 
oxygen therapy.  
 
The main findings from each study are: 
  
Oxygen Prescription Charts 
 
 The prescription and administration of oxygen therapy is suboptimal in hospital 
inpatients. 
 An oxygen prescription section on hospital drug charts improves the prescription of 
oxygen but not clinical practice. 
 
Pre-Hospital Oxygen therapy in AECOPD 
 
 A significant proportion of patients with AECOPD continue to receive high flow oxygen 
therapy on ambulance transfer to our Emergency Department, contrary to local and 
international guidelines 
 The risk of adverse outcomes increases progressively with increased PaO2 
 
Randomised controlled trial of oxygen therapy in Community acquired pneumonia 
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 High concentration oxygen leads to a rise in arterial carbon dioxide tensions when 
administered to patients presenting acutely with community acquired pneumonia.  
 There is a three fold relative risk increase in PtCO2 of at least 4 mmHg when compared 
to titrated oxygen  
 There is a six fold relative risk increase in PtCO2 of at least 8 mmHg when compared to 
titrated oxygen 
 There was no change in respiratory rate between the two groups, but the reduction in 
heart rate was greater in the high concentration group. 
 CRB-65 score and rates of hospital admission did not differ between the two groups 
 The rate of increase in PtCO2 was significantly greater in the high concentration group. 
   
  
Randomised controlled trial of oxygen therapy in acute severe asthma 
 
 High concentration oxygen therapy results in a significant increase in PtCO2 compared 
to titrated oxygen when administered to patients with acute severe asthma.   
 There is a two fold relative risk increase in PtCO2 of at least 4 mmHg when compared 
to titrated oxygen  
 There is a four fold relative risk increase in PtCO2 of at least 8 mmHg when compared 
to titrated oxygen 
 All 10 patients who became hypercapnic (PtCO2 ≥45mmHg) at the end of the study 
received high concentration oxygen. 
 The rate of increase in PtCO2 was significantly greater in the high concentration group. 
 After adjustment for baseline predictors of severity, high concentration oxygen 
therapy was not statistically significant as a predictor of hospital admission. 
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Randomised controlled trial of hyperoxia in obesity hypoventilation syndrome 
 
 Breathing 100% oxygen leads to worsening hypercapnia in subjects with obesity 
hypoventilation syndrome.  
 After 20 minutes of breathing 100% oxygen, the PtCO2 increased by a mean of 5mmHg 
 Three of the 24 patients were withdrawn before completion from the study while 
breathing oxygen due to an increase in PtCO2 of at least 10 mmHg 
 Worsening hypercapnia is due to both an increase in the physiological dead space and 
a reduction in minute ventilation.   
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4.2 Implications of findings 
 
The oxygen prescription chart audit has demonstrated that oxygen is a commonly used 
drug. Even after the introduction of a specific prescribing section on the drug chart, oxygen 
prescription remained substandard. Furthermore, clinical practice did not improve with 
oxygen prescription. The implications of poor oxygen practice have been highlighted in the 
recent NPSA alert which have resulted in serious adverse events, including deaths. This 
study endorses the mandatory requirement for a robust oxygen delivery policy in the 
hospital setting. 
The AECOPD audit, once again highlights the continued practice of administering high flow 
oxygen in this vulnerable group of patients with respiratory disease. The implications of this, 
as demonstrated by our results, show that patients may unnecessarily be dying or requiring 
mechanical ventilation. This is despite these risks being clearly documented in national and 
international guidelines.    
The findings of both the pneumonia and asthma study have demonstrated an increase in 
PtCO2 in patients receiving high flow oxygen. The rise in PtCO2 of ≥4mmHg and ≥8mmHg 
have potential physiological and clinical significance, particularly if occurring in patients with 
life-threatening episodes of respiratory failure. The higher rate of increase of PtCO2 in the 
high concentration group is pertinent to clinical practice when oxygen is often delivered for 
several hours to days to relieve dyspnoea, which may result in even higher levels of PaCO2 
not seen in these studies. Additionally, asthma patients who develop hypercapnia require 
admission to a high dependency area which potentially could be avoided if oxygen was 
delivered to achieve a target saturation. 
Both these studies have demonstrated a rise in PtCO2 with high concentration oxygen 
therapy in respiratory disorders, other than COPD. This raises issues about the underlying 
mechanism of oxygen induced CO2 retention which occurs with V/Q mismatch. The historical 
theory of “loss of hypoxic” drive is unlikely to contribute to this effect indicating that rises in 
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CO2 with high flow oxygen may potentially occur in all patients with respiratory disease and 
V/Q mismatch. 
Finally, although the BTS guidelines have highlighted a detrimental effect of high flow 
oxygen therapy in patients with OHS, this has not previously been supported with evidence 
from a randomised controlled trial. This study not only demonstrates the effects of 100% 
oxygen on PtCO2 but also highlights how rapidly acute respiratory failure can ensue. OHS 
patients are often under-recognised and under-treated. The cautious administration of 
oxygen to all obese patients would potentially prevent this life-threatening complication. 
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4.3 Methodological Issues 
 
The major methodological issues have been discussed in detail in the discussion sections of 
the relevant chapters and are listed below, to summarise: 
 Retrospective nature of AECOPD audit 
 Lack of blinding in pneumonia and asthma RCTs 
 Short study time in pneumonia and asthma RCTs 
 Use of transutaneous CO2 monitoring to estimate PaCO2 in all three RCTs 
 Ability to exclude patients with COPD from pneumonia and asthma studies 
 Measuring deadspace in OHS study 
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4.3 Future directions 
 
Oxygen Prescription 
We have shown from our audit that whilst a dedicated oxygen section on a drug chart 
improves the prescription of oxygen, this does not improve clinical practice. It would be 
relevant to know whether a prescription together with a specific observation chart 
recording respiratory rate, saturation and oxygen therapy facilitates monitoring and 
titration of oxygen therapy. A working example is from the BTS guidelines is shown below13. 
 
Figure 22. Working Example of respiratory section for Observation Chart13 
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We have also shown from our audit that clinical practice was better in the ED. It would be 
beneficial to know whether there were specific wards or clinical areas which had 
deficiencies in their prescribing practices and administration of oxygen, so that staff 
education could be targeted in these areas. 
In this audit, we did not look specifically at the other scenario involving the down-titration 
of oxygen in response to hyperoxia.  As discussed throughout this thesis, the physiological 
effects of hyperoxia can potentially be detrimental.  
The use of physiological monitoring  “track and trigger” systems such as the modified Early 
Warning Score (MEWS) are useful for monitoring patients.212  Oxygen saturation has been 
shown to be an important predictor of mortality213 and the Standardised Early Warning 
Score (SEWS) (which incorporates oxygen saturation) has been shown to correlate with both 
in-hospital mortality and length of stay.214 Further studies are required to show the benefits 
of such scoring system so that the measurement of SpO2 can be incorporated as a 
mandatory observation by nursing and medical staff. 
The BTS has appointed “Oxygen Champions” in most acute UK hospitals to help introduce 
the guidelines to improve oxygen use, enhance patient safety and audit usage 
 
Oxygen therapy in AECOPD 
AECOPD is one of the few conditions in which the potential dangers of oxygen therapy are 
widely accepted. There is a large body of evidence illustrating the mechanisms of oxygen 
induced hypercapnia 74 75 78 82  as well as the detrimental clinical outcomes 85-88 92. Despite 
this, our audit has shown that oxygen continues to be administered to this group of 
vulnerable patients. Limitations of our study have been its retrospective nature and the 
inability to control for disease severity. The one randomised trial of oxygen therapy in the 
pre-hospital setting has shown better outcomes by targeting a saturation range of 88-92%. 
However, further trials are needed to define the ideal target oxygen saturation level for 
optimal outcome. The results of such studies need to be disseminated to not only nurses 
and medical staff but also paramedics who are invariably the first point of contact for 
patients. 
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Duration of study time 
As discussed previously, the duration of the study was very short. Given that the difference 
in PtCO2 between the high concentration and titrated oxygen groups progressively 
increased throughout the 60 minute period it would be useful to extend the study time to 
beyond 60 minutes and even up to several hours.  This is clinically relevant as relief of 
dyspnoea in pneumonia may take many days and oxygen therapy is often continued until 
the dyspnoea resolves.  
 
Clinical Outcomes 
 
To our knowledge, this is the first study to investigate the effects of oxygen on carbon 
dioxide levels in patients with CAP. We did not look at clinical outcomes such as ICU 
admission or mortality. Clearly the results of this study need to be extended to investigate 
whether rises in CO2 have clinical implications as occur in patients with AECOPD. 
  
If adverse outcomes did occur, then further work would be required to determine the ideal 
target oxygen saturation which would treat hypoxaemia without causing hypercapnia. 
 
Oxygen concentrations 
It is rare for 100% oxygen to be given outside of intensive care units. We chose this 
concentration of oxygen to ensure the patients in the OHS study were hyperoxic. It would 
be informative to examine the effects of different FiO2 levels on the CO2 level and on 
minute ventilation. Similarly to patients with AECOPD, an ideal target saturation range 
needs to be identified. 
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4.4 Overall Conclusion 
 
Oxygen is a drug used widely in clinical practice. Despite this, there is a paucity of well-
designed randomised clinical trials to support its use, as highlighted in the British Thoracic 
Society’s “Emergency Oxygen use in Adult Patients”13. The UK’s National Patients Safety 
Agency has recently reported nearly 300 adverse incidents and 9 deaths from poor oxygen 
management. The prescription of oxygen will help to reduce such untoward incidents, as 
well as the education of both hospital and pre-hospital staff. 
The risks of administering uncontrolled oxygen to a subgroup of patients with COPD have 
been known for over 60 years and are well documented in international guidelines.  Despite 
this, oxygen is continuously administered to patients with AECOPD without full appreciation 
of the risks.    As highlighted by this thesis, the potential risks of oxygen induced hypercapnia 
and respiratory acidosis need to be extended to other common respiratory disorders  in 
which abnormal gas exchange or respiratory drive are present. Oxygen should be 
administered according to documented low oxygen saturations rather than presumed need. 
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WELLINGTON HOSPITAL OXYGEN AUDIT 
DATA COLLECTION FORM 
2008 
 
Patient Demographics 
 
NHI    
    
Age    
    
 M  F 
Sex    
    
Ward    
 
Date of admission     
 
Date today  
 
 
 
 
  Y  N 
1. Is the patient on oxygen at the time of the audit?     
     
If no, go to question 7     
     
2. If yes, what is the     
     
WARD 
186 
 
 
(a) Device     
 
 Nasal 
Prongs 
 Hudson 
Mask 
 Venturi  NRBM  NIPPV 
 
(b) Flow rate or FiO2?  
      
  Y  N 
3. Was oxygen started on the ward?     
  Y  N 
4. If yes, were the sats ≤ 92% prior to commencing 
oxygen? 
    
 
 
PRESCRIPTION (if on oxygen)        
 Y  N  D/K   
5. Is O2 prescribed in the drug chart?        
        
6. If yes, is there a specified:        
 Y  N     
(a) Device        
 Y  N     
(b) Flow rate or FiO2        
 Y  N     
(c) O2 sats target range        
 
 
 
MONITORING AND TITRATION 
(last 24 hrs) 
       
 Y  N     
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7. Were sats recorded  on ≥ 2 occasions in the last 24 
hours? 
       
        
Go to question 10 if <2        
 Y  N  N/A   
8. If sats were ≥ 96% on ≥2 occasions, was O2 reduced or 
stopped? 
       
 Y  N  N/A   
9. If O2 sats were ≤ 92% on ≥2 occasions was O2 
increased or commenced? 
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 Y  N  
10. Was the patient brought in by ambulance?     
If no, go to question 15     
 
INDICATION        
 Y  N     
11. Was oxygen administered in the ambulance?        
        
If oxygen not administered, go to 15        
 Y  N     
12. Was oximetry documented prior to commencing 
oxygen? 
       
        
 Y  N  D/K   
13. Were the sats ≤ 92% prior to commencing  
oxygen? 
       
        
14. How much oxygen was administered?        
        
 
 
 
 
 Y  N  
15. Was the patient admitted via ED?     
If no, audit complete     
 
 
AMBULANCE 
EMERGENCY DEPARTMENT 
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INDICATIONS Y  N  D/K   
16. Was oximetry/ABG documented on air on arrival?       
 
 
  
Y 
  
N 
  
D/K 
  
17. Was the patient on O2 on arrival?        
        
Answer Qs 18-19 if on oxygen on arrival, Answer Qs 20-22 if on air on arrival   
18. If documented, what were the sats?        
  ≤ 92%   93-95%   ≥96%  
 
19. What was the next course of action? 
  O2 
downtitrated 
  O2 
uptitrated 
  O2 
continued 
 
          
    Y  N    
20. Was oxygen administered at anytime in 
ED? 
         
    Y  N    
21. If yes, were the sats ≤ 92% prior to 
commencing? 
         
    Y  N    
22. If no, were the sats ≤ 92% at anytime?          
 
PRESCRIPTION        
 Y  N     
23. Was O2 prescribed in the drug chart?        
        
24. If yes, was there a specified:        
 Y  N     
(a) Device        
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 Y  N     
(b) Flow rate or FiO2        
 Y  N     
(c) O2 sats target range        
 
MONITORING AND TITRATION        
 Y  N  D/K   
25. Were sats documented on ≥2 occasions?        
 Y  N  N/A   
26. If sats were ≥ 96% on ≥2 occasions, was O2 
reduced or stopped? 
       
 Y  N  N/A   
27. If sats were ≤ 92% on ≥2 occasions was O2 
increased or commenced? 
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COPD AMBULANCE AUDIT 
WELLINGTON HOSPITAL  
2007 
 
 
                                            Audit number _____ 
Section 1: Demographics 
 
1. NHI    
    
2. Age    
 M  F 
3. Sex    
   
4. Date of presentation     
 
Section 2: Current prescribed drug therapy 
 
 
 Y  N  If yes 
Long term oral steroids      mg/day 
 
 Y  N 
Current or recent (completed in the last 5 days) 
short course oral steroids  
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 Y  N 
Long term antibiotics    
 Y  N 
Current or recent (completed in the last 5 days 
)short course antibiotics 
   
 Y  N 
Inhaled corticosteroids    
 Y  N 
Long acting beta agonist    
 Y  N 
Tiotropium (Spiriva)    
 Y  N 
Theophylline    
 
 
DI  NEB 
   Y N  Y N 
Short acting beta agonist      
 
MDI  NEB 
   Y N  Y N 
Ipratropium      
 
MDI  NEB 
   Y N  Y N 
Combivent      
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 Y  N  If yes 
Home oxygen      l/min 
 
Section 3: Background clinical details 
 
 Y  N 
Previous episode of CO2 retention? 
(PaCO2 > 45mmHg) 
   
 
If yes: 
 
Highest CO2 pH Date 
  
 
   
CO2 Lowest  pH Date 
  
 
   
 
 Y  N 
Previous acute BiPAP or CPAP?    
 
 Y  N 
Previous intubation?    
 
Number of hospital admissions with COPD in 
the 12 months  prior to this exacerbation  
 
 
 Y  N  Best result  
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Outpatient (stable) FEV1 in the 12 months prior 
to admission? 
     
litres 
 
Comments  
 
 
 
 
 
Section 4: Initial Ambulance Recordings 
 
Time of arrival at scene  
 
Time first recordings documented  
 
 M V E  Total 
First GCS      
 
 Resp 
rate 
Heart 
rate 
 
BP 
 
O2 sats 
First vital signs      
 
 Y  N 
Were oxygen saturations clearly documented 
prior to commencing oxygen? 
   
 
  
O2 initiated by ambulance staff  l/min 
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Time oxygen started  
 
Section 5: Ambulance Management (From time located to triage, including initial recording 
and final recording) 
 Y  N  D/K 
Were sats documented on ≥ 2 occasions?      
 Y  N  N/A 
If sats were ≥ 96% on ≥  1 occasions, was O2 
reduced or stopped? 
     
 Y  N  N/A 
If sats were ≤ 92% on ≥  1 occasions was O2 
increased or commenced? 
     
 
 NEB  MDI  
Total dose of salbutamol in ambulance   
mg 
  
mcg 
 
 NEB  MDI  
Total dose of ipratropium in ambulance 
 
  
mg 
  
mcg 
 
Section 6: Final Ambulance Recordings (if more than one set done) 
 
Time of final recordings 
 
 
 M V E  Total 
Final GCS      
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 Resp 
rate 
Heart 
rate 
 
BP 
 
O2 sats 
Final vital signs      
 
  
O2 flow rate at time final sats recorded   l/min 
 
 scene  destination  
Patient status  at 
 
  
 
  
 
 
Comments  
(including comments on mental status or consciousness level –direct quotes) 
 
 
 
 
 
Section 7: ED Data (Triage) 
 
Triage time and category    
Time 
  
Category 
 
 
 M V E  Total 
Triage GCS (if done)      
 
 Resp 
rate 
Heart 
rate 
 
BP 
 
O2 sats 
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Triage vital signs (if done)     
 
Section 8: ED Data (first clinical assessment) 
 M V E Total  Time 
ED GCS (if done)      
 
 Resp 
rate 
Heart 
rate 
 
BP 
O2 
sats 
 Time 
First ED vital signs       
 
  
O2 flow rate at time first sats recorded   l/min 
 
 Y  N  
ABG done?    If no go to section 10 
 
Time of first ABG       
 
 
Oxygen flow rate when ABG taken    
l/min 
   
 
 pH pCO2 pO2 HCO3 Sats  
ABG result      
 
 
Comment  
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Section 9: ED treatment prior to first ABG   (ABG time __________) 
 
(Excluding triage , from ED observation chart printout including the first clinical assessment )  
If no ABG done treatment in the first 4 hours in ED from triage time. 
 
 Y  N  D/K 
Were sats documented on ≥ 2 occasions?      
 Y  N  N/A 
If sats were ≥ 96% on ≥ 1 occasions, was O2 
reduced or stopped? 
     
 Y  N  N/A 
If sats were ≤ 92% on ≥ 1 occasions was O2 
increased or commenced? 
     
 
 NEB  MDI  
Total dose of salbutamol in ED   
mg 
  
mcg 
 
 NEB MDI  
Total dose of ipratropium in ED 
 
  
mg 
  
mcg 
 
Comments  
(including comments on mental status or consciousness level –direct quotes) 
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Section 10: Outcome 
 
 Y  N 
ICU admission    
 
 Y  N 
HDB required    
 
 Y  N 
BiPAP or CPAP    
 
 Y  N 
Intubated    
 
 D/C  Died 
Patient discharged or died?    
 
 Date  Time 
Date and time of discharge or death    
 
  
DOA 
ED or 
SSU 
Ward or 
ICU 
Place of death 
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Data extraction by: 
 
Name   ________________________     Date_______________ 
Comments: 
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Oxygen in acute community acquired pneumonia 
 
 
Name:___________________________ ___ INITALS( _____) SEX:  __         DOB: 
___/____/_____________ 
 
ID number: ______     Hospital Number      __________  
 
 
INCLUSION/EXCLUSION CRITERIA CHECKLIST 
 Aged 18 – 65 years   
 Cough 
 Respiratory rate ≥ 18/min 
 At least one systemic feature (sweating, rigors and/or fever >37.8° C) 
 No previous diagnosis of COPD/emphysema 
 
Consent signed   Yes / No  
 
OXYGEN PROTOCOL:    
 High flow     
 Titrated 
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TIME 
(MINS) 
Resp Rate 
(Beats/min) 
Blood 
Pressure 
Heart Rate 
(Beats/min) 
CRB score 
 
tCO2 
(mmHg) 
T = 0      
T = 20      
T = 40      
T = 60      
 
ABG (if done) at T= ____min: pH______ PCO2______ PO2______ HCO3______ 
SATS______ 
 
tCO2 at time ABG taken _____ mmHg 
 
ADMITTED TO HOSPITAL (circle):  YES  NO  UNKNOWN 
 
 
Withdrawn from study? State reason below: 
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MEDICATION ADMINISTERED 
 
TIME 
GIVEN  
(T=X) 
DRUG  DOSE 
   
   
   
   
   
   
   
   
   
 
 
Evidence of consolidation on chest X-ray report? 
 YES     
 NO 
 UNKNOWN 
 
 
Final diagnosis: 
 Pneumonia     
 Bronchitis 
 Non-pneumonic viral illness (including influenza) 
 Heart failure 
 Pulmonary embolism 
 Other 
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Oxygen in severe acute asthma 
 
 
Name:___________________________ ___ INITALS( _____) SEX:  __         DOB: ___/____/____ 
 
ID number: ______     Hospital Number      __________  
 
 
INCLUSION/EXCLUSION CRITERIA CHECKLIST 
 Aged 18 – 65 years   
 History of asthma 
 Current exacerbation of asthma and FEV1 ≤ 50% predicted 
 No previous diagnosis of COPD/emphysema 
 
Consent signed   Yes / No  
 
OXYGEN PROTOCOL:    
 High flow     
 Titrated 
 
FEV1 at baseline ______L/min   AGE____ HEIGHT______     PREDICTED 
FEV1:______L/min 
 
 
FEV1 % PREDICTED: ________ 
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TIME 
(MINS) 
RESP 
RATE 
(Beats/min) 
HEART 
RATE 
(Beats/min) 
FEV1 
(L/min) 
tCO2 
(mmHg) 
T = 0     
T = 20     
T = 40     
T = 60     
 
ABG (if done) at T= ____min: pH______ PCO2______ PO2______ HCO3______ 
SATS______ 
 
tCO2 at time ABG taken _____ mmHg 
 
 
ADMITTED TO HOSPITAL (circle):  YES  NO  UNKNOWN 
 
 
Withdrawn from study? State reason below: 
 
 
 
 
 
 
 
206 
 
 
 MEDICATION ADMINISTERED 
 
TIME 
GIVEN  
(T=X) 
DRUG  DOSE 
   
   
   
   
   
   
   
   
   
 
Time 
(minutes)  
Oxygen 
Saturation (%) O2 (L/min) 
0     
5     
10     
15     
20     
25     
30     
35     
40     
45     
50     
55     
60     
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Oxygen and Obesity Hypoventilation Syndrome 
 
Name_______________________________ DOB_______________ 
 
NHI_________________________ Study ID______ 
 
Wt_________Kg         Ht_______cm           BMI______________    
  
 
 
Screening 
  
O2 sats______%  tCO2_______mmHg            
 
ABG (if known) PaO2______mmHg  PaCO2______mmHg 
 
 
Randomised Treatment 
 
Visit Date Treatment A or B 
1   
2   
     
Visit 1 
 
 RR tCO2 MV Vd/Vt 
Baseline     
20 minutes      
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Visit 2 
 
 RR tCO2 MV Vd/Vt 
Baseline     
20 minutes      
 
Withdrawn from study?  Y   N 
 
If Yes, 
state reason, visit and time:________________________________________ 
 
Investigator:___________________________________________________ 
 
Date:_____________________ 
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Participant Information Sheet  
 
 
Full Study Title: 
A COMPARISON OF HIGH FLOW VERSUS TITRATED OXYGEN THERAPY IN THE EMERGENCY 
DEPARTMENT TREATMENT OF RESPIRATORY DISORDERS 
 
Introduction 
You are invited to take part in a clinical research study.  Please take the time to read this 
information sheet carefully to determine if the study is of interest to you. You may wish to 
discuss the information in this sheet with your family or whanau. Please ask us if you have 
any questions about the study. Your involvement in this study is voluntary and you have the 
right not to take part and to withdraw at any time.   
 
Aim of the Study 
It is currently standard treatment to prescribe high flow oxygen to people with severe 
asthma or pneumonia. However high flow oxygen may cause complications and it is now 
recognised that high flow oxygen can be detrimental to patients with emphysema. Few 
studies have looked at the use of high flow oxygen in asthma or pneumonia. An alternative 
regime is one where the amount of oxygen you receive is varied depending on the oxygen 
level in your blood (oxygen saturation). This can be measured by a probe which sits on your 
finger.   
If you choose to participate in this study you will be randomly assigned to receive either 
high flow oxygen or have the flow of oxygen varied according to your oxygen saturation.  
During this study and throughout your admission you will receive the optimal treatment for 
your medical condition. 
 
Where will the study be conducted? 
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The study will be conducted in the Emergency Department of Wellington Hospital, Riddiford 
Street, Wellington. 
 
What tests and procedures will be carried out? 
Once you have been randomised to either high flow or variable flow oxygen therapy, you 
will receive oxygen for 1 hour.  During the 1 hour of the study you will have the following 
measurements made. 
 
Carbon dioxide 
Carbon dioxide is a waste gas produced by the body and it sometimes increases when 
people have problems breathing. It is measured with a device that attaches to the earlobe. 
It is painless. 
 
Pulse oximetry 
This is a test to measure the percentage of your blood that is saturated with oxygen (oxygen 
saturations). It involves wearing a probe on your finger for the duration of the 1 hour 
period. This will be monitored closely by the doctor and nurses looking after you. If you have 
been assigned to the variable oxygen regime, it is this test that will determine how much 
oxygen you need to be given. The probe simply clips on to your finger and does not hurt at 
all. 
 
Respiratory rate, pulse and blood pressure 
Your doctor or nurse will measure your rate of breathing, pulse rate and blood pressure 
throughout the study. 
 
Forced expiratory volume in one second (FEV1) 
We will measure how well your lungs are working by asking you to blow into a machine as 
hard as you can.  This enables us to assess how much air you can breathe out in one second 
and is a measure of how well your lungs are working. 
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These tests are the same ones you would receive if you were not participating in the study. 
 
Possible Risks and Discomforts 
 
You will receive optimal care for your condition while you are in the study, including any 
blood tests and x-rays that may be required. The extra tests done as part of the study are 
painless and do not present a risk to you. 
 
Possible Benefits 
The benefits to you of participating in this study are that you will be very closely 
monitored by an experienced doctor for the duration of the study.  The level of 
monitoring will be more intensive than you would otherwise receive.  
You will be contributing valuable information to an important study that may change the 
way we treat patients with asthma and pneumonia.  
 
Alternative Therapy 
You will remain on your usual medication during this study. Your medical care will not be 
compromised in any way by your participation in the study. 
 
Participant Rights and Study Withdrawal 
Participation in this study is entirely voluntary and you do not have to take part. Your 
decision whether or not to participate will not affect your health care in any way or your 
future relations with the hospital.  If you agree to participate, you may withdraw from the 
study at any time.  If you refuse to participate or if you choose to withdraw (at any time) this 
will not affect your health care or any benefits to which you are otherwise entitled.  The 
study doctor, the sponsor or a government health authority may terminate your 
participation at any time. 
 
Termination of Patient’s Study Participation 
Your participation in the study may be stopped for any of the following reasons: 
 
 If you don’t follow the investigator’s instructions. 
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 The investigator decides it is in the best interest of your health and welfare to 
discontinue. 
 
Compensation for Injury 
In the unlikely event of a physical injury as a result of your participation in this study, you 
may be covered by ACC under the Injury Prevention, Rehabilitation and Compensation Act.  
ACC cover is not automatic and your case will need to be assessed by ACC according to the 
provisions of the 2002 Injury Prevention Rehabilitation and Compensation Act.  If your claim 
is accepted by ACC, you still might not get any compensation.  This depends on a number of 
factors such as whether you are an earner or non-earner.  ACC usually provides only partial 
reimbursement of costs and expenses and there may be no lump sum compensation 
payable.  There is no cover for mental injury unless it is a result of physical injury.  If you 
have ACC cover, generally this will affect your right to sue the investigators. 
 
If you have any questions about ACC, contact your nearest ACC office or the investigator. 
 
Confidentiality and Data Privacy 
If you decide to participate in the study, the study doctor and MRINZ staff will collect 
medical and personal information about you as part of doing the study.   
By agreeing to take part in this research, you will allow your medical information and results 
to be seen by people who check that the research was done properly. 
Ethical Guidelines 
This study has been reviewed and approved by the Central Ethics Committee in Wellington. 
 
Patient’s Rights  
If you have any queries or concerns regarding your rights as a participant in this study, you 
may wish to contact a Health and Disability Services Consumer Advocate at telephone 
number: 0800 423 638. 
 
Contact 
If you have any questions about the study you can contact one of the study doctors: 
 
213 
 
 
Professor Richard Beasley 
Telephone:  04-385 5999, pager 6794 
Fax:  04-385 5550 
Richard.Beasley@ccdhb.org.nz 
 
Dr Kyle Perrin 
Telephone: 04 4729120 
Fax: 04 4729224 
kyle.perrin@mrinz.ac.nz 
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Participant Information Sheet  
 
 
Full Study Title: 
A Study To Investigate The Effects Of Hyperoxia On Carbon Dioxide Levels And Ventilation In 
Patients With Obesity Hypoventilation Syndrome 
 
Short Study Title: 
A Study To Investigate The Effects Of Oxygen In Obesity Hypoventilation Syndrome 
 
Introduction 
You are invited to take part in a clinical research study.  Please take the time to read this 
information sheet carefully to determine if the study is of interest to you. You may wish to 
discuss the information in this sheet with your family or whanau. Please ask us if you have 
any questions about the study. Your involvement in this study is voluntary and you have the 
right not to take part and to withdraw at any time.   
 
Aim of the Study 
It is currently standard treatment to administer high flow oxygen to patients with low levels 
of oxygen with obesity hypoventilation syndrome. However high flow oxygen may cause 
complications and it is now well recognised that this practice can be detrimental to patients 
with emphysema. To date, no studies have investigated the effects of high flow oxygen in 
patients with known or suspected obesity hypoventilation syndrome.   
 
Where will the study be conducted? 
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The study will be conducted at the Medical Research Institute of New Zealand, Bowen 
Hospital, Crofton Downs.  
 
What tests and procedures will be carried out? 
You will be asked to breathe through a mouthpiece for 20-25 minutes. This will be done in a 
comfortable, seated position. Oxygen will be delivered via the mouthpiece, but this will be 
no different from breathing air.  
 
Carbon dioxide and Oxygen saturations 
Carbon dioxide is a waste gas produced by the body and it sometimes increases when 
people have problems breathing. It is measured with a device (called a probe) that attaches 
to the earlobe. The device is painless. Oxygen saturations measure the percentage of your 
blood which is saturated with oxygen. These are also measured by the probe on your 
earlobe. 
 
 
Forced expiratory volume in one second (FEV1) 
We will measure how well your lungs are working by asking you to blow into a machine as 
hard as you can.  This enables us to assess how much air you can breathe out in one second 
and is a measure of how well your lungs are working. 
 
Measurements of ventilation 
We will also measure your tidal volume (the amount of air going in and out of your lungs) as 
well as your “dead space” (the amount of air that is inhaled, but does not take part in gas 
exchange). These measurements will be done by an experienced respiratory scientist whilst 
you are breathing through the mouthpiece, and you will not be aware that they are being 
taken. 
 
What are the Possible Risks and Discomforts? 
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The oxygen delivered may cause a rise in your carbon dioxide levels. If the levels become 
too high, the oxygen will be stopped. 
 
What are the Possible Benefits 
You will be contributing valuable information to an important study that may change the 
way we treat patients with asthma and obesity hypoventilation syndrome. 
 
Is there an Alternative to Participating? 
You have the choice not to take part in this study.  If you do decide to take part, you will 
remain on your usual medication during this study. 
 
Will I have to Cost Me Anything to Participate? 
Participation in this study is free; however, you may have travel expenses to get to Bowen 
Hospital and these will be reimbursed. 
 
Participant Rights and Study Withdrawal 
Participation in this study is entirely voluntary and you do not have to take part. Your 
decision whether or not to participate will not affect your health care in any way or your 
future relations with the hospital.  If you agree to participate, you may withdraw from the 
study at any time.  If you refuse to participate or if you choose to withdraw (at any time) this 
will not affect your health care or any benefits to which you are otherwise entitled.  The 
study doctor, the sponsor or a government health authority may terminate your 
participation at any time. 
 
Termination of Patient’s Study Participation 
Your participation in the study may be stopped for any of the following reasons: 
 
 If you don’t follow the study doctor’s instructions. 
 The study doctor decides it is in the best interest of your health and welfare to 
discontinue. 
 
Compensation for Injury 
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In the unlikely event of a physical injury as a result of your participation in this study, you 
may be covered by ACC under the Injury Prevention, Rehabilitation and Compensation Act.  
ACC cover is not automatic and your case will need to be assessed by ACC according to the 
provisions of the 2002 Injury Prevention Rehabilitation and Compensation Act.  If your claim 
is accepted by ACC, you still might not get any compensation.  This depends on a number of 
factors such as whether you are an earner or non-earner.  ACC usually provides only partial 
reimbursement of costs and expenses and there may be no lump sum compensation 
payable.  There is no cover for mental injury unless it is a result of physical injury.  If you 
have ACC cover, generally this will affect your right to sue the investigators. 
 
If you have any questions about ACC, contact your nearest ACC office or the investigator. 
 
Confidentiality and Data Privacy 
If you decide to participate in the study, the study doctor and MRINZ staff will collect 
medical and personal information about you as part of doing the study.   
By agreeing to take part in this research, you will allow your medical information and results 
to be seen by people who check that the research was done properly. 
No material which could personally identify you will be used in any reports on this study.  
Your subject data will be identified by a code number. 
Ethical Guidelines 
This study has been reviewed and approved by the Central Ethics Regional Committee in 
Wellington. 
 
Patient’s Rights  
If you have any queries or concerns regarding your rights as a participant in this study, you 
may wish to contact a Health and Disability Services Consumer Advocate at telephone 
number: 0800 423 638. 
 
Contact 
If you have any questions about the study you can contact one of the study doctors: 
 
Professor Richard Beasley 
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Telephone:  04-385 5999, pager 6794 
Fax:  04-385 5550 
Richard.Beasley@ccdhb.org.nz 
 
Dr Meme Wijesinghe 
Telephone: 04 4729110 or 021 024 777 30 
Fax: 04 4729224 
Meme.wijesinghe@mrinz.ac.nz 
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Acute Pneumonia and High Flow Oxygen 
 
Full Title 
A randomised controlled trial of high flow versus titrated oxygen therapy in the emergency 
department management of patients with community acquired pneumonia. 
Methods 
 
Inclusion criteria: 
 
1. Age 16-75 years 
2. Cough  
3. At least one systemic feature (sweating, rigors and/or fever >37.8° C) 
4. Respiratory Rate >18 breaths/min 
 
Exclusion criteria: 
 
1. Respiratory failure requiring mechanical ventilation  
2. Diagnosis of COPD/emphysema 
3. Acute ECG changes suggesting ischaemia 
4. Suspected neutropaenic sepsis 
5. Known or suspected chronic hypercapnic respiratory failure as a result of any of the 
following disorders: 
 Neuromuscular disease 
 Chest wall disease 
 Obesity hypoventilation syndrome 
 
Intervention: 
 
Patients will be randomly assigned to receive one of two oxygen regimes for 1 hour: 
1. Continuous high flow oxygen (8L/min via Hudson mask)  
2. Oxygen titrated to achieve an oxygen saturation of 93-95% via nasal prongs or 
Hudson mask as required. See oxygen titration protocol below. 
 
(The clinical assessment and management of the patient for the time they are under the trial 
protocol lies with the attending research registrar. At the end of the trial period the patient’s 
management is handed over to an E.D. doctor. The research registrars have full staff status 
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and are working as E.D. doctors under the clinical supervision of the duty E.D. consultant for 
the purposes of this trial). 
 
Primary outcome variables: 
1.    Proportion of patients with an increase in PaCO2 ≥ 4mmHg at 1hour 
 
Secondary outcome variables:  
1.   Proportion of patients with a PaCO2 ≥ 38mmHg and an increase of ≥ 4mmHg at 1hour 
2.   Mean change in respiratory rate and heart rate 
3.   Mean change in PaCO2 
4.   Need for hospital admission 
5.  Combined primary endpoint with asthma/oxygen study 
 
Detailed study protocol: 
1. The on duty triage nurse will notify the on-duty/on-call research registrar via a designated 
cell phone when any patient presents to the emergency department between 0800 and 
1700 with symptoms of a chest infection or suspected pneumonia (this includes patients 
who self-present, arrivals via ambulance and patients referred for assessment by the 
medical registrar). 
2. If the patient meets the above inclusion criteria, the trial is discussed with the patient and 
the short consent form signed (the long information sheet and consent will be read and 
signed at an appropriate time during the trial period). 
3. If the patients oxygen saturations are >92% whilst breathing room air, they will remain 
off oxygen for at least 10 minutes, If the saturations are <92%, titrated oxygen will be 
commenced according to the protocol below. 
4. The patient is randomised and an initial transcutaneous CO2 (TCO2) level is recorded 
(Time = 0) and the oxygen protocol is started.  
5. At 20 minute intervals oxygen saturations, TCO2 level and CRB score will be recorded. 
The final TCO2 recording is made at Time=60 
6. If a patient requires any nebulised medication, those randomised to the titrated oxygen 
group will have them driven with room air while continuing with oxygen via nasal prongs 
(if required). Patients in the high flow oxygen group will continue to receive 8l/min of 
oxygen through the nebuliser. 
7. Patients will be removed from the trial if they require more than 8l/min of oxygen via a 
Hudson Mask to maintain oxygen saturations above 90% 
8. Patients will receive the usual investigations including a CXR, blood tests and arterial 
blood gases where indicated. 
9. If the CRB score is ≥2 at any time, the ED consultant will be notified and decide if the 
patient should continue in the trial 
10. The treating clinician can withdraw the patient from the trial at any time if there are any 
other clinical concerns 
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Treatment Protocol 
 
1.  History and physical examination. Calculation of the CRB score: 
Confusion: new mental confusion defined as an Abbreviated Mental Test score of 8 
or less 
Respiratory rate: raised ≥ 30/min 
Blood pressure: Systolic <90mmHg and/or diastolic ≤ 60mmHg 
65 Aged 65 or over 
(1 feature present = non-severe CAP, 2 or more features present = severe CAP) 
 
2. If the clinical suspicion of community acquired pneumonia is high, empirical antibiotic 
treatment will be administered as follows (BTS guidelines): 
 
Severity Antibiotic Regimen 
Non-severe 
(previously 
untreated in 
community) 
Amoxycillin 500mg-1.0g tds po 
 
Non-severe Amoxycillin 500mg-1.0g tds po plus erythromycin 500mg qds po 
Or if intravenous required: 
Co-amoxiclav 1.2g iv qds  plus erythromycin 500mg qds iv 
Severe Cefuroxime 1.5g tds iv plus erythromycin 500mg qds iv 
 
3. All patients will have a chest x-ray. Other therapies (intravenous fluids and analgesia) 
are administered at the discretion of the attending registrar. 
 
Oxygen Dose Adjustment for the titrated oxygen group 
 
Oxygen Saturation Dose Adjustment L/min Next Saturation Check  
> 98% Reduce by 2 L In 5 minutes 
96% - 97% Reduce by 1L  In 5 minutes 
93% - 95% No change In 5 minutes 
91% - 92% Increase by 1L In 5 minutes 
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89% - 90% Increase by 2L In 5 minutes 
86% - 88% Increase by 4L In 5 minutes  
<86% withdraw    
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 Patient arrives in ED with suspected 
pneumonia. 
 Triage nurse notifies research fellow via 
cell phone 
 
 Room air for at least 10 minutes or 
titrated oxygen if sats <92% 
 Consent and randomise  
 CRB 65 score 
 
T = 0 
 Baseline TCO2  
 Start O2 protocol  
 Baseline recordings 
 
 
 At T = 20 and 40 mins: 
 
 CRB score 
 O2 saturations 
 TCO2  
At T= 60 mins: 
 CRB score and O2 saturations 
 Final TCO2 
 
Study protocol ends 
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Severe Asthma and High Flow Oxygen 
 
Full Title 
A randomised controlled trial of high flow versus titrated oxygen therapy in the emergency 
department management of patients with severe asthma. 
Methods 
 
Inclusion criteria: 
1. History of asthma  
2. Presentation to the emergency department with an acute exacerbation of asthma 
3. Age 16-65 years 
4. FEV1 ≤ 50% predicted  
 
Exclusion criteria: 
6. Diagnosis of COPD/emphysema 
7. Asthma attack requiring mechanical ventilation  
8. Patient unconscious, unable to speak or unable to perform spirometry on arrival 
9. Known or suspected chronic hypercapnic respiratory failure as a result of any of the 
following disorders: 
 Neuromuscular disease 
 Chest wall disease 
 Obesity hypoventilation syndrome 
 
Intervention: 
Patients will be randomly assigned to receive one of two oxygen regimes for 1 hour: 
3. Continuous high flow oxygen (8L/min via Hudson mask)  
4. Oxygen titrated to achieve an oxygen saturation of 93-95% via nasal prongs or 
Hudson mask as required. See oxygen titration protocol below. 
 
(The clinical assessment and management of the patient for the time they are under the trial 
protocol lies with the attending research registrar. At the end of the trial period the patient’s 
management is handed over to an E.D. doctor. The research registrars have full staff status 
and are working as E.D. doctors under the clinical supervision of the duty E.D. consultant for 
the purposes of this trial). 
 
 
Primary outcome variables: 
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2.    Proportion of patients with an increase in PaCO2 ≥ 4mmHg at 1hour 
 
Secondary outcome variables:  
6.   Proportion of patients with a PaCO2 ≥ 38mmHg and an increase of ≥ 4mmHg at 1hour 
7.   Change in respiratory rate, heart rate, and FEV1 during the treatment period 
8.   Mean change in PaCO2 
9.   Need for hospital admission  
10.   Combined primary endpoint with pneumonia/oxygen study 
 
Detailed study protocol: 
11. The on duty triage nurse will notify the on-duty/on-call research registrar via a designated 
cell phone when any patient presents to the emergency department with acute asthma 
(this includes patients who self-present, arrivals via ambulance and patients referred to 
the medical registrar for assessment). 
12. The research fellow will attend and obtain initial spirometry (if not already done by triage 
nurse).  
13. If FEV1 < 50% predicted: the patient given 2.5mg salbutamol and 0.5mg ipratropium via 
air driven nebuliser. If the oxygen saturations are <92%, oxygen will be given via nasal 
prongs to achieve a saturation of 93-95% (see titration protocol below). 
14. The trial is discussed with the patient and the short consent form signed (the long 
information sheet and consent will be read and signed at an appropriate time during the 
trial period). 
15. The patient is randomised, and after at least 10 minutes of breathing room air or titrated 
oxygen if initially hypoxaemic, the transcutaneous CO2 (TCO2) level is recorded (Time 
= 0) and the oxygen protocol is started.   
16. At 20 minute intervals FEV1, TCO2, respiratory rate, heart rate and oxygen saturations 
will be recorded. A questionnaire regarding recent beta-agonist use will be administered. 
The final TCO2 recording is made at Time=60. 
17. Patients randomised to the titrated oxygen group will have all nebulised medications 
driven with room air while continuing with oxygen via nasal prongs (if required). Patients 
in the high flow oxygen group will continue to receive 8l/min of oxygen through the 
nebuliser. 
18. Patients will receive the usual investigations including a CXR, blood tests and arterial 
blood gases where indicated. 
19. Patients will be removed from the trial if they require more than 8l/min of oxygen via a 
Hudson Mask to maintain oxygen saturations above 90% 
20. The treating clinician can withdraw the patient from the trial at any time if there are 
clinical concerns 
21. The E.D. physician will be consulted regarding any patient with: 
 An FEV1 that decreases despite treatment 
 An FEV1 < 30% that fails to increase despite treatment 
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 An initial PaCO2 above 45mmHg 
 Saturations of less than 90% despite oxygen at 8L/min (withdraw from trial) 
 
Treatment protocols: 
 
1. Severe asthma (FEV1 30 to 50% predicted) 
 Salbutalmol 2.5mg and ipratropium bromide 0.5mg via nebuliser on arrival 
 Salbutamol 2.5mg via nebuliser every 20 minutes 
 Prednisone 40mg P.O.  
 
2. Very severe asthma (FEV1 < 30% predicted) 
 Salbutalmol 2.5mg and ipratropium bromide 0.5mg via nebuliser on arrival 
 Salbutamol 2.5mg via nebuliser every 15 minutes 
 Prednisone 40mg P.O. and hydrocortisone 100mg I.V. 
 Magnesium sulphate 2g in 100ml normal saline over 20min 
 
 
 
 
 
Oxygen Dose Adjustment for the titrated oxygen group 
 
Oxygen Saturation Dose Adjustment L/min Next Saturation Check  
> 98% Reduce by 2 L In 5 minutes 
96% - 98% Reduce by 1L  In 5 minutes 
93% - 95% No change In 5 minutes 
91% - 92% Increase by 1L In 5 minutes 
89% - 90% Increase by 2L In 5 minutes 
86% - 88% Increase by 4L In 5 minutes  
<86% withdraw    
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 Patient arrives in ED with acute 
exacerbation of asthma 
 Triage nurse notifies research fellow 
 Baseline FEV1 recorded 
FEV1 ≤ 50% predicted? 
  
 
 
  Room air for at least 10 minutes or start 
titrated oxygen if sats <92% 
 2.5mg salbutamol + 0.5mg ipratropium 
 Consent and randomise  
 
 
T = 0 
 Baseline TCO2 
 Start O2 protocol  
 Baseline recordings 
 
 
FEV1 30 to 50% 
Asthma treatment protocol 1 
(Severe) 
FEV1 < 30% 
Asthma treatment protocol 2 
(Very severe) 
At T = 20 and 40 mins: 
 FEV1 
 Respiratory rate 
 O2 saturations 
 TCO2 
 
At T = 20 and 40 mins: 
 FEV1 
 Respiratory rate 
 O2 saturations 
 TCO2 
 
 
At T=60mins:  
 Final recordings 
 Final TCO2 recorded 
Study protocol ends 
At T=60mins: 
 Final recordings 
 Final TCO2 recorded 
Study protocol ends 
Yes 
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Obesity Hypoventilation Syndrome and High Flow Oxygen 
 
 
Full Title 
 
A Randomised Double-Blind Cross-Over Study To Investigate The Effects Of 
Hyperoxia On Carbon Dioxide Levels And Ventilation In Patients With Obesity 
Hypoventilation Syndrome. 
 
 
 
Methods 
 
Inclusion criteria: 
 
1. Patients with a new diagnosis of Obesity Hypoventilation Syndrome: 
 BMI >30kg/m2,  
 Daytime hypercapnia (pCO2 >45mmHg) 
 
Exclusion criteria: 
 
1. Diagnosis of chronic airflow obstruction post-bronchodilator FEV1 to FVC ratio <0.7 and 
FEV1 <80% predicted and > 10 pack year smoking history 
 
2. Patients already receiving  treatment  with CPAP or non-invasive positive pressure 
ventilation 
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Intervention 
 
24 patients will be recruited 
 
Patients will attend the laboratory on two occasions within 7 days. 
 
Patients will have the following measured as baseline on room air whilst breathing into a 
pneumotachygraph via a mouthpiece: 
 
 Heart rate and respiratory rate  
 Transcutaneous carbon dioxide levels and oxygen saturations 
 Minute ventilation  
 Dead space to tidal volume ratio 
 
 
The patient will be randomized, in a double-blind fashion, to receive 100% oxygen or room air  
delivered for 20 minutes. 
 
 
The following measurements will be made during the last 2 minutes of each treatment period 
 
 Heart rate, respiratory rate and oxygen saturations  
 Transcutaneous carbon dioxide levels  
 Minute ventilation  
 Dead space to tidal volume ratio 
 
Oxygen saturations, transcutaneous carbon dioxide and heart rate will be monitored continuously 
 
On the patient’s second visit, the study protocol will be repeated with the other gas. 
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Outcome Measures  
 
Primary: 
 
1. Change in PaCO2 from baseline 
 
 
Secondary Outcome Measures: 
 
 
1. Change in minute ventilation  
 
2. Change in dead space to tidal volume ratio 
 
3. Change in PaCO2 from baseline of ≥ 4mmHg 
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Bohr Equation 
Expired CO2 = inspired CO2 + CO2 given out by lungs 
Or:  FE  X  VT  = ( FI  X  VT )  +  (FA  X VA ) 
Where FE = fractional concentration of CO2 in expired gas 
FI= fractional concentration of CO2 in inspired gas 
FA = fractional concentration of CO2 in alveolar gas 
VT =tidal volume 
VA = alveolar component of tidal volume 
Since inspired CO2 is negligible, it may be ignored: 
I.e. FE  X  VT  = FA  X VA 
 But VA= VT – VD  
Therefore FE  X  VT  = FA  X (VT – VD) 
  = (FA  X  VT)- (FA  X  VD) 
Or: FA  X  VD = (FA  X  VT) – ( FE  X  VT  ) 
  = VT ( FA  - FE) 
Therefore VD = FA-FE 
      VT    FA 
Since partial pressure is proportional to concentration: 
   VD = PACO2 – PECO2 
   VT            PAO2 
Where  PAO2= alveolar partial pressure of CO2 
 PECO2=mixed expired partial pressure of CO2 
237 
 
 
Since alveolar PCO2 approximately equals arterial PCO2, 
 VD = PaCO2 – PECO2 
   VT            PaO2 
Where PaO2= arterial partial pressure of CO2 
 
